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Abstract 
 
Background - Although acute hyperglycemic episodes are linked to lower glucose 
uptake, underlying mechanisms driving this process remain unclear.  We 
hypothesized that acute hyperglycemia triggers reactive oxygen species (ROS) 
production and increases non-oxidative glucose pathway (NOGP) activation, i.e. 
stimulation of advanced glycation end products (AGE), polyol pathway (PP), 
hexosamine biosynthetic pathway (HBP) and protein kinase C (PKC) activation. 
These mechanisms attenuate cellular function, and may indeed decrease insulin-
mediated cardiac glucose uptake.  The role of the pentose phosphate pathway (PPP) 
under high glucose/diabetic conditions is a subject of contention. Activation of the 
PPP enzyme transketolase (TK) (by benfotiamine/BFT or thiamine) reduces flux via 
the other four NOGPs, and is associated with beneficial outcomes. Our aim was 
therefore to evaluate the effects of acute hyperglycemia on insulin-mediated glucose 
uptake in a cardiac-derived cell line. Specifically, we aimed to elucidate the role of 
ROS and NOGP induction under these conditions. 
 
Methodology - H9c2 cardiomyoblasts were exposed to 25 mM glucose for 24 hr vs. 
5.5 mM glucose controls ± modulating agents during last hour of glucose exposure: 
a) antioxidant #1 for mitochondrial ROS (250 μM 4-OHCA), b) antioxidant #2 for 
NADPH oxidase-generated ROS (100 μM DPI), c) NOGP inhibitors – 100 µM 
aminoguanidine (AGE), 5 μM chelerythrine (PKC); 40 μM DON (HBP); and 10 μM 
zopolrestat (PP).  We also employed BFT (50 and 100 µM) in vitro, while the effects 
of in vivo thiamine administration were assessed in hearts of an obese/diabetic rat 
model of pre-diabetes and diabetes, the OLETF strain. We evaluated insulin 
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sensitivity by glucose uptake assay (flow cytometry), GLUT4 translocation 
(transfection of HA-GLUT4-GFP construct) and protein kinase B (Akt) activity assay. 
ROS levels (mitochondrial, intracellular) were measured by flow cytometry analysis of 
specific fluorescent probes. Markers of each NOGP were also assessed.   
 
Results - Acute hyperglycemia elevated ROS, activated NOGPs and blunted 
glucose uptake. However, TK activity (marker of PPP) did not change.  Respective 4-
OHCA and DPI treatment blunted ROS production, diminished NOGP activation and 
normalized glucose uptake.  NOGP inhibitory studies identified PKCβII as a key 
downstream player in lowering insulin-mediated glucose uptake. When we employed 
BFT (known to shunt flux away from NOGPs and into the PPP), it decreased ROS 
generation and NOGP activation, and restored glucose uptake under acute 
hyperglycemic conditions. In vivo thiamine administration reduced markers of the 
other NOGP, while it attenuated (mainly in the pre-diabetic phase) the metabolic 
dysfunction observed in the OLETF rats. 
 
Conclusions - This study demonstrates that acute hyperglycemia elicits a series of 
maladaptive events that function in tandem to reduce glucose uptake, and that 
antioxidant treatment and/or attenuation of NOGP activation (PKC, polyol pathway) 
may limit the onset of insulin resistance.   
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Opsomming (Uittreksel) 
 
 
Agtergrond – Alhoewel akute hiperglisemie voorvalle gekoppel is aan verlaagde 
glukose opname, is die onderliggende meganismes wat die proses dryf steeds 
onduidelik. Ons hipotetiseer dat akute hiperglisemie aanleiding gee tot die produksie 
van reaktiewe suurstofspesies (RSS) en toename in nie-oksidatiewe glukose weg 
(NOGW) aktivering, i.e. stimulering van gevorderde glukasie eindprodukte (GGE), 
poliolweg (PW), heksosamien biosintetiese weg (HBW) en proteïenkinase C (PKC) 
aktivering. Hierdie meganismes verminder sellulêre funksie, en mag inderdaad 
insulien-bemiddelde kardiêre glukose opname verlaag. Die rol van die 
pentosefosfaatweg (PFW) onder hoë glukose/diabetiese kondisies is ‘n onderwerp 
van stryd. Aktivering van die PFW ensiem transketolase (TK) (deur benfotiamien/BFT 
of tiamien) verminder fluks deur die ander vier NOGWë, en is geassosieer met 
voordelige uitkomste. Ons doel was dus om die effekte van akute hiperglisemie op 
insulien-bemiddelde glukose opname te evalueer in ‘n kardiaal-afkomstige sellyn. 
Meer bepaald het ons gepoog om die rol van RSS en NOGW induksie onder hierdie 
kondisies te verstaan. 
 
Metode – H9c2 kardiomioblaste is aan 25 mM glukose vir 24 h blootgestel vs. 5.5 
mM glukose kontroles ± moduleeragente tydens die laaste uur van glukose 
blootstelling: a) anti-oksidant #1 vir mitochondriese RSS (250 μM 4-OHCA), b) anti-
oksidant #2 vir NADPH oksidase-gegenereerde RSS (100 μM DPI), c) NOGW 
inhibeerders – 100 µM aminoguanidien (GGE), 5 μM cheleritrien (PKC); 40 μM DON 
(HBW); en 10 μM zopolrestaat (PW).  Ons het ook BFT (50 en 100 µM) in vitro 
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aangewend, terwyl die effek van in vivo tiamien aanwending geassesseer is in die 
harte van ‘n vetsugtige/diabetiese rotmodel van pre-diabetes en diabetes, die OLETF 
lyn. Ons het insuliensensitiwiteit deur ‘n glukose opname toets (vloeisitometrie), 
GLUT4 translokasie (transfeksie van HA-GLUT4-GFP konstruk) en proteïenkinase B 
(Akt) aktiwiteitstoets, geëvalueer. RSS vlakke (mitochondries, intrasellulêr) is gemeet 
deur vloeisitometriese analise van spesifieke fluoresserende peilers. Merkers van 
elke NOGW is ook geassesseer.   
 
Resultate - Akute hiperglisemie het RSS verhoog, NOGWë geaktiveer en glukose 
opname versag. TK aktiwiteit (merker van PFW) het egter nie verander nie. 
Onderskeidelike 4-OHCA en DPI behandeling het RSS produksie versag, NOGW 
aktivering verminder en glukose opname genormaliseer. NOGW onderdrukking 
studies het PKCβII geïdentifiseer as ‘n sleutel deelnemer in verlaging van insulien-
bemiddelde glukose opname. Die aanwending van BFT (bekend vir die wegvoer van 
fluks vanaf NOGWë na die PFW), het RSS skepping en NOGW aktivering verlaag, 
en glukose opname herwin onder akute hiperglisemiese kondisies. In vivo tiamien 
toediening het merkers van die ander NOGW verlaag, terwyl dit die metaboliese 
disfunksie waargeneem in die OLETF rotte (hoofsaaklik in die pre-diabetiese fase) 
verminder het. 
 
Gevolgtrekking – Hierdie studie demonstreer dat akute hiperglisemie ‘n reeks van 
wanaangepaste voorvalle ontlok wat gesamentlik funksioneer om glukose opname te 
verlaag, en dat anti-oksidant behandeling en/of vermindering van NOGW aktivering 
(PKC, poliolweg), die aanvang van insulien weerstand mag beperk.   
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CHAPTER 1 
Perspective 
 
Metabolic disorders, once considered diseases of wealthy, industrialized or 
westernized nations, are now becoming more prevalent globally. Developing nations 
now face daunting prospects in terms of disease prevalence, management and 
treatment. Moreover, future projections are alarming despite substantial efforts made 
to understand the pathophysiology, and also implementation of preventative or 
therapeutic possibilities. The umbrella term ‘metabolic disorders’ include the 
metabolic syndrome, insulin resistance and type 2 diabetes mellitus (T2DM), that are 
all complex, inter-linked and multi-factorial diseases with various secondary 
complications arising at different stages during the pathogenesis. 
 
Treatment and management of such disorders are difficult and expensive, resulting in 
a significant economic and social burden on health care systems. Furthermore, 
therapeutic advances are relatively limited, with the majority of promising drugs 
triggering moderate to severe side-effects.  Lifestyle interventions are also promising 
as a preventative strategy, but are generally difficult to adhere to. These problems 
augment the ever rising incidence in morbidity and mortality associated with such 
diseases. 
 
Our current understanding of the pathogenesis of T2DM shows various stages of 
dysregulated glucose metabolism. Initially, glucose homeostasis becomes impaired 
at the cellular uptake level, resulting in elevated (compensatory) insulin secretion by 
the pancreas. Insulin signaling at the target organs becomes severely attenuated, 
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resulting in elevated blood glucose levels. The pancreatic islet β-cells eventually 
become impaired, leading to decreased insulin secretion.  
 
The pathogenesis of human diabetes occurs over decades and affects adults during 
the latter stages of their lives. Secondary defects associated with diabetes, e.g. 
nephropathy, neuropathy and cardiovascular diseases also develop later-on during 
the disease progression. However, the first signs of reduced glucose metabolism 
(impaired glucose tolerance-IGT), occur during the early stages of T2DM 
pathogenesis. Furthermore, obesity and the metabolic syndrome (a cluster of 
metabolic risk factors – refer Section 1.4) are strongly implicated as precursors for 
the development of T2DM. Thus, metabolic alterations may also occur earlier-on in 
young and working age individuals; signaling the initial stages of T2DM disease 
progression. 
 
Current therapeutic options target the management of blood glucose levels at a late 
stage (during overt diabetes). The primary goal of these therapies is to prevent 
secondary defects and limit cellular damage caused by hyperglycemia. The majority 
of such drugs act to limit glucose levels in the bloodstream by targeting one or more 
of the following mechanisms: reducing glucose absorption in the gut, increasing 
insulin output in the pancreas (or insulin treatment itself when pancreatic β-cell 
dysfunction occurs), elevating peripheral tissue glucose uptake, or reducing hepatic 
glucose output. Although many pharmacological treatments result in successful 
glucose control, their efficacy is lost over time, e.g. onset of hypoglycemia and weight 
gain are disease risk factors. Moreover, reducing the secondary disease burden can 
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still remain problematic. Thus research work to investigate alternative options to blunt 
the ever increasing incidence of metabolic disorders is imperative. 
 
For this study, we endeavored to develop a deeper understanding of the molecular, 
cellular defects, and pathophysiology of insulin resistance at a relatively early stage. 
Our rationale was to identify maladaptive events during the early stages, and also to 
evaluate therapeutic targets to attenuate/reverse the development of insulin 
resistance. We are of the opinion that prevention of metabolic dysfunction/insulin 
resistance constitutes a useful approach. We focused on the effects of acute 
hyperglycemia per se as a risk factor for disrupted insulin action and glucose uptake, 
and suggest that this may lead to the pathogenic outcome of insulin resistance. As 
metabolic diseases impact on the heart’s function, we focused on the effects on 
cardiac-derived cells.  
 
This chapter reviews the current state of affairs and future projections of lifestyle-
dependent metabolic diseases and associated risk factors, specifically in developing 
nations such as South Africa. We also explore the mechanisms and impact of the 
metabolic syndrome, obesity and diabetes, and conclude by providing a problem 
statement outlining the rationale for this study. 
 
1.1. Metabolic dysfunction and lifestyle diseases 
 
The growing contribution of non-communicable diseases (NCDs) to global cases of 
preventable mortality and disability recently came under the spotlight at the United 
Nations (UN) General Assembly (United Nations, 2011). Here, the contribution of 
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NCDs to preventable death and disability, and the resulting socio-economic and 
development burden were considered to be of epidemic proportions. The UN and the 
World Health Organization (WHO) proposed that urgent steps are taken to reduce 
NCD-related mortalities by 25% by the year 2025 among adults aged 30 to 70 years 
–  adopting the slogan “25 by 25” (Hunter and Reddy, 2013; United Nations, 2011; 
World Health Organization, 2012). Furthermore, low- and middle-income countries 
are particularly affected as about 80% of deaths from NCDs occur in these countries, 
while a high proportion of mortality occurs in middle age (working) populations (World 
Health Organization, 2013). These factors may lead to dire economic consequences 
with the dual burden of inflated health care costs and significant loss of economic 
productivity. Indeed, global projections estimated a cumulative output loss of $47 
trillion between 2011 and 2030 (Bloom et al., 2011). The Global Burden of Diseases, 
Injuries and Risk Factors Study 2010 (GBD 2010) calculated the sum of years of life 
lost from premature death and years lived with disability (DALY) (Murray et al., 2012), 
and reported that DALYs increased from 43% in 1990 to 54% in 2010. Here, the 
largest increases in DALYs occurred due to cardiovascular diseases, cancer and 
diabetes.     
 
These three disease clusters fall under the top four related to mortality, contributing 
to about 80% of deaths due to NCDs (Lozano et al., 2012). The incidence and 
projections of diabetes is particularly alarming as it, along with obesity, is inextricably 
linked to a number of secondary complications, including cardiovascular diseases – 
the number one cause of mortality from NCDs. Previous estimations projected a rise 
in diabetes incidence from 135 million individuals affected in 1995 to 300 million by 
2025 (King et al., 1998), while the WHO extended this projection to ~366 million by 
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2030 (Wild et al., 2004). However, the 366 million mark was already surpassed in 
2011 and recent projections by the International Diabetes Federation (IDF) suggest 
this number could rise to 552 million by 2030 (International Diabetes Federation, 
2011).  
 
Type 1 (insulin-dependent) diabetes mellitus manifests mainly as an autoimmune 
disease leading to defective pancreatic β-cell function and impaired insulin secretion 
(Retnakaran and Zinman, 2008). T2DM is a complex, multifactorial condition mainly 
characterized by impaired insulin sensitivity and action that eventually develops into 
impaired insulin secretion (Kahn, 1998). Such metabolic dysfunction is strongly 
implicated as cardiovascular disease risk factors. Furthermore, obesity and metabolic 
syndrome incidence are also alarmingly high (discussed in Section 1.3 and 1.4). 
These facts highlight the need for implementation of urgent measures to blunt the 
epidemic of metabolic disorders. A more holistic understanding of the mediators of 
these disorders is however needed. We start by reviewing the risk factors associated 
with the pathogenesis of metabolic disorders next.    
 
1.2. Risk factors 
 
Metabolic syndrome, obesity and T2DM arise from common lifestyle-dependent risk 
factors, including poor dietary habits and physical inactivity. A salient feature of 
recent epidemiological research is that lifestyle risk factors increased globally, 
particularly in developing nations where the association between risk factors, their 
physiological mediators and disease incidence are well established (Danaei et al., 
2013; Ezzati and Riboli, 2013). Dietary patterns, specific foods and nutritional content 
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are indeed associated with cardiovascular diseases and diabetes (Mozaffarian et al., 
2011), and with intermediate outcomes including weight gain, hypertension, insulin 
resistance and hyperglycemia (He et al., 2013; Mozaffarian et al., 2011; Sacks et al., 
2009). For example, a number of observational studies and randomized trials 
highlight the benefit of lower salt intake, replacement of saturated fat with 
polyunsaturated fat and generally healthy dietary patterns (Estruch et al., 2013; He et 
al., 2013; Mozaffarian et al., 2010; Rossi et al., 2013; Sacks et al., 2009). 
Conversely, low intake of fruits, vegetables, whole grain, nuts, seeds or high intake of 
salt contribute significantly to global disease burden (Lim et al., 2012). Individuals 
adopting a high caloric, “Western” diet, have drastically increased serum cholesterol 
levels (Farzadfar et al., 2011). Modulation of dietary intake can help to blunt such 
effects. For example, a recent prospective study on the Greek cohort of the 
European Prospective Investigation into Cancer and Nutrition (EPIC) study assessed 
the effect of adherence to the Mediterranean diet and glycemic load on T2DM risk 
(Rossi et al., 2013) and found that adherence to the Mediterranean diet or a diet with 
a low glycemic load was associated with reduced risk for T2DM. Others also showed 
an association between consumption of a Mediterranean diet and prevention of 
cardiovascular diseases (Estruch et al., 2013). By contrast, consumption of diets with 
a high glycemic load correlated positively with diabetes risk.  
 
The intake of large amounts of sugar also increased substantially in recent decades, 
with consumption of added sugars contributing largely to such increases (Marriott et 
al., 2010; Welsh et al., 2011). Natural sugars, consisting of monosaccharides 
(glucose, fructose, galactose) and polysaccharides (sucrose and lactose) form part of 
a healthy diet and are found in fruit, vegetables, dairy products and cereals. Added 
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sugars – sugars or syrups added to food during preparation, processing or at the 
table – have drastically increased in diets since the introduction of modern food 
production methods (Johnson et al., 2009). Sugars and sweeteners available for 
consumption in the United States increased from 25 teaspoons (400 calories) to 29.8 
teaspoons (475 calories) per day, representing a 19% increase from 1970 to 2005 
(Wells and Buzby, 2008). The National Health and Nutrition Examination Survey 
(NHANES) reported a mean intake of 22.2 teaspoons (355 calories) per day from 
2001 to 2004 for all persons; while the estimated average intake for children aged 14 
to 19 years was 34.5 teaspoons (549 calories) (Marriott et al., 2009). These reported 
intakes far exceed the recommended allowance for discretionary calories proposed 
in the 2005 US Dietary Guidelines (Marriott et al., 2010). Moreover, the American 
Heart Association (AHA) recently recommended that ingestion of added sugars be 
reduced to at least 80 calories (5 teaspoons) for a daily energy expenditure of 1,800 
calories in an average adult woman, and to at least 144 calories (9 teaspoons) for a 
daily energy expenditure of 2,200 calories in an average adult man (Johnson et al., 
2009).  
 
The primary source of added sugars comes in the form of sugar-sweetened 
beverages, including sodas, fruit juices, energy drinks and vitamin water drinks 
(Johnson et al., 2009; Tappy and Lê, 2010). Recent data show that children and 
adults in the US consume 172 and 175 kcal per day, respectively, from sugar-
sweetened beverages (Brownell et al., 2009). High fructose corn syrup is the most 
common sugar used as sweetener for beverages. It is preferred by manufacturers 
due to its cost effectiveness and longer shelf life, and it exerts a higher perception of 
sweetness compared to sucrose (Tappy and Lê, 2010). Consumption of high fructose 
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corn syrup have increased drastically over the past thirty years and accounts for 
~42% of total caloric sweetener consumption in the US (Marriott et al., 2009).  
 
A number of prospective studies show a link between sugar-sweetened beverage 
consumption and risk for T2DM, weight gain and risk for obesity, and the metabolic 
syndrome (Bray, 2012; Fung et al., 2009; Mozaffarian et al., 2011; Popkin et al., 
2012; Schulze et al., 2004). Women consuming one serving of sugar-sweetened 
beverages per day gained significantly more weight and had an 83% greater risk for 
developing T2DM compared to those consuming one serving per month in an 8-year 
follow up study (Schulze et al., 2004). Furthermore, data from the Framingham 
Offspring Study show that individuals (followed for four years) who consume one to 
two servings of soft drinks daily have about 40% greater risk of developing obesity 
and metabolic syndrome, and a 22% higher incidence of hypertension compared to 
those who do not consume soft drinks (Dhingra et al., 2007). Additionally, soft drink 
consumers displayed elevated triglycerides and reduced high density lipoprotein 
cholesterol levels versus non-consumers. Data from the NHANES also show a 
significant correlation between dietary added sugars and dysregulated serum lipid 
levels (Welsh et al., 2011), while sugar-sweetened beverage consumption is also 
implicated in the risk for coronary heart disease (Fung et al., 2009). 
 
Although high dietary lipid and sucrose may trigger metabolic abnormalities and 
result in myocardial dysfunction (Chess and Stanley, 2008; Gonsolin et al., 2007; 
Sharma et al., 2007a; Stanhope and Havel, 2008), fructose is thought to be a major 
contributor to pathogenic outcomes (Bray, 2013, 2012; Elliott et al., 2002; Havel, 
2005; Kasim-Karakas et al., 1996; Sharma et al., 2007b). For example, visceral 
Stellenbosch University  http://scholar.sun.ac.za
9 
 
obesity was increased and insulin sensitivity decreased after consumption of 
fructose-sweetened, but not glucose-sweetened beverages in obese individuals 
(Stanhope et al., 2009). Moreover, a high fructose diet resulted in increased mortality 
and decreased left-ventricular contractile function compared to high starch, high fat 
or ”Western” diet in hypertensive rats (Sharma et al., 2007b). Fructose also induced 
significantly greater obesity, hyperinsulinemia, hypertriglyceridemia and impaired 
glucose utilization versus high sucrose and control (where fructose and sucrose were 
substituted with corn starch and dextrinized corn starch) diets in hamsters (Kasim-
Karakas et al., 1996). Furthermore, individuals subjected to 100 grams sucrose, or 
50 g glucose and 50 g fructose displayed higher triglyceride levels in the sucrose and 
fructose groups compared to the glucose alone, seven hours after ingestion (Cohen 
and Schall, 1988). These studies signify the importance of excess dietary sugar 
intake, specifically fructose, in developing metabolic dysfunction and subsequent 
disease phenotypes. Possible pathophysiological mechanisms resulting from dietary 
fuel overabundance will be discussed in Chapter 2.   
 
1.3. The obesity paradox 
 
The prevalence of obesity has drastically increased worldwide since 1980 (Ezzati 
and Riboli, 2013). Furthermore several observational studies related different 
measures of adiposity and excess body weight with increased mortality and 
increased risk of disease and death from diabetes, ischemic heart diseases and 
other pathologies (Ezzati and Riboli, 2013; Finucane et al., 2011; Ni Mhurchu et al., 
2004; Pischon et al., 2008; Renehan et al., 2008; Stevens et al., 2012; Whitlock et 
al., 2009; Wormser et al., 2011). Overweight and obesity are typically defined by the 
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body mass index (BMI; the weight of an individual in kilograms divided by the square 
of the height in meters), where individuals with a BMI 18.5 - 24.9 considered normal 
weight, those with a BMI of 25 - 29.9 overweight, and a BMI ≥ 30 considered as 
obese (Berrington de Gonzalez et al., 2010; Flegal et al., 2013; Whitlock et al., 2009) 
Obesity is further classified (based on the BMI) into grade 1 (30 - 34.9), grade 2 (35 - 
39.9) and grade 3 (≥ 40).  
 
A U-shaped relationship between BMI and mortality have also been described, where 
BMI values higher than 30 and lower than 18.5 (obese and underweight, 
respectively) both contributed to disease and mortality (Berrington de Gonzalez et al., 
2010; Whitlock et al., 2009). Although a high BMI is strongly related to detrimental 
outcomes, some studies suggested the converse, i.e. obesity improves survival 
associated with various chronic diseases  (Carnethon et al., 2012; Flegal et al., 2013; 
Kokkinos et al., 2012; Tseng, 2013). A recent study by Flegal and colleagues (2013) 
investigated the association between BMI and mortality and found increased all-
cause mortality among obese individuals (grade 1, 2 and 3 combined) compared to 
normal weight individuals (Flegal et al., 2013). However, grade 1 obesity (alone) and 
overweight individuals were associated with no increase or a decrease in mortality 
compared to normal weight individuals, respectively. Furthermore, others also found 
inverse correlations between BMI and mortality (Carnethon et al., 2012; Kokkinos et 
al., 2012; Tseng, 2013). For example, BMI was also inversely related to mortality in 
African-American and Caucasian males with diabetes (Kokkinos et al., 2012).  Of 
note, some individuals may display a normal weight BMI but are then “metabolically 
unhealthy”, i.e. characterized by hyperinsulinemia and insulin resistance and 
predisposed to T2DM and cardiovascular diseases (Wildman et al., 2008).   
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The seemingly counterintuitive notion of overweight or obesity having positive effects 
on health and mortality can be explained by the difficulties of only relying on the BMI 
as a measure of obesity. However, the BMI fails to distinguish between muscle and 
fat accumulation, the distribution of fat, age and gender- and ethnic-based 
differences (Bray, 2012; Gómez-Ambrosi et al., 2012; Heymsfield et al., 2009; Kang 
et al., 2011; Lumeng and Saltiel, 2011). Here fat localization is an important 
consideration, e.g. excess visceral (central or abdominal) fat may predispose 
individuals to the metabolic syndrome, and downstream outcomes such as insulin 
resistance, diabetes and cardiovascular diseases. By contrast, it is proposed that 
peripheral fat storage may be metabolically inert. Therefore, normal weight 
individuals who are metabolically unhealthy may present with excess (central) fat 
mass, together with  lower muscle mass (Lee et al., 2011). Loss of skeletal muscle as 
a result of aging or physical inactivity may also lead to impaired insulin sensitivity, as 
muscle is the major site of glucose disposal, resulting in adverse metabolic defects 
and cardiovascular outcomes (Fogelholm, 2010). A low BMI may also mask poor 
nutritional status that also has negative effects on health (Ahima and Lazar, 2013).  
 
The validity of the notion that a low BMI can be associated with unhealthy metabolic 
status may come into question. A recent study by Wildman et al. (2008) investigated 
the prevalence of various body size phenotypes (based on BMI) and its link to 
cardiometabolic abnormalities in a cross-sectional sample of 5,440 participants of the 
NHANES 1999-2004 (a nationally representative sample of the adult US population) 
(Wildman et al., 2008). The researchers estimated that ~10% of the US adult 
population display an obese BMI but are metabolically healthy, 8% have a normal 
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BMI but metabolically unhealthy, 21% have an obese BMI with metabolic 
abnormalities and 26% are lean (normal BMI) and display a metabolically healthy 
phenotype (Ahima and Lazar, 2013; Wildman et al., 2008). Others found that more 
than 10% of participants in a Korean study of adults aged 40 or higher displayed 
normal weight with various metabolic derangements, and the researchers concluded 
that identification of the metabolically obese but normal weight subjects may aid in 
the early detection of groups with high risk for cardiovascular disease (Lee et al., 
2011).     
 
These studies outline some of the uncertainties that may result when employing the 
BMI as a sole indicator of pathogenic obesity. Therefore, several additional factors 
should be taken into account when classifying individuals at risk for metabolic 
dysfunction. A number of studies have proposed waist circumference for indicating 
obesity as a leading complement to BMI and it may also be a better predictive tool for 
obesity-related mortality (Janssen et al., 2005; Kuk and Ardern, 2009). In fact, a 
recent report by the WHO proposed that waist circumference could be used as an 
alternative predictive tool for disease to BMI (World Health Organization, 2012). The 
new body shape index (ABSI) was recently developed and tested on a US population 
sample of 14,105 individuals from the NHANES 1999-2004, with a follow-up period of 
five years (Krakauer and Krakauer, 2012). The ABSI calculation included waist 
circumference, weight and height, with a high ABSI indicating that waist 
circumference is higher for a given weight and height, corresponding to more central 
obesity. High ABSI may therefore correspond to higher visceral fat versus peripheral 
fat. The ABSI appeared to be a better predicator of mortality risk across age, gender 
and ethnicity in the US compared to BMI or waist circumference alone (Krakauer and 
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Krakauer, 2012). Using ABSI along with BMI and waist circumference may provide a 
more complete picture about the metabolic “fitness” and disease risk for a certain 
individual.  
 
1.4. Metabolic syndrome, insulin resistance and type 2 diabetes 
 
The metabolic syndrome is described by a cluster of metabolic aberrations, including 
dyslipidemia, hypertension, impaired glucose homeostasis and obesity (specifically 
visceral adiposity), and is associated with the risk for development of T2DM and 
cardiovascular disease (Reaven, 1988).  These factors are inter-related and occur in 
tandem rather than individually, and the presence of an array of such factors is 
required to define the metabolic syndrome. Various criteria and definitions for the 
diagnosis of metabolic syndrome have surfaced since its original description. 
However, controversy surrounds the definitions of measurable factors, with 
differences in age, gender, ethnicity and lifestyle factors playing a role in one sense, 
while cut-off values and inclusion of certain factors (e.g. waist circumference) can 
also give rise to uncertainty. A recent joint statement by a number of organizations1 
produced revised interim criteria for the definition and diagnosis of metabolic 
syndrome in an attempt to unify criteria (Alberti et al., 2009). This statement 
suggested that any three out of five criteria constitutes diagnosis of the metabolic 
syndrome, and that a single set of cut-off points were defined for all components 
except waist circumference. More work is needed to evaluate waist circumference 
data and national or regional cut-off points should be used in the meantime. The 
researchers highlighted that the process of determining a unified definition and 
                                                          
1
 International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung 
and Blood Institute; American Heart Association; World Health Federation; International 
Atherosclerosis Society; and International Association for the Study of Obesity. 
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criteria is an evolutionary process and requires further investigation. The criteria put 
forth in the statement are summarized in Table 1.1.  
 
    Table 1.1 Criteria for diagnosis of metabolic syndrome (Alberti et al., 2009) 
Metabolic risk factor Suggested cut-off points 
Elevated waist circumference Population- and country-specific   
Elevated serum triglycerides ≥1.7 mmol/l 
Reduced  HDL cholesterol 
<1.0 mmol/l in males 
<1.3 mmol/l in females 
Elevated blood pressure 
Systolic ≥130 mm Hg and/or 
Diastolic ≥80 mm Hg 
Elevated fasting plasma glucose ≥5.6 mmol/l 
 
 
1.5. The South African context 
 
Despite limited information available in reporting obesity-related diseases in 
developing nations, early work shows that obesity and poor lifestyle choices are at 
alarming levels and still increasing (Ezzati and Riboli, 2013). Moreover, Sub-Saharan 
Africa is facing a multiple disease burden, with metabolic diseases increasing 
concomitantly with epidemics of infectious diseases (e.g. HIV/AIDS, tuberculosis and 
malaria) (Levitt et al., 2011). For example, South Africa has one of the largest 
populations of HIV-infected individuals, and here both HIV/AIDS and NCDs 
contribute largely to national mortality and disability figures (Norman et al., 2007). 
Interestingly, the South African Burden of Diseases Study (2000) showed that 
Stellenbosch University  http://scholar.sun.ac.za
15 
 
mortality and disability due to HIV/AIDS and other infectious diseases was higher in 
rural (and more impoverished) provinces compared to those with a higher average 
income (Bradshaw et al., 2008). Conversely, NCDs accounted for high rates of death 
and disability across all provinces, rates of hypertension, diabetes, obesity and 
overweight and associated complications are on the rise. Recent evidence suggests 
that HIV-positive patients on antiretroviral therapy may be particularly susceptible to 
metabolic alterations, including dyslipidemia, diabetes and myocardial infarction 
(Bradbury and Samaras, 2008; Friis-Møller and Worm, 2007; Friis-Møller et al., 
2003). Indeed, our laboratory recently suggested experimental evidence for disrupted 
lipid metabolism accompanied by cardiac contractile dysfunction in a rat model 
exposed to the protease inhibitor class of antiretroviral therapy (Reyskens et al., 
2013).     
 
The prevalence of metabolic risk factors is also alarmingly high among children and 
young adults. A ‘nutrition paradox’ exists, i.e. the simultaneous manifestation of 
under- and overweight in some sectors of the population. This may result in South 
African children exhibiting overweight and obesity on the one hand, and stunted on 
the other (Kimani-Murage, 2013; Steyn et al., 2005). Such disparity in nutritional 
status may weigh heavily on future projections for metabolic disorders, and more 
attention is warranted to determine risk factor prevalence in children. Indeed, Matsha 
and colleagues recently investigated novel waist-to-hip ratio cut-off criteria to 
determine cardiovascular risk associated with overweight and obesity in children 
(Matsha et al., 2013b). A study by our laboratory also showed that metabolic 
syndrome risk factors are high among young male and female university students 
(with gender-specific differences) and this may be attributable to poor eating habits 
Stellenbosch University  http://scholar.sun.ac.za
16 
 
and a sedentary lifestyle (Smith and Essop, 2009). This serious situation will require 
creative, cost-effective interventions. For example, exercise intervention in the form 
of Tae-bo effectively reduced cardio-metabolic risk factors in obese/overweight and 
previously sedentary female university students (Mathunjwa et al., 2013). 
 
Determination of metabolic risk factor cut-off points, specifically waist circumference, 
is difficult owing to the ethnic diversity of South Africa. A number of studies attempted 
to define criteria for different ethnic populations to best predict metabolic syndrome 
and cardio-metabolic risk. However, differences in suggested cut-off points for the 
same populations still persist (Motala et al., 2011; Prinsloo et al., 2011). Nonetheless, 
the use of a variety of currently available definitions and criteria shows good 
concordance and agreement to  determine the prevalence of metabolic risk factors in 
different South African populations in both the rural and urban settings (Erasmus et 
al., 2012; Matsha et al., 2013a; Motala et al., 2011; Prinsloo et al., 2011). Alarmingly, 
the prevalence of T2DM and impaired fasting glucose (IFG) has severely increased 
in the Mixed Ancestry community of the Western Cape, while a large proportion of 
cases are undiagnosed or newly diagnosed (Erasmus et al., 2012). Recent data from 
the same study population also showed a drastic worsening of glucose tolerance in 
~20% of participants over a follow-up period of three years (Matsha et al., 2013b). 
These studies outline the growing burden of metabolic dysfunction and lifestyle 
diseases through a spectrum of the South African population.         
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1.6. Problem statement 
 
In conclusion, metabolic dysfunction and lifestyle diseases contribute to a significant 
health care burden, morbidity and mortality. Of particular concern is the rising 
incidence in developing nations, including South Africa, and the higher level of young 
and middle-aged individuals affected. Poor dietary habits and physical inactivity are 
among the chief lifestyle factors influencing the negative medical outcomes. Such 
factors contribute to metabolic dysregulation and associated elevations in 
metabolites (hyperglycemia, hyperlipidemia), blood pressure, cholesterol and weight 
gain. Subsequent elevation in obesity, metabolic syndrome, pre-diabetes and insulin 
resistance give rise to development of diabetes and cardiovascular diseases later in 
life. Current diabetes medication succeed to an extent in meeting the main aims of 
treatment – curbing weight gain and reducing blood glucose levels – but fail to limit 
the associated secondary outcomes (e.g. cardiovascular diseases). Drug side-effects 
also limit development of successful treatment regimens for diabetic patients. 
Preventative measures including, national and individual restrictions on glycemic 
intake, limiting refined foods and promoting healthy lifestyle are essential, but may 
also be hampered by several factors, including individual adherence.  
 
It is therefore imperative to explore therapeutic and preventative strategies early on 
in the disease etiology. However, a better understanding of metabolic dysregulation 
and the associated molecular changes is first required. Acute hyperglycemic 
episodes may be prevalent in the early stages of diabetes development (pre-
diabetes, metabolic syndrome, obesity) or “simply” as a result of high glycemic 
dietary intake coupled to physical inactivity. Numerous studies underline molecular 
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alterations as a result of hyperglycemia (mainly in the chronic setting) and implicate 
these alterations in a wide variety of diabetic complications (reviewed in Chapter 2). 
For the present study, we proposed that similar molecular alterations may be at work 
as a result of acute hyperglycemic episodes. Here biochemical pathways of non-
oxidative glucose metabolism and various sources of intracellular oxidative stress 
may be inter-linked and may exert molecular defects. We employed a novel, holistic 
approach to assess such mechanisms in a single model and propose a mechanism 
that may desensitize cardiac myocytes to insulin action. This may lead to insulin 
resistance if the acute hyperglycemic episodes manifests over a long period of time. 
The description of these mechanisms may open doors to new (affordable) 
preventative treatment options to help curb the growing burden of metabolic diseases 
in South Africa and other developing nations – thus contributing to the UN and WHO 
“25 by 25” initiative.           
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CHAPTER 2 
Cardiomyocyte metabolism in the physiological state 
 
2.1. Introduction 
 
Cardiovascular complications constitute a major cause of death and disability among 
individuals burdened with diabetes mellitus.  Here myocardial insulin resistance may 
play an important role in the progression of diabetic cardiomyopathy and heart failure 
(Chavali et al., 2013; Chiha et al., 2012; Gustafsson et al., 2004). Cardiac 
abnormalities may therefore be strongly linked to metabolic dysfunction. As outlined 
in Chapter 1, the detrimental consequences of lifestyle and metabolic diseases are 
taking its toll world-wide. There is a growing number of obese individuals, those 
presenting with metabolic syndrome risk factors and individuals with undiagnosed or 
newly diagnosed diabetes, IFG or IGT.  
 
Hyperglycemia, a hallmark of diabetes, may in fact exert detrimental cardio-metabolic 
effects. For example chronic hyperglycemia is strongly correlated with higher 
incidence of myocardial infarction and markers of cardiac damage in humans (Barr et 
al., 2007; Rubin et al., 2012). Furthermore, effective glucose uptake and metabolism 
is particularly important in the ischemic heart (Tian and Abel, 2001), and also to 
prevent cardiac dysfunction associated with heart failure (Liao et al., 2002).  
However, optimal glucose lowering interventions for the treatment of diabetic 
complications pose unique challenges within the clinical setting (Radke and 
Schunkert, 2008).  Prevention of insulin resistance at an early stage is therefore of 
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utmost importance to help curb the growing global burden of cardio-metabolic 
complications.  
 
Chronically elevated nutrients (hyperglycemia, hyperlipidemia) can initiate 
detrimental metabolic and molecular events. For example, increased hyperglycemia-
induced production of reactive oxygen species (ROS) is considered a central factor in 
mediating damaging outcomes (Brownlee, 2005; Giacco and Brownlee, 2010). 
Oxidative stress may be linked to disrupted metabolic flux, particularly in the case of 
glucose metabolism. Here, a block in glycolytic flux may occur, leading to diversion of 
excess glucose-derived metabolites into alternative non-oxidative glucose pathways 
(NOGPs), resulting in harmful vascular complications associated with diabetes 
(Giaccari et al., 2009).  
 
Poor lifestyle and dietary habits can also give rise to the prevalence of acute 
hyperglycemic episodes (e.g. high postprandial excursions and impaired glucose 
tolerance) in diabetic and non-diabetic individuals. However, the role of ROS and 
associated activation of NOGPs under acute hyperglycemic conditions in insulin-
responsive cells remains poorly understood. The focus of the current study was 
therefore to investigate the effects of ROS on NOGP activation and insulin-mediated 
glucose uptake within the setting of in vitro acute hyperglycemia. As the focus is on 
myocardial glucose uptake and cardio-metabolic dysfunction, we will review the 
physiological metabolic mechanisms of cardiomyocytes in this chapter. Mechanisms 
associated with perturbed metabolism in disease states will be addressed in Chapter 
3.  
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2.2. Homeostatic metabolism in cardiomyocytes 
 
2.2.1. Fuel substrates 
 
The mammalian heart requires a continuous output to maintain blood flow and 
homeostasis throughout the body. Myocardial energy demands are therefore 
extremely high in order to maintain contractile function, ion pumps and general 
homeostasis of the heart. An intricate and well controlled series of biochemical 
mechanisms maintain optimal levels of adenosine triphosphate (ATP), the chemical 
energy “currency” of cells. The majority of ATP (~95%) is produced via oxidative 
phosphorylation in the mitochondrial electron transport chain, while glycolysis and 
guanidine triphosphate (GTP) formation in the citric acid cycle contributes to a lesser 
extent to the ATP pool (reviewed in Stanley et al., 2005). The energy required to fuel 
mitochondrial oxidative phosphorylation is supplied by electrons that are transferred 
from carbon fuel substrates to generate reducing equivalents, nicotinamide adenine 
dinucleotide reduced (NADH) and flavin adenine dinucleotide reduced (FADH2) 
(Figure 2.1). The fatty acid (FA) β-oxidation pathway and the citric acid cycle 
contribute primarily to the pool of electrons used to fuel oxidative phosphorylation, 
with lesser contributions from the pyruvate dehydrogenase reaction and glycolysis 
(reviewed in Stanley et al., 2005).  
 
 
Figure 2.1 Myocardial substrated utilization. Metabolic fuel sources are converted to reducing 
equivalents that can be used for energy production in the form of ATP,  that is subsequently utilized for 
myocardial functioning. ATP: adenosine triphosphate; FADH2: flavin adenine dinucleotide reduced; 
NADH: nicotinamide adenine dinucleotide reduced; SR: sarcoplasmic reticulum.   
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The citric acid cycle can be viewed as a central mediator of energy metabolism. It is 
fueled by acetyl-CoA from the decarboxylation of pyruvate or from FA β-oxidation, 
resulting in the supply of reducing equivalents that are subsequently used for 
oxidative phosphorylation (Figure 2.2). Since the adult heart is capable of utilizing 
different substrates (therefore referred to as being “omnivorous”), the choice of 
substrate utilized at any given time depends on substrate availability, energy 
demand, rate of oxidation and hormonal concentrations (Atkinson et al., 2002; 
Grynberg and Demaison, 1996; King et al., 2005; Neely et al., 1972; Opie, 1991; 
Stanley et al., 1997b; Taegtmeyer, 1994). 
 
 
 
Figure 2.2 Metabolic flux of myocardial substrate utilization. Myocardial metabolic fuel sources 
(glucose, lactate and FAs) are transported into the cell. Metabolic breakdown of these substrates yield 
acetyl-CoA, which is in turn used for the production of reducing equivalents in the citric acid cycle, and 
finally coupled to ATP production in the mitochondrial ETC. GLUT: glucose transporter protein; G-6-P: 
glucose-6-phosphate; MCT: monocarboxylic acid transporter; PDH: pyruvate dehydrogenase; CoA; 
co-enzyme A; ETC: electron transport chain; H
+
: proton; FAT: fatty acid translocaser; CPT1: carnitine 
palmatoyl transferase-1; FA: fatty acid.  
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Under physiological conditions, the adult heart utilizes FAs as the major substrate, 
with ~60 to 90% of acetyl-CoA formed as a result of FA β-oxidation and ~10 to 40% 
from pyruvate oxidation via glycolysis and lactate oxidation  (Gertz et al., 1988; 
Stanley et al., 1997a; Wisneski et al., 1985a, 1985b, 1990). However, after 
consumption of a meal, the myocardium is exposed to elevated levels of glucose and 
insulin, resulting in increased glucose utilization that may account for ~60 to 70% of 
ATP production (Bertrand et al., 2008). The next section will focus on the metabolic 
mechanisms required to utilize glucose and FA in myocardial cells. 
 
2.2.2. Glucose uptake 
 
Glucose is one of the primary carbohydrate fuel sources in the heart. It may be 
derived from the diet or endogenous sources (e.g. intracellular glycogen). A range of 
stimuli, including adrenergic stimulation, intense exercise, ischemia and a low level of 
myocardial ATP may stimulate glycogenolysis (Figure 2.3) (Goldfarb et al., 1986; Hue 
et al., 1995; Stanley et al., 1997a). The myocardial glycogen pool is, however, 
relatively small compared to that of skeletal muscle, while the rate of its turnover is 
also high (Bøtker et al., 1994; Stanley et al., 1992). Intracellular glycogen 
concentrations are kept constant via replenishment by extracellular substrates or 
periods of hyperinsulinemia (Figure 2.3) (Henning et al., 1996). Dietary 
carbohydrates contribute largely to elevated glucose availability, and glucose 
becomes the primary fuel substrate in the myocardium in the fed state.  
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Figure 2.3 Sources of glucose and regulation of glycogen storage and breakdown. 
Glycogenolysis is stimulated by hyperinsulinemia and exogenous fuel substrates, and inhibited by 
adrenergic stimulation, low ATP levels, ischemia and intense exercise.  ATP: adenosine triphosphate; 
GLUT: glucose transporter. 
 
2.2.2.1. Glucose transporter proteins 
 
Cardiomyocyte glucose uptake is dependent on its extracellular concentration, as 
well as the number, distribution and activity of glucose transporter proteins (Luiken et 
al., 2004; Mueckler, 1994; Young et al., 2000). Glucose metabolic flux is regulated at 
different steps, including uptake, glycolysis and pyruvate decarboxylation (An and 
Rodrigues, 2006). The metabolism of any nutrient substrate is, however, decidedly 
dependent on its uptake. Glucose is taken up into cardiomyocytes by facilitated 
diffusion via glucose transport proteins in the sarcolemma. The major role players in 
glucose uptake are the glucose transporters (GLUTs) – a family of 50 kDa proteins 
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with twelve membrane spanning domains and six extracellular loops (Figure 2.4) 
(Huang and Czech, 2007; Mueckler, 1994).  
 
 
 
Figure 2.4 Schematic depictions of GLUT transporter proteins. GLUT transporters contain twelve 
membrane-spanning domains (indicated by the solid black bars) and six extracellular loops (indicated 
by the solid lines). The first exofacial loop is often used as a site for epitope labeling. COOH: carboxy-
terminal; NH2: amino-terminal. 
 
A number of GLUT isoforms have been identified in cardiomyocytes. In the adult 
heart, GLUT1 and GLUT4 are responsible for the majority of glucose uptake. GLUT4 
is the more abundant transporter, with the ratio of GLUT1/GLUT4 varying between 
0.1 and 0.6 (Kraegen et al., 1993). GLUT3 is highly expressed in the fetal heart, with 
expression levels peaking at embryonic day 15 (Santalucía et al., 1999). However, its 
expression levels decline in the adult heart, pointing toward a possible role in cardiac 
development (Shepherd et al., 1992). GLUT12 shares similar di-leucine motifs with 
that of GLUT4, with 29% sequence homology between the two proteins (reviewed in 
Abel, 2004). It is also expressed in adipose tissue and skeletal muscle, while its 
mRNA expression is high within the human heart (Rogers et al., 2002). GLUT11 is 
present in cardiac and skeletal muscle, and is mainly located at the sarcolemma (Wu 
et al., 2002). It is homologous to the fructose transporter, GLUT5, however its 
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glucose uptake function is not inhibited by fructose, pointing toward a possible dual 
role for glucose and fructose transport (Doege et al., 2001; Wu et al., 2002). GLUT8 
may also be present in the myocardium, but together with GLUTs 5, 11 and 12, their 
function and prominence remains to be elucidated (Dawson et al., 2001; Doege et 
al., 2000). The sodium-glucose co-transporter (SGLT1) have recently been identified 
in the heart and may play a role in glucose uptake, however, the precise mechanisms 
involved need further elucidation (Balteau et al., 2011).  
 
Basal glucose uptake is primarily carried out via GLUT1, which is mainly present at 
the sarcolemma (Brosius et al., 1997; Buchanan et al., 2005). Insulin may play an 
important role in GLUT1 expression. This is evident in cardiomyocytes with deletion 
of the insulin receptor, where GLUT1 expression and basal glucose uptake was 
reduced (Belke et al., 2002). GLUT4 is considered the most important regulator of 
myocardial glucose uptake. Indeed transgenic GLUT4+/- mice displayed decreased 
GLUT4 protein levels and whole body insulin resistance (reviewed in Huang and 
Czech, 2007; Li et al., 2000; Rossetti et al., 1997). These effects were reversed by 
GLUT4 overexpression in the same model (Tsao et al., 1999). Furthermore, GLUT4 
whole body or cardiac-specific knockout, or transgenic animals developed 
deleterious cardiometabolic and functional derangements, including dysregulated 
energy metabolism, contractile dysfunction, hypertrophy and excessive ischemic 
damage (reviewed in Abel, 2004).    
 
GLUT4 is stored in intracellular vesicles, termed GLUT4 storage vesicles (GSVs), 
around the perinuclear region in the basal state. Here GLUT4 is co-localized with 
insulin-regulated aminopeptidase (IRAP) in the same vesicles, residing in the 
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tubulovesicular structures (Hanpeter and James, 1985). This resembles GSVs from 
adipocytes and skeletal myocytes where GLUT4 and IRAP contained in the same 
GSVs possess similar di-leucine and acidic motifs in the carboxy- and amino 
terminals, features believed to play important roles in the kinetic aspects of GSV 
endocytosis and exocytosis (reviewed in Huang and Czech, 2007). Although it 
continuously cycles to and from the sarcolemma and T-tubules, only about 3 to 10% 
of GLUT4 is present at the sarcolemma with about 90% stored in GSVs in the basal 
state (Ishiki and Klip, 2005). Following a rise in extracellular glucose concentrations, 
insulin is secreted from the pancreas, travels to target cells and triggers greater 
mobilization of GSVs to the sarcolemma and T-tubules. This results in a significant 
increase in sarcolemmal GLUT4 content and subsequent uptake of glucose. 
Although it is primarily located at the sarcolemma and plays a prominent role in basal 
glucose uptake, GLUT1 may also be part of an intracellular storage pool and 
increases at the sarcolemma in response to insulin stimulation. Indeed, insulin 
stimulation results in increased GLUT1 and GLUT4 at the sarcolemma, which could 
by reversed by wortmannin (a PI3K inhibitor), suggesting a role for the 
phosphoinositol-3-kinase (PI3K) signaling pathway in this process (Egert et al., 
1999). 
 
Similar to GSVs from adipocytes and skeletal muscle, cardiomyocyte GSVs contain 
the cellular machinery that governs their exocytosis, tethering, docking, fusion and 
endocytosis. These include v-snare protein cellubrevin/VAMP3 and the t-SNARE 
proteins SNAP25, syntaxin-1A and syntaxin-1B (Sevilla, 1997). Cardiomyocytes may 
contain two distinct pools of GLUT4. Pool 1, the large insulin responsive/storage pool 
mainly contains GLUT4 (reviewed in Abel, 2004). The second (endosomal) pool 
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consists of GLUT1, SCAMP39 and a small number of GLUT4. Insulin stimulation 
recruits all GLUT4 from pool 1 and all GLUT1 from pool 2, however, GLUT4 from 
pool 2 is only mobilized when the first insulin responsive pool is depleted. 
Furthermore, rotenone stimulates the recruitment of GLUT1 and GLUT4 from the 
endosomal pool, but not GLUT4 from the insulin responsive pool. Together, this 
suggests that a “reserve” of GLUT4 is stored in the endosomal pool, which may have 
migrated from the insulin responsive pool. Insulin withdrawal stimulates re-entry of 
GLUT1 and GLUT4 to their respective pools (Becker et al., 2001; Doenst et al., 2000; 
Kraegen et al., 1993). This ensures availability of transporters for rapid upregulation 
of glucose uptake. Although tethering, docking and fusion events at the sarcolemma 
are integral to glucose uptake, the activation and translocation of GSVs are the 
primary events. This involves movement upon cytoskeletal proteins, including 
microtubules and cortical actin (Bose et al., 2002; Semiz et al., 2003; Thurmond et 
al., 2003). Glucose uptake is terminated when GLUT4-containing GSVs are 
transported back to the site of storage via endocytosis. 
 
2.2.2.2. Insulin signaling mechanisms 
 
The anabolic hormone insulin promotes several cellular processes, including storage 
of nutrients from the circulation into various cell types (Koonen et al., 2005). Insulin 
initiates two main intracellular signaling pathways – the mitogen activated protein 
kinase (MAPK) pathway and PI3K pathway (Coort et al., 2007; Koonen et al., 2005; 
Watson and Pessin, 2001). While the MAPK pathway is mainly involved in the 
regulation of gene expression, the PI3K is an essential regulator of metabolism. 
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Inhibition or expression of dominant negative PI3K may reduce the effects of insulin 
on glucose uptake and glycogen and lipid synthesis (Shepherd et al., 1995).  
 
Insulin is secreted from pancreatic β-cells when blood glucose levels rise following a 
meal. Here, glucose is taken up into the β-cells by insulin-independent GLUT1, 
GLUT2 and GLUT3. The increased oxidative metabolism of glucose results in 
elevated ATP/ADP ratios, leading to closure of ATP-sensitive potassium (KATP) 
channels. This in turn results in opening of voltage-gated calcium (Ca2+) channels 
and a rapid influx of Ca2+, which in turn stimulates the fusion of insulin-containing 
granules with the plasma membrane, leading to insulin exocytosis (Kahn et al., 
2006). Cyclic AMP, FA and protein kinase C(PKC)–mediated pathways may also 
contribute to release of intracellular Ca2+ stores and a global rise in β-cell Ca2+ levels, 
with the subsequent release of insulin into the bloodstream. The major targets of 
insulin-mediated glucose uptake are skeletal muscle, adipose tissue, the liver and the 
heart. For the purposes of this thesis, we will focus on insulin action at the 
cardiomyocyte.  
 
Insulin signaling is initiated upon binding of the hormone with its receptor on the 
exofacial leaflet of the sarcolemma (Fig 2.5). The tetrameric insulin receptor consists 
of two extracellular α-subunits and two transmembrane β-subunits (Kasuga et al., 
1982). Upon binding, the receptor undergoes a conformational change that initiates 
the intrinsic tyrosine kinase activity of β-subunits. These events activate auto-
phosphorylation of the tyrosine residues of the β-subunits, as well as those of insulin 
receptor substrate-1 (IRS-1), the downstream target of the insulin receptor (Bertrand 
et al., 2008; Craparo et al., 1997; Hotamisligil et al., 1996). The activated IRS-1 
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subsequently binds to and activates PI3K. This is achieved by exposing and binding 
phospho-tyrosine binding sites on Src homology two (SH2) domains on adapter 
proteins or on the p85 regulatory subunit of PI3K directly (Wu et al., 2007). The p85 
regulatory subunit usually stabilizes and suppresses the catalytic activity of the p110 
subunit of PI3K in unstimulated cells. Activation of the p85 subunit upon stimulation 
activates the catalytic action of the p110 subunit. This results in the phosphorylation 
of the D3 inositol ring of plasma membrane lipids, notably phosphatidylinositol-4,5-
biphosphate (PIP2), generating phosphatidylinositol-3,4,5-triphosphate (PIP3) 
(Cantrell, 2001). These lipids are generated in the inner leaflet of the sarcolemma, 
resulting in pools of second messengers present at this site upon insulin stimulation. 
Additional signaling cascades may also activate PI3K via recruitment and 
transphosphorylation of adapter proteins and stimulation of integrin dependent cell 
adhesion (Cantley, 2002).  
 
The PIP3 lipid mediators are able to interact with plecstrin homology (PH) domain-
containing proteins which are specialized to bind phosphoinositides 
(Vanhaesebroeck et al., 2001). Many of these proteins, including protein kinase B 
(Akt) and 3-phosphoinositide-dependent kinase 1 (PDK1), associates with PIP3 at the 
sarcolemma. These PH-domain containing proteins have a high affinity for 
phosphatidylinositol lipid products, and therefore accumulate in close proximity to the 
sarcolemma upon insulin stimulation (Vanhaesebroeck et al., 2001). The 
serine/threonine kinase Akt (also known as protein kinase B or PKB) is an important 
effector of insulin signaling, with involvement in multiple cellular processes. These 
include cell survival, proliferation and growth, gene expression, angiogenesis and 
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metabolic regulation, among others. It is also a central effector of GLUT4 
translocation to the sarcolemma and the subsequent uptake of glucose. 
 
Activation of membrane-bound Akt is achieved through dual phosphorylation of 
serine 473 and threonine 308 residues by mammalian target of rapamycin (mTOR) in 
complex with rictor and SIN1 (also known as rictor-mTORC2) and PDK1, respectively 
(Sarbassov et al., 2005). Both phosphorylation events are believed to be necessary 
for full activation of Akt. Rictor-mTORC2 and Akt are both recruited to the 
sarcolemma following PI3K-mediated PIP3 formation, where they bind via their PH 
domains. As they are localized in close proximity, the rictor-mTORC2 phosphorylates 
Akt on the serine 473 residue of its C-terminal regulatory domain (Sarbassov et al., 
2005). Next, PDK1 phosphorylates the threonine 308 residue in the activation loop of 
the kinase domain, leading to complete activation of Akt (Stephens et al., 1998). The 
distal signaling events involving Akt are diverse, with a number of Akt substrates 
involved. The phosphorylation of glycogen synthase kinase (GSK3β) is among one of 
the substrates, promoting glycogen storage (Elchebly et al., 1999; Stanley et al., 
1997a; Steinbusch et al., 2011).      
 
The recently identified Rab GTPase-activating protein (RabGAP) called Akt substrate 
of 160 kD (AS160, also known as TBC1D4), is believed to be directly involved in the 
mobilization of GSVs (Kane et al., 2002; Sano et al., 2003). Data generated thus far 
indicate that active (i.e. unphosphorylated) AS160 associates with GSVs and thereby 
keeps it immobilized in the basal condition, while insulin results in its phosphorylation 
and inhibition, leading to its dissociation from the GSV and dimerization with 14-3-3 
proteins (Larance et al., 2005; Peck et al., 2006) (Fig 2.5). Phosphorylation occurs on 
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six sites in vivo, of which five are identical to the Akt substrate sequence. Cells 
expressing mutant AS160 lacking the Akt-specific phosphorylation sites inhibits 
insulin-mediated GLUT4 translocation, suggesting it acts as a negative regulator 
which is inactivated by insulin (Larance et al., 2005; Peck et al., 2006; Sano et al., 
2003). These studies therefore show that decreased Akt activity would also attenuate 
AS160 function, resulting in reduced GLUT4 translocation and glucose uptake. In 
vitro experiments show that AS160 catalyzes the inactivation of Rab proteins 2A, 8A, 
10 and 14. Here the Rab proteins are inactivated by GDP binding (Fig 2.5). These 
Rab proteins are important regulators of intracellular vesicle trafficking (Zerial and 
McBride, 2001). Hence, the Akt-mediated phosphorylation of AS160 leads to its 
inactivation, thereby increasing the amount of active (GTP-bound) Rab proteins 
which in turn facilitates the mobilization of GSVs (refer red arrows in Fig 2.5).  AS160 
can also bind to IRAP, however, it is not clear whether this interaction is Akt-
dependent  (Larance et al., 2005; Peck et al., 2006). The interaction of AS160 with 
14-3-3 proteins may be dependent on phosphorylation at threonine 642 (Ramm et 
al., 2006). RNAi knockdown studies suggest that AS160 plays a role in GLUT4 
mobilization to the sarcolemma, but not in its endocytosis (Eguez et al., 2005; 
Larance et al., 2005; Zeigerer et al., 2004). Although insulin-stimulated AS160 
phosphorylation is decreased by ~39% in skeletal muscle of diabetic patients 
(Karlsson et al., 2005), overall myocyte GLUT4 translocation is reduced by ~90% 
(Ryder et al., 2000). This may suggest that additional mechanisms are also impaired 
in diabetes.    
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Figure 2.5  Insulin signaling and GLUT4 translocation. Insulin exerts a cascade of phosphorylation 
events upon binding to the insulin receptor. These phosphorylation events recruit PI3K and Akt to the 
sarcolemma, leading to its activation. Akt is a central mediator of insulin action, and inactivates AS160 
by phosphorylation, followed by binding to 14-3-3 proteins. This leads to upregulation of active (GTP-
bound) Rab proteins, which stimulates GSV mobilization. Akt: protein kinase B; AS160; Akt substrate 
of 160 kDa; GLUT4: glucose transporter 4; GSV; GLUT4 storage vesicle; IR: insulin receptor;  IRS-1; 
insulin receptor substrate-1; mTOR; mammalian target of rapamycin; PI3K: phosphatidyl inositol-3 
kinase; PIP2: phosphoinositide-3,4-diphosphate; PIP3: phosphoinositide-3,4,5-triphosphate; PDK-1; 3-
phosphoinositide-dependent kinase-1.  
 
Termination of insulin signaling and glucose uptake can be mediated by endocytosis 
and degradation processes, as well as inhibitory phosphorylation events. De-
phosphorylation of the insulin receptor and IRS-1 tyrosine residues is regulated by 
tyrosine phosphatases (PTPases). Protein tyrosine phosphatase 1B (PTP1B) has 
been identified to play a role, as transgenic mice lacking PTP1B showed prolonged 
insulin receptor and IRS-1 phosphorylation accompanied by higher insulin sensitivity 
(Elchebly et al., 1999). Furthermore, serine/threonine kinases may attenuate the 
activity of the insulin receptor by interfering with tyrosine phosphorylation (Craparo et 
al., 1997; Hotamisligil et al., 1996). These inhibitory phosphorylation processes act 
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as negative feedback systems to insulin action, but may also be involved in 
attenuated signaling processes giving rise to insulin resistance (Saltiel and Kahn, 
2001).  
 
Signaling mechanisms in addition to the PI3K-Akt-AS160 axis have also been 
implicated in the translocation of GLUT4. The downstream activation of atypical PKC 
λ/ζ by PI3K is implicated in exerting insulin-mediated GLUT4 translocation 
(Bandyopadhyay et al., 2002). However, the precise mechanisms involved and 
importance toward contributing to glucose uptake remain to be elucidated. A novel 
signaling pathway involving CAP/Cbl/TC10 may also exert GLUT4 translocation 
independent of and in concert with PI3K, downstream of IR tyrosine phosphorylation 
(Chiang et al., 2001). Contraction of skeletal muscle is an important regulator of 
GLUT4 translocation and glucose uptake, independent of insulin action (Nesher et 
al., 1985; Zorzano et al., 1986).  
 
Although this mechanism is difficult to determine in the heart due to its continuous 
contraction, some studies suggest it may play a role. For example, in vivo working 
heart experiments using mice with cardiomyocyte ablation of the IR showed a ~2-fold 
increase in GLUT4 levels and glucose uptake, despite decreased GLUT1 levels 
(Belke et al., 2002). Overexpression of GLUT4 in transgenic mice showed an 
increase in glycolysis in working heart preparations (Belke et al., 2001). Furthermore, 
field stimulation (in vitro contraction) of cardiomyocytes resulted in increased GLUT4 
translocation and glucose uptake in the absence of insulin (Kolter et al., 1992). This 
effect could be reversed by wortmannin treatment, contrasting findings to that in 
skeletal muscle (Wheeler et al., 1994). As in skeletal muscle, contraction-mediated 
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GLUT4 translocation may be exerted via adenosine monophosphate protein kinase 
(AMPK) activation. Indeed, increased myocardial workload is associated with greater 
AMPK activity and GLUT4 translocation (Coven et al., 2003). Here, higher 
intracellular Ca2+ concentrations and an increase in the AMP/ATP ratio may activate 
upstream kinases leading to AMPK activation, e.g. LKB-1 (reviewed in Huang and 
Czech, 2007). Myocardial ischemia may also upregulate GLUT1 and GLUT4 
translocation by activation of AMPK (Egert et al., 1999; Fuller et al., 2001). Indeed, 
AICAR (a pharmacological activator of AMPK) increased GLUT4 translocation via 
PI3K independent mechanisms, while inhibition of AMPK decreased hypoxia-induced 
GLUT4 translocation and glucose uptake (Russell et al., 1999). Furthermore, 
transgenic mice with AMPK inactivation were more prone to ischemic injury (Xing et 
al., 2003). To summarize, glucose uptake is governed by multiple intracellular 
mechanisms, however insulin stimulated GLUT4 translocation represents the most 
prominent means of glucose transport.  
 
2.2.2.3. Physiological regulation of glucose uptake 
 
The regulation of glucose uptake is an important mechanism to control myocardial 
substrate usage. Elevated availability of various alternative substrates inhibits GLUT4 
translocation and glucose uptake at the cardiomyocyte, e.g. high citrate and malate 
levels in response to increased metabolic flux from alternative fuel sources may 
negatively regulate cardiac glucose uptake (independent to the regulation of PDH) 
(Beauloye et al., 2002). Long-chain FA, e.g. palmitate, resulted in the reduction of 
GLUT1 and GLUT4 at the sarcolemma (Wheeler et al., 1994). The metabolism of 
lipids, amino acids and ketone bodies have also been associated with reduced 
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GLUT4 translocation (Tardif et al., 2001; Terruzzi et al., 2002). Additionally GLUT4 
translocation may be promoted by α-lipoic acid, serotonin, bradykinin, endothelin-1, 
lactate and the intracellular pH, while cGMP impairs its translocation to the 
sarcolemma (Bergemann et al., 2001; Dransfeld et al., 2002; Fischer et al., 1995; 
Medina et al., 2002; Morin et al., 2002; Ramrath et al., 1999; Rett et al., 1997, 1996; 
Wu-Wong et al., 2000; Yang et al., 2002). The information summarized here 
highlights the physiological mechanisms and regulation of myocardial glucose 
uptake. The next section reviews the fate of glucose upon entering cells under 
physiological conditions.     
 
2.2.3. Glycolysis 
 
Upon entry of glucose into the cell, it is rapidly phosphorylated to glucose-6-
phosphate and enters the glycolytic pathway. Glycolysis is also the major metabolic 
pathway utilized within conditions of low oxygen availability (e.g. during ischemia). 
Exogenous glucose supply and glycogen stores are the major sources of glycolytic 
substrates. The rapid phosphorylation of glucose by hexokinase-2 produces glucose-
6-phosphate(G-6-P), rendering it impermeable to the sarcolemma and hence 
trapping it inside the cell (Bouché et al., 2004). Next, isomerase converts G-6-P to 
fructose-6-phosphate(F-6-P), followed by the phosphofructokinase-1 (PFK-1) 
reaction, resulting in the production of fructose-1,6-bisphosphate (F-1,6-BP). The 
hexokinase-2 and PFK-1 reactions each utilize one molecule of ATP. The myocardial 
glycolytic rate is controlled by several steps, including glucose uptake, its 
phosphorylation, and the PFK-1 catalyzed reaction (Rider et al., 2004). PFK-1 is 
regulated by several stimuli. Here low pH, citrate, and ATP inhibits the enzyme, while 
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ADP, AMP, phosphate and fructose-2,6-bisphosphate(F-2,6-BP) stimulates its 
activity (Depre et al., 1999; Rider et al., 2004). Phosphofructokinase-2 (PFK-2) 
catalyzes the conversion of F-1,6-BP  to F-2,6-BP  (Hue and Rider, 1987). PFK-2 
activity may alternatively be upregulated by PKC, protein kinase A (PKA) and PI3K 
(An and Rodrigues, 2006; Depre et al., 1998; Marsin et al., 2000). These stimulatory 
mechanisms lead to increased F-2,6-BP generation, which subsequently activates 
PFK-1 and promotes glycolysis. 
 
The next step in glycolysis involves the splitting of the six-carbon F-1,6-BP into two 
triose phosphates, namely dihydroxy-acetone phosphate (DHAP) and 
glyceraldehyde-3-phosphate (G-3-P) in a reaction catalyzed by aldolase. Triose 
phosphate isomerase catalyzes the inter-conversion of DHAP and G-3-P; however 
G-3-P is rapidly utilized in the subsequent glycolytic reactions. It is converted to 1,3-
bisphosphoglycerate(1.3-BPG) by glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). This is another regulatory step in glycolytic flux, and the regulation of 
GAPDH activity under increased nutrient conditions is an important factor. The 
GAPDH reaction results in the transfer of H+ of NAD+ molecules that results in the 
production of NADH. Next, phosphoglycerokinase transfers a phosphate from 1,3-
BPG to ADP, forming ATP. As there are two molecules of 1,3-BPG, the net result of 
the reaction is two ATP and two 3-phosphoglycerate molecules. The enzyme 
phosphoglyceromutase relocates the phosphate from the third to the second carbon 
of 3-phosphoglycerate. The resulting 2-phosphoglycerate is then converted to 
phosphoenolpyruvate (PEP) by enolase. In the final step, PEP is converted to 
pyruvate by pyruvate kinase, a reaction that yields a further two ATP molecules. The 
main reactions and regulatory mechanisms of glycolysis are depicted in Figure 2.6. 
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Figure 2.6 Reactions and regulation of glycolysis. Intracellular glucose (taken up from exogenous 
sources or from glycogen breakdown) is metabolized to pyruvate in a series of glycolytic steps.  The 
reactions catalyzed by PFK-1 and GAPDH are regulated by various stimuli. AMPK: adenosine 
monophosphate (AMP) activated kinase; 1,3-BPG: 1,3-bisphosphoglycerate; DHAP: dihidroxy acetone 
phosphate; F-6-P: fructose-6-phosphate; F-1,6-BP: fructose-1,6-bisposphate; F-2,6-BP: fructose-2,6-
bisphosphate; G-6-P: glucose-6-phosphate; G-3-P: glyceraldehyde-3-phosphate; LDH: lactate 
dehydrogenase; PFK-1: phosphofructokinase-1; PFK-2: phosphofructokinase-2; PDH: pyruvate 
dehydrogenase; PKC: protein kinase C; PKA; protein kinase A; PI3K: phosphoinositide-3-kinase TIM: 
triose phosphate isomerase. 
 
The net result of glycolytic flux yields two ATPs per glucose molecule under oxygen 
rich conditions, contributing to ~10% of total myocardial ATP production (Opie and 
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Knuuti, 2009). Glycolytic-derived ATP may play an important role in the maintenance 
of ion pumps, including sarcoplasmic reticulum ATPases (Hasin and Barry, 1984; 
Opie and Knuuti, 2009). This is highlighted by studies showing that glycolytic ATP 
may enhance sarcoplasmic calcium re-uptake and enhance diastolic relaxation in 
isolated heart tissues (Hasin and Barry, 1984; Jeremy et al., 1992; Kusuoka and 
Marban, 1994; Schönekess et al., 1995; Weiss and Hiltbrand, 1985). Furthermore, 
glycolytic ATP may inhibit cardiac ATP-sensitive potassium channels, while it is 
important for optimal function of the Na+/K+ ATPase to prevent Na+ accumulation 
(Weiss and Lamp, 1989). 
 
Glycolysis yields NADH and pyruvate, which can subsequently be shuttled into the 
mitochondrial matrix where these products can be further utilized for energy 
production via oxidative metabolic processes. When oxygen is limiting, pyruvate is 
converted to lactate by lactate dehydrogenase with the oxidation of NADH to NAD+. 
Lactate is taken up into the myocardium via the monocarboxylic acid transporter-1 
(MCT-1). With tightly regulated energy metabolism and myocardial work in the 
healthy heart, the cardiomyocyte utilizes lactate as a substrate (Kaijser and Berglund, 
1992; Massie et al., 1995; Stanley, 1991).  However, with impaired pyruvate 
oxidation and accelerated glycolysis it becomes a net producer of lactate, e.g. during 
ischemia or diabetes (Avogaro et al., 1990; Hall et al., 1996b; Stanley et al., 1997a).  
 
Upon entering the mitochondrial matrix, pyruvate may be decarboxylated to form 
acetyl-CoA or carboxylated to form oxaloacetate or malate. This anaplerotic reaction 
leads to maintenance of citric acid cycle intermediates (Comte et al., 1997; England 
and Robinson, 1969; Gibala et al., 2000; Paradies et al., 2001; Vincent et al., 2004). 
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The pyruvate dehydrogenase (PDH) complex located in the mitochondrial matrix is a 
key mediator of glucose metabolism, coupling glycolysis to oxidative phosphorylation 
by the irreversible conversion of pyruvate to acetyl-CoA (Randle, 1986). The enzyme 
complex consists of pyruvate decarboxylase, dihydrolipoyl transacetylase, 
dihydrolipoyl dehydrogenase and the co-factors thiamine pyrophosphate, lipoic acid, 
co-enzyme A, flavin adenine dinucleotide (FAD) and nicotinamide adenine 
dinucleotide (NAD) (reviewed in Taegtmeyer, 1994).  
 
PDH is regulated by various mechanisms. Phosphorylation on the E1 subunit by 
PDH kinase-4 (PDK-4) inactivates the enzyme complex (Randle and Priesman, 
1996). PDK-4 is the major PDK isoform in the heart and its expression and activity 
may be rapidly regulated by fasting, diabetes and ligands of the peroxisome 
proliferator-activated receptor-α (PPAR-α), a key FA transcriptional regulator 
(Bowker-Kinley et al., 1998; Harris et al., 2001; Wu et al., 2001). Pyruvate itself 
together with decreases in acetyl-CoA/CoA and NADH/NAD+ ratios, also inhibit PDK-
4 (Bowker-Kinley et al., 1998; Holness and Sugden, 2003). The inhibition of PDH by 
increased FA metabolism (the Randle cycle) is another regulatory mechanism 
whereby FA oxidation inhibits glucose metabolism. This is discussed in Section 2.2.6. 
Activation of PDH occurs via de-phosphorylation by a PDH phosphatase contained 
within the PDH complex (Panchal et al., 2000). The PDH phosphatase activity is in 
turn increased by elevated Ca2+ and Mg2+ levels as occurs during adrenergic 
stimulation of the myocardium (McCormack and Denton, 1989, 1984; McCormack et 
al., 1990). The regulation of PDH is described in Figure 2.7 below.       
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Figure 2.7 Regulation of the pyruvate dehydrogenase complex. PDH facilitates the conversion of 
pyruvate to acetyl-CoA in the mitochondria. PDH activity is controlled by 
phosphorylation/dephosphorylation events via PDK-4 and PDH phosphatase. These enzymes are in 
turn regulated by various stimuli. PDH activity is also directly inhibited by acetyl-CoA and NADH.  
ADP: adenosine diphosphate; ATP: adenosine triphosphate; Ca
2+
: calcium; CoA: co-enzyme A; FA: 
fatty acid: LDH: lactate dehydrogenase; Mg
2+
: magnesium; NAD
+
: nicotinamide adenine dinucleotide 
oxidized; NADH: nicotinamide adenine dinucleotide reduced; PDH: pyruvate dehydrogenase. 
 
 
2.2.4. Fatty acid uptake and fate 
 
Cardiomyocyte FA uptake is mainly dependent on the concentration of plasma FAs 
(Bing et al., 1954; Lopaschuk et al., 1994a; Wisneski et al., 1987). FAs travel through 
the circulation as part of chylomicrons, bound to albumin or esterified in very low 
density lipoproteins (VLDLs) (Spector, 1984; Stremmel et al., 1985). The 
concentration of FAs may increase by up to 5-fold during ischemia or in diabetes 
(Kurth-Kraczek et al., 1999; Stanley et al., 2005). FAs are released from storage 
during the fasted state, leading to elevated plasma levels, uptake and metabolism. 
Esterified FAs must be hydrolyzed by lipoprotein lipase, while those bound to 
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albumin can freely dissociate. FAs are mainly transported into cardiomyocytes with 
the aid of membrane transport proteins, although a small proportion is taken up by 
passive diffusion (Stahl et al., 2002). Transporter-mediated FA uptake is regulated 
via fatty acid translocase (FAT), plasma membrane fatty acid binding protein 
(FABPpm) and fatty acid transport proteins (FATP-1 and FATP-6) (Coburn et al., 
2001; Coort et al., 2007; Glatz et al., 2002; Luiken et al., 2001; Stahl et al., 2001; 
Stanley et al., 2005). The 88 kDa protein CD36 is the predominant FAT protein 
expressed in the heart, while FATP-6 is more abundant than FATP-1 in 
cardiomyocytes (Gimeno et al., 2003; Schaap et al., 1997). FATP co-localizes with 
CD36 at the sarcolemma and they are considered to act in concert to achieve FA 
uptake (Gimeno et al., 2003). During uptake, FFA bind to FABPpm and are 
subsequently esterified to fatty acyl-CoA by fatty acyl-CoA synthase (FACS). CD36-
associated FABP and FACS proteins may also be present in the cytoplasm, rapidly 
converting intracellular FFAs to fatty acyl-CoA (Schaffer, 2002). Insulin may increase 
the expression of CD36 and FATP (Egert et al., 1999; Gimeno et al., 2003; Kurth-
Kraczek et al., 1999; Stahl et al., 2001). Additionally, CD36 may be located in 
intracellular storage vesicles and transported to the sarcolemma (similar to GLUT4), 
upon stimulation by insulin, increased energy demand or in response to contraction 
(Glatz et al., 2002; Luiken et al., 2001, 2003, 2004). These mechanisms are, 
however, not clear in the in vivo setting and warrants further investigation.  
 
After uptake and esterification, fatty acyl-CoA may be utilized for metabolic 
conversion to ATP, for triglyceride synthesis or for incorporation into the intracellular 
lipid pool. Acyl-CoAs are transported across the outer mitochondrial membrane via 
CPT-1, forming fatty acylcarnitine in the intermembrane space. Indeed, studies using 
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radiolabeled oleate or palmitate suggest that (in the normal heart), 70 to 90% of FAs 
taken up are converted to acylcarnitine, while 10 to 30% are used for triglyceride 
storage (Lopaschuk et al., 1994a; Saddik and Lopaschuk, 1992, 1991). CPT-1 is a 
key regulator of mitochondrial acylcarnitine uptake. The transporter itself is negatively 
regulated by malonyl-CoA, which is formed from the carboxylation of acetyl-CoA in a 
reaction catalyzed by acetyl-CoA carboxylase (ACC) (Goodwin and Taegtmeyer, 
1999; Hall et al., 1996a, 1996b; Kudo et al., 1995; Ruderman et al., 1999; Saddik et 
al., 1993; Thampy, 1989). The amount of malonyl-CoA, and by extension the activity 
of CPT-1, is regulated by AMPK and the activities of ACC and malonyl-CoA 
decarboxylase (MCD). Here AMPK inhibits ACC activity driving the conversion of 
acetyl-CoA to malonyl-CoA resulting in the inhibition of CPT-1 and increased uptake 
of acyl-CoA into the mitochondria. MCD catalyzes the reverse reaction, i.e. 
conversion of malonyl-CoA to acetyl-CoA. Its inhibition would therefore increase 
malonyl-CoA and prolong CPT-I inhibition.  
 
Acylcarnitine formed within the intermembrane space is transported across the inner 
mitochondrial membrane via carnitine acyl translocase (CAT), which exchanges 
acylcarnitine for free carnitine. Carnitine palmatoyl transferase-II (CPT-II) regenerates 
fatty acyl-CoA by transferring the acyl groups from acylcarnitine to free CoA, thereby 
replenishing carnitine that is shuttled back to the intermembrane space via CAT 
(Kerner and Hoppel, 2000; Lopaschuk et al., 1994b; Schulz, 1994). Both CPT-II and 
CAT are located in the inner mitochondrial membrane. Upon entering the 
mitochondrial lumen, fatty acyl CoA is subjected to β-oxidation. This process involves 
repeated cleavage of two-carbon acetyl-CoA units, producing NADH and FADH2. The 
final reaction catalyzed by 3-ketoacyl-CoA thiolase (3-KAT), regenerates acyl-CoA 
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that enters another round of β-oxidation, and releases acetyl-CoA for the citric acid 
cycle. NADH is formed by 3-hydroxyacyl-CoA dehydrogenase and FADH2 by acyl-
CoA dehydrogenase. FA uptake and utilization is outlined in Figure 2.8. 
 
 
 
 
Figure 2.8 Fatty acid uptake and metabolism. FAs are transported into cells via transporter proteins 
and are converted into fatty acyl-CoA in the cytosol. Transport into the mitochondria is facilitated via 
CPT-1 (which is inhibited by malonyl-CoA) across the outer mitochondrial membrane. Fatty acyl-
carnitine is formed in the inter-membrane space and transport across the inner membrane is facilitate 
by CPT-II. CAT plays a role here by removing and recycling the carnitine groups. Once in the matrix, 
fatty acyl-CoAs are utilized for β-oxidation. ACC: acetyl-CoA carboxylase; CAT: carnitine 
acyltransferase; CoA: co-enzyme A; CPT: carnitine palmatoyl transferase; FAs: fatty acids; FABPpm: 
plasma membrane fatty acid binding protein; FACS: fatty acyl-CoA synthase; FADH2: flavin adenine 
dinucleotide reduced: FAT/CD36: fatty acid translocase; FATP: fatty acid transport protein; LPL: 
lipoprotein lipase; MCD: malonyl-CoA decarboxylase; NADH: nicotinamide adenine dinucleotide 
reduced. 
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2.2.5. Mitochondrial energetics 
 
Mitochondria are the major sites of ATP production in cells, hence it is often referred 
to as the “powerhouses” of the cell. These organelles possess tightly regulated and 
dynamic pathways and processes that facilitate the conversion of energy-rich 
substrates into electrons and, finally, ATP. Mitochondria are equipped with its own 
genome which supplies the necessary enzymes and regulatory proteins needed to 
operate efficient, “factory-like” work. Cardiomyocytes are enriched with mitochondria 
to maintain ATP levels. Mitochondria may in fact make up ~25 to 35% of total 
cardiomyocyte volume (Dobson and Himmelreich, 2002), and exist in two sub-
populations, i.e. intramyofibrillar mitochondria (IFM) and subsarcolemmal 
mitochiondria (SSM) (Palmer et al., 1977). There are distinctive differences between 
the two sub-populations including structure of the cristae, respiration rates and 
expression patterns of metabolic proteins (Palmer et al., 1977; Roden et al., 1996). 
Both sub-populations supply energy for the maintenance of both ATP-dependent 
processes and of ion balance (Ishiki and Klip, 2005). The citric acid cycle and the 
electron transport chain (ETC) operate in tandem to turn metabolic substrates into 
energy. After converting acetyl-CoA (generated from glycolysis, lactate oxidation and 
FA β-oxidation) to reducing equivalents in the citric acid cycle, the electron transport 
chain uses the reducing equivalents to produce ATP. NADH derived from glycolysis 
enters the mitochondrion via the malate-aspartate shuttle, where aspartate is 
exchanged for malate (Kavazis et al., 2009). The reactions occurring in the 
machinery of the mitochondria (the citric acid cycle and electron transport chain) will 
now be explained in detail below. 
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2.2.5.1. Citric acid cycle 
 
The citric acid cycle (also known as the tricarboxylic acid cycle or Krebs cycle) is the 
first processing point for myocardial mitochondrial energy metabolism (Figure 2.9). 
The major products of the cycle include NADH, FADH2 and GTP, which are used as 
electron donors to form ATP. The cycle is fueled by acetyl-CoA produced by 
upstream metabolism of carbohydrates, FAs and to a lesser extent, proteins (Gibala 
et al., 2000; Neely et al., 1972). Malate, 2-oxoglutarate, succinyl-CoA, oxaloacetate 
and fumerate are involved in anaplerotic reactions to replenish cycle intermediates 
(Gibala et al., 2000; Russell and Taegtmeyer, 1991; Taegtmeyer et al., 1980). The α-
ketoglutarate dehydrogenase reaction converts α-ketoglutarate to succinyl-CoA, with 
the formation of NADH and CO2. The NADH produced here is crucial for oxidative 
phosphorylation (Cooney et al., 1981; Humphries and Szweda, 1998; Moreno-
Sánchez et al., 1990). The enzyme is highly regulated by the ATP/ADP and 
NADH/NAD+ ratios, calcium and substrate availability, and requires thiamine 
pyrophosphate as a co-factor. It may be a key regulatory point of control of citric acid 
cycle flux (Garland, 1964; Johnson and Hansford, 1975; Taegtmeyer et al., 1980; 
Tretter and Adam-Vizi, 2000). The NADH and FADH2 produced in the citric acid cycle 
are shifted to the electron transport chain, which is in close proximity in the inner 
mitochondrial membrane (Humphries and Szweda, 1998; Kerner and Hoppel, 2000). 
The cycle can thus be described as a metabolic link between the upstream 
breakdown of fuel substrates and downstream conversion of this fuel into energy. It 
thereby acts as an important cog in the chain of events governing energy 
metabolism. 
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Figure 2.9 Reactions of the citric acid cycle. The acetyl group of acetyl-CoA is transferred to 
oxaloacetate in the initial reaction, generating citrate. The 6-carbon citrate is subsequently subjected 
to decarboxylation and oxidative reactions to generate the 4-carbon compound, malate, in a cyclic 
series of reactions. CoA: co-enzyme A; FADH2: flavin adenine dinucleotide reduced; FFA: free fatty 
acids; GDP: guanidine diphosphate; GTP: guanidine triphosphate; LDH: lactate dehydrogenase; PDH: 
pyruvate dehydrogenase. 
 
 
2.2.5.2. Electron transport chain and oxidative phosphorylation 
 
The electron transport chain is composed of protein complexes in the inner 
mitochondrial membrane. The multi-unit complexes I, II, III and IV along with ATP 
synthase (complex V) transfers electrons provided by high-energy donors (reducing 
equivalents NADH and FADH2) to molecular oxygen, with the formation of ATP and 
water (Figure 2.10). The entry point for electrons is NADH:ubiquinone 
oxidoreductase (complex I), a large multimeric protein complex consisting of at least 
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45 subunits (Carroll et al., 2005, 2002; Cecchini, 2003).  This complex catalyzes the 
transfer of electrons from NADH to ubiquinol (Q) via a series of redox centers, 
including a flavin moiety, seven to nine iron-sulfur clusters, and up to three 
ubisemiquinone species (Friedrich and Scheide, 2000; Koopman et al., 2005; 
Ohnishi, 1998; Yano et al., 2000). Four protons are translocated across the inner 
mitochondrial membrane, coupled to electron transfer in a process that conserves 
energy. The complex I reaction therefore contributes to the proton motive force 
required for ATP synthesis, maintaining the NAD+:NADH ratio in the matrix and 
providing ubiquinol to complex III (Hirst, 2005).  The phospholipid cardiolipin may be 
essential for optimal functioning of complexes, specifically that of complex I (Dröse et 
al., 2002; Fry and Green, 1981; Paradies et al., 2001; Ragan, 1978; Robinson, 1993; 
Schlame et al., 2000).  
 
The multi-faceted succinate dehydrogenase (complex II, also known as 
succinate:ubiquinone oxidoreductase) contributes to the citric acid cycle and electron 
transport chain. The reduction of ubiquinone occurs in the inner mitochondrial 
membrane after complex II couples the oxidation of succinate to fumerate in the 
matrix (Cecchini et al., 2002; Yankovskaya, 2003). Complexes I and II produces 
ubiquinol, which is oxidized by complex III (ubiquinol:cytochrome c oxidoreductase, 
also known as the cytochrome bc1 complex). Here, the electrons from ubiquinol are 
transferred to cytochrome c, developing the proton motive Q cycle (Cecchini, 2003). 
Electrons from complexes I and III fuel the Q-cycle, while cytochrome b (a complex III 
subunit) transfers electrons to complex IV (di Rago et al., 1990). Cytochrome c is a 
mobile electron carrier located between complexes II and IV (Gupte and 
Hackenbrock, 1988). The thirteen subunit complex IV generates a proton gradient 
Stellenbosch University  http://scholar.sun.ac.za
56 
 
and ultimately reduces oxygen to two water molecules (Belevich et al., 2006; 
Cecchini, 2003; Gupte and Hackenbrock, 1988; Ludwig et al., 2001; Saraste, 1999; 
Yoshikawa, 2003; Yoshikawa et al., 2006). ATP synthase (complex V or the F1F0 
ATPase) forms the final component of the electron transport chain. The enzyme 
complex pumps protons against the electrochemical gradient, generating ATP in the 
process (Cecchini, 2003).  
    
 
 
Figure 2.10 Electron transport chain. 
 
 
2.2.6. The regulatory link for metabolic substrate switching – the Randle cycle 
 
Metabolic substrate regulation, i.e. the preference between carbohydrate or FA 
metabolism, involves interlinked mechanisms. The preference of cardiomyocytes for 
FA oxidation may be explained by these mechanisms. Here, elevated FA metabolism 
may lead to the inhibition of glucose metabolic flux at various steps, including 
glucose uptake, glycogen synthesis and different glycolytic steps (Itani et al., 2000; 
Stellenbosch University  http://scholar.sun.ac.za
57 
 
Paz et al., 1997). The metabolism of long-chain FA and ketone bodies can reduce 
glucose transport in isolated hearts (Paz et al., 1997). FA β-oxidation produces 
citrate, which may downregulate glycolysis at the phosphofructokinase reaction 
(Randle et al., 1964). The regulation of PDH, as first described by Randle and 
colleagues (Randle et al., 1964) is one the best described mechanisms of fuel 
substrate regulation (refer Figure 2.7). Increased production of acetyl-CoA and 
NADH from FA β-oxidation may exert inhibitory effects on PDH, thereby promoting 
FA utilization and suppressing that of glucose (Stanley et al., 2005). This is further 
demonstrated by experimental inhibition of FA oxidation (e.g. CPT-1 inhibition with 
etomoxir) resulting in improvement of glucose metabolism and cardiac function (An 
and Rodrigues, 2006; Campbell et al., 2002; Stanley et al., 2005). The negative 
regulator of PDH, PDK-4, may be transcriptionally upregulated by elevated circulating 
lipids and intracellular accumulation of FAs. Here PPAR-α mediates PDK-4 
expression, resulting in increased phosphorylation and therefore inactivation of PDH 
(Huang et al., 2002; Wu et al., 2001).  If uncontrolled, these mechanisms may lead to 
insulin resistance and impaired glucose uptake. The reverse scenario of elevated 
carbohydrates inhibiting FA metabolism may also play a role with excess substrate 
availability.  
 
Chapter 2 provides as with the most important concepts of myocardial metabolism 
under physiological conditions. We reviewed the metabolism and regulation glucose 
and FA metabolic flux – important considerations when taking the homeostatic 
control of these substrates into account. For example, dysregulated glucose 
homeostasis is the core defect of insulin resistance (the focus of this thesis). The 
information reviewed in this chapter provides a basis to evaluate pathophysiological 
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mechanisms involving glucose dysregulation and insulin resistance – the topic of 
Chapter 3.   
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CHAPTER 3 
Metabolic alterations and myocardial insulin resistance  
 
3.1. Principles and pathogenesis of insulin resistance and diabetes 
 
Having reviewed the mechanisms of myocardial metabolism under physiological 
conditions in Chapter 2, we now turn our attention to pathophysiological alterations 
during conditions of metabolic dysregulation. We place specific emphasis on 
literature outlining the etiology of insulin resistance – the topic of this thesis – and 
review the impact of metabolic fuel overabundance (specifically acute high glucose 
episodes) on this process. Lastly, we describe dysregulated glucose metabolic flux 
and its associated molecular defects, as put forth by the unifying hypothesis of 
diabetic complications. We propose that this may provide valuable insights and 
contribute to the development of hypotheses regarding the role of acute 
hyperglycemia in the onset of myocardial insulin resistance. However, we first pay 
attention to the description of insulin resistance, its diagnosis and etiology.   
 
3.1.1. Introduction 
 
The homeostatic control of glucose depends on its uptake and utilization by tissues, 
resulting in its clearance from the bloodstream. This process is chiefly governed by 
hormonal control by the release of insulin from the pancreatic β-cells (Kraegen et al., 
1993). Insulin exerts intracellular signaling cascades within target cells resulting in 
glucose uptake, storage or metabolic utilization (refer Chapter 2). The homeostatic 
mechanisms governing glucose utilization become impaired in conditions of insulin 
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resistance – the failure of insulin to effect the stimulation of glucose uptake in target 
cells. Insulin resistance is a complex, multifactorial and progressive condition that 
usually culminates in diabetes (reviewed in Petersen and Shulman, 2006; Stumvoll et 
al., 2005). It is associated with various metabolic pathologies, and poor 
lifestyle/dietary habits contribute greatly to its progression. Skeletal muscle and 
adipose tissue are the main sites of glucose uptake, however, insulin resistance and 
the subsequent dysregulation of glucose homeostasis may impact cardiac 
metabolism and function (An and Rodrigues, 2006; Hu et al., 2008; Leonard et al., 
2005; Ren et al., 2003; Zhang et al., 2011; Zhu et al., 2013). The influence of insulin 
resistance in terms of defective glucose uptake in cardiomyocytes has not been 
given much attention in literature. A thorough understanding of the mechanisms of 
insulin resistance at play in the heart, and its consequences for cardiomyocyte 
function is therefore warranted. Furthermore, because insulin resistance develops 
gradually over time, it may be a beneficial approach to target an early time point for 
intervention during its pathogenesis. Here acute hyperglycemic episodes may play a 
role in exerting detrimental effects in the pre-diabetic state or as a result of increased 
dietary intake of sugars (Mapanga et al., 2012; Parsons et al., 2002; Williams et al., 
1998; Wisneski et al., 1990; Yang et al., 2009). The aim of this thesis is to investigate 
possible mechanisms of myocardial insulin resistance under acute hyperglycemic 
conditions. In light of this, we review mechanisms of metabolic alterations and 
myocardial insulin resistance in this chapter.     
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3.1.2. Diagnosis of insulin resistance and diabetes 
 
The current diagnosis of insulin resistance and diabetes is based on the 2010 ADA 
recommendations and the 2011 WHO addendum report, using either glycosylated 
hemoglobin (HbA1c), fasting plasma glucose (FPG) or the oral glucose tolerance test 
(OGTT) (Malkani and DeSilva, 2012). Specific cut-off values for the outcome of each 
test defines glucose homeostasis in terms of normal (physiological/healthy), impaired 
fasting glucose (IFG – initial defect in the pathogenesis and indicative of pre-
diabetes) and diabetes (severe loss of glucose homeostasis characterized by chronic 
hyperglycemia). The diagnostic criteria for diabetes and insulin resistance were 
developed over many years from different sets of criteria, as was the case for the 
diagnosis of the metabolic syndrome (refer Section 1.4). The currently used 
guidelines do not endorse any one specific detection method (Malkani and DeSilva, 
2012) and specific cut-off values are continually revised to improve diagnostic utility 
across populations. However, despite the significant ground gained in the 
development of diagnostic criteria, current tests and criteria remain non-conforming 
and may result in inconsistencies when diagnosing insulin resistance and diabetes 
across populations (Borch-Johnsen and Colagiuri, 2009; Malkani and DeSilva, 2012). 
Each testing method also has peculiar features that may hamper efficient detection, 
while a significant number of individuals (mainly in developing countries) go 
undiagnosed due to various socio-economic factors (reviewed in Chapter 1). 
Nonetheless, to gain a better understanding of the etiology of insulin resistance, we 
will now briefly review the diagnostic screening methods, i.e. the OGTT, HbA1c and 
the FPG. The diagnostic criteria currently used are summarized in Table 3.1 below. 
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Table 3.1 Criteria for diagnosis of insulin resistance and diabetes (Malkani and DeSilva, 
2012) 
  2010 ADA criteria 2011 WHO guidelines 
OGTT 
Normal <7.8 mmol/l <7.8 mmol/l 
IFG 7.8-10.9 mmol/l 7.8-10.9 mmol/l 
Diabetes ≥11 mmol/l ≥11 mmol/l 
FPG 
Normal <5.6 mmol/l <6.1 mmol/l 
IFG 5.6-6.9 mmol/l 6.1-6.9 mmol/l 
Diabetes ≥7 mmol/l ≥7 mmol/l 
HbA1c 
Normal <5.7% Not specified 
IFG 5.7-6.4% Not specified 
Diabetes ≥6.5% ≥6.5% 
 
 
The OGTT is acknowledged as the ‘gold standard’ screening tool for the detection of 
diabetes (Park et al., 2010) and is widely utilized in a range of different experimental 
studies (Barr et al., 2002). However, the OGTT has several methodological and 
biological pitfalls. For example, individuals to be tested  have to be available for more 
than 2 hours, while intra- individual variability and reproducibility are not optimal 
(Selvin et al., 2007). The clinical utility of the OGTT is further hampered by 
differences in the rate of glucose absorption between males and females (Anderwald 
et al., 2011). 
 
HbA1c provides a measure of a person’s average glucose metabolism over a longer 
time period (reviewed in Saudek et al., 2006). Despite it being accredited as a highly 
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specific method for diabetes diagnosis, it has limited sensitivity and fails to detect 
short-term fluctuations in blood glucose (e.g. postprandial spikes and pre-diabetes) 
(reviewed in Derr et al., 2003; Saudek et al., 2008). The HbA1c tests are also more 
expensive compared to others, hampering the economic viability of its 
implementation (Bonora and Tuomilehto, 2011; George, 2011). Furthermore, several 
factors can influence HbA1c assay results and lead to misinterpretation, e.g. some 
hemoglobinopathies, iron deficiency, ageing, ethnicity and antiretroviral drugs (Amod, 
2010; Bonora and Tuomilehto, 2011; Malkani and DeSilva, 2012). 
 
The FPG test is frequently utilized as a diagnostic tool and is the most standardized 
and inexpensive means of diabetes identification (Malkani and DeSilva, 2012). 
However, it fails to specify daily glycemic fluctuations and excludes both the fasted 
and postprandial states as possible contributors to glucose levels observed (Wang et 
al., 2009). This may lead to a lack of reproducibility and may result in day-to-day 
variation of results (Selvin et al., 2007). 
  
The pitfalls associated with the current diabetes diagnostic tests significantly 
hampers early and efficient detection of pre-diabetes and diabetes. This, together 
with the global prevalence of metabolic disorders, poor dietary and lifestyle habits 
and undiagnosed diabetes cases world-wide (reviewed in Chapter 1), makes the 
clinical identification of the etiology of insulin resistance difficult. It is therefore 
imperative that such measures are continuously re-evaluated and refined, but that 
the molecular events driving the etiology of insulin resistance are also better 
understood with the aim to enhance its detection. Although not all patients with 
impaired glucose tolerance (IGT) or impaired fasting glucose develop diabetes, it is 
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strongly associated with higher risk for development of diabetes, and patients in this 
group may be an important target for intervention (Edelstein et al., 1997; Giugliano et 
al., 2008; Tuomilehto et al., 2001). In accordance, we are of the opinion that the 
transition from normal to IGT/IFG (a feature of pre-diabetes) may be an important 
time point to consider intervention, and that investigation of acute hyperglycemic 
episodes (which may be frequent during this transition) and its impact on myocardial 
glucose uptake is therefore an important pursuit. We next review literature 
concerning the etiology of insulin resistance to gain a better understanding of current 
knowledge in this regard.  
 
3.1.3. Etiology of insulin resistance 
 
Insulin resistance arises when physiological concentrations of insulin in response to 
increased blood glucose fail to exert its function. Pancreatic insulin release is 
subsequently elevated to attempt compensation for the loss of insulin sensitivity, 
developing into hyperinsulinemia. The pathophysiology of insulin resistance can be 
linked to mitochondrial dysfunction, glucocorticoids, inflammation, oxidative stress 
and the induction of non-oxidative glucose pathways (NOGPs) (to be discussed in 
section 3.4) (Ceriello and Motz, 2004; Hotamisligil et al., 1993; Saini, 2010). Elevated 
metabolic fuel substrate availability (hyperglycemia, hyperlipidemia) may in itself 
contribute to the downregulation of insulin action (discussed in section 3.2.1 below) 
(Gao et al., 2010; Marshall et al., 1991; Petersen and Shulman, 2006; Ragheb et al., 
2009; Roden et al., 1996).  
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The pathogenesis of diabetes progresses slowly over a long period and insulin 
resistance may precede full-blown diabetes by more than a decade (reviewed in 
Poornima et al., 2006). Pancreatic β-cells upregulate insulin secretion in an attempt 
to maintain glucose homeostasis as the responsiveness to insulin decreases 
progressively (Stumvoll et al., 2005). The elevated (supraphysiological) insulin 
concentrations effectively maintain normal glucose homeostasis during the early 
stages of insulin resistance (Dankner et al., 2009; Savage et al., 2007). This is 
evident by a normoglycemic-hyperinsulinemic state in which individuals are insulin 
resistant but display fasting plasma glucose levels in the normal range (Dankner et 
al., 2009; Saltiel, 2001; Warram et al., 1990). Pancreatic insulin secretion then 
progressively becomes impaired and β-cells fail to secrete the insulin concentrations 
required to maintain glucose homeostasis (Jurczak et al., 2011; Lebovitz, 2011). 
Moreover, hyperinsulinemia contributes independently to the pathogenesis of insulin 
resistance (Shanik et al., 2008; Weyer et al., 2000). This leads to a pre-diabetic 
setting (displaying impaired glucose tolerance IGT/IFG) that is initially characterized 
by hyperinsulinemia and hyperglycemia (reviewed in Stolk et al., 1997; Zimmet et al., 
1999). The function of β-cells decline progressively due to prolonged exposure to 
insulin resistance, hyperinsulinemia and glucolipotoxicity (Sicree et al., 1987; 
Stumvoll et al., 2005). 
 
Although the pre-diabetic states of IFG and IGT are both characterized by insulin 
resistance (Qiao et al., 2003), differences occur  regarding  the exact sites of 
decreased insulin sensitivity. Here IFG mainly presents as hepatic insulin resistance, 
while IGT is primarily characterized by muscle insulin resistance (Abdul-Ghani et al., 
2006; Nathan et al., 2007). An understanding of the biphasic kinetics of insulin 
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secretion is important in order to evaluate the implications for insulin resistance 
(Gerich, 2002). The first phase lasting up to 15 min is a rapid release of insulin, 
peaking at 2-4 min after a glucose stimulus (Cavahan, 2004). The insulin secreted in 
this first phase is pre-formed and stored in granules within the β-cell (refer Chapter 2) 
(Cavahan, 2004). The second phase of insulin secretion is gradual and increases 
progressively for up to 3 h (Gerich, 2002). Individuals with IFG experience altered 
early-phase insulin response, while those with IGT show reduced first phase insulin 
secretion and a major reduction in the second phase (Nathan et al., 2007). These 
features help to elucidate differences in glycemia between the two pre-diabetic 
states. Glycogenolysis in the liver together with defective early phase insulin release 
lead to excess hepatic glucose output and subsequent elevations in fasting plasma 
glucose levels observed in IFG (Nathan et al., 2007). Conversely, decreased muscle 
glucose uptake and blunted late phase insulin secretion results in post-prandial 
hyperglycemia during IGT (Nathan et al., 2007). Individuals with combined IFG/IGT 
experience both hepatic and muscle insulin resistance (Nathan et al., 2007). 
 
During the latter stages of insulin resistance, the steady decline in insulin secretion 
correlates with more severe hyperglycemia, raising glucose concentrations into the 
diabetic glucose range (Zimmet et al., 1999). Overt type 2 diabetes is characterized 
by severe hyperglycemia and dysregulated glucose homeostasis coupled to 
drastically declined insulin levels (Mahler and Adler, 1999). Patients with established 
overt diabetes display complete β-cell failure (the major feature of type 1 diabetes) 
and therefore require insulin therapy (Lebovitz, 2011).  
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The review of the basic principles and features of insulin resistance, its diagnosis and 
etiology provides us with a foundation to next explore the molecular basis and 
mechanisms of insulin resistance.  
 
3.2. Molecular mechanisms of insulin resistance 
 
The physiological regulation of insulin action is reviewed in section 2.2.2. For the 
purpose of this study, we next review the pathophysiologic mechanisms contributing 
to insulin resistance. Specifically, we highlight the role metabolic fuel overabundance, 
the inter-relationship of lipid and glucose metabolism and mechanisms initiated by 
the (deranged) metabolism of hyperglycemia and hyperlipidemia leading to insulin 
resistance. 
 
3.2.1. Dysregulation of insulin action by fuel substrate overabundance – Randle 
cycle revisited 
 
Diabetes is characterized by hyperlipidemia, insulin resistance and compensatory 
hyperinsulinemia, and hyperglycemia (Poornima et al., 2006). The excess fuel 
substrates in this state contribute to the etiology of insulin resistance.  For example, 
hyperlipidemia usually presents with elevated blood levels of non-esterified fatty 
acids (NEFAs) and triglycerides (Poornima et al., 2006). NEFAs play a significant role 
in the development of insulin resistance via several molecular mechanisms (Boden, 
1997; Karpe et al., 2011; Kelley et al., 1993; Roden et al., 1996). For example, 
increased citrate levels (as a result of high fatty acid β–oxidation) inhibit PFK-1, 
leading to an accumulation of glucose-6-phosphate and the inhibition of hexokinase II 
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activity. This causes elevated intracellular glucose concentrations and decreased 
GLUT4 translocation and glucose uptake (Randle et al., 1963). 
 
The Randle cycle (refer Chapter 2) describes the mechanisms of fuel substrate 
switching, where elevated fatty acid availability inhibits the metabolism of glucose by 
inhibition of PDH (Holness and Sugden, 2003; Randle et al., 1963). Numerous 
studies have since revisited and further developed the Randle hypothesis (Boden, 
1997; Dresner et al., 1999; Griffin et al., 1999; Roden et al., 1996). For example,  
Shulman and colleagues (2000) suggest that elevated fatty acid metabolites 
(diacyglycerol, fatty acyl CoAs, ceramide) can disrupt insulin signaling pathways by 
activating PKCθ (Shulman, 2000). This in turn leads to the phosphorylation of serine 
residues on IRS-1. Normal insulin signaling requires tyrosine phosphorylation of the 
IRS-1 β-subunits (refer Chapter 2), while serine phosphorylation serves as a negative 
regulatory signal. PKCθ-mediated serine phosphorylation of IRS-1 therefore inhibits 
insulin action (Kim et al., 2001; Shulman, 2000). This is supported by several rodent 
and human studies (Dresner et al., 1999; Griffin et al., 1999; Morino et al., 2005; Yu 
et al., 2002). Non-esterified fatty acids (NEFAs) can also regulate the expression of 
peroxisome proliferator-activated receptor γ (PPARγ), thereby mediating the 
transcription of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) 
(Schwartzbauer and Robbins, 2001). Subsequently PTEN catalyzes the 
dephosphorylation of PIP3, thereby attenuating the insulin signaling cascade by 
limiting Akt activation (Poornima et al., 2006). Additionally, FAs may reduce insulin 
action by attenuation of IR gene expression (Bhattacharya et al., 2007).  
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High glucose levels may also play a significant role in the reduction of its own uptake, 
e.g. by the down regulation of AMPK, subsequently decreasing (specifically 
contraction-mediated) GLUT4 translocation (Itani et al., 2003). In addition, increased 
glycolytic flux triggers greater oxidative stress production, thereby leading to 
downstream metabolic defects (discussed below). For example, induction of PKC 
isoforms and elevated hexosamine biosynthetic pathway (HBP) flux are important 
contributors to reduced glucose uptake under hyperglycemic conditions (Davidoff et 
al., 2004; Park et al., 2005; Ren et al., 2013; Vosseller et al., 2002) The mechanisms 
of high glucose-induced insulin resistance are further elucidated in this thesis. We will 
specifically focus on the role of acute hyperglycemia, a feature of the early events in 
the etiology of insulin resistance. The rationale here is that an understanding of the 
molecular events in the early phase of pathogenesis may provide insight regarding 
intervention strategies to stop the progression of insulin resistance. We therefore 
next review various aspects of acute hyperglycemia. 
 
3.3. Acute hyperglycemia 
 
Non-diabetic individuals may display acute hyperglycemia due to a combination of 
undiagnosed diabetes, IGT (Norhammar et al., 2002) and a severe response to acute 
stress (Capes et al., 2000; Lazzeri et al., 2009; Oswald et al., 1986). IGT precedes 
the progression to T2DM and is defined as having fasting plasma glucose levels 
below 7 mmol/l, and 2 hour post-prandial values  between 7.8 mmol/l and 11.0 
mmol/l (refer Section 3.1.2) (Mitrakou et al., 1992). The ADA defines post-prandial 
hyperglycemia as blood glucose levels higher than 7.8 mmol/l in a 2 hour post-
prandial period, with HbA1C <4% and normal FPG (Erlinger and Brancati, 2001). 
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Post-prandial hyperglycemia arises after glucose homeostasis becomes impaired 
and insulin fails to restore glucose levels after a meal. For example, in subjects with 
IGT insulin-mediated suppression of hepatic glucose production, enhancement of 
glucose uptake and reduction of FAs are impaired after consumption of a meal 
(Balkau et al., 1999). Post-prandial hyperglycemia mainly manifests during the 
progression towards T2DM due to loss of the first phase of insulin secretion (Del 
Prato and Tiengo, 2001).  
 
Fasting hyperglycemia results mainly from elevated glucose release (by 
gluconeogenesis) by the liver and kidneys (Dinneen et al., 1992; Meyer et al., 1998). 
Rates of glucose uptake are generally increased in individuals with fasting 
hyperglycemia, mainly because of the mass action effects of hyperglycemia. 
Moreover, fasting hyperglycemia may also occur due to precursor post-prandial 
hyperglycemia, i.e. the higher the hyperglycemia after an evening meal, the greater 
the hyperglycemia in the morning and vice versa. Hence treatment should therefore 
aim to control both post-prandial and fasting hyperglycemia.  
 
Acute hyperglycemic episodes are major features of the early phases during the 
etiology of insulin resistance (e.g. pre-diabetes), while high dietary intake of sugars 
may also contribute to acute hyperglycemic episodes (Edelstein et al., 1997; 
Tuomilehto et al., 2001). A number of studies implicate acute hyperglycemia to 
cardio-metabolic derangements and vascular derangements (Ceriello et al., 2002; 
Mapanga et al., 2012; Parsons et al., 2002; Williams et al., 1998; Wisneski et al., 
1990; Yang et al., 2009). For the current study, we propose that acute hyperglycemia 
may induce insulin resistance in cardiac-derived cells. We next review mechanisms 
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which mediate hyperglycemic (chronic and/or acute) derangements in an attempt to 
gain further insight.  
                                                                                                                                                                                                                                               
3.4. Glucose-metabolic dysregulation and diabetic complications 
 
Hyperglycemia (chronic and acute) contributes to various vascular complications by 
initiating detrimental molecular events. The upregulation of oxidative stress plays an 
important role in a diverse range of complications. Indeed, it may be a central factor 
governing the downstream metabolic dysregulation of glucose flux at the center of 
pathologies. Oxidative stress is also implicated in the etiology of insulin resistance. 
We now review various mechanisms of oxidative stress induction under 
hyperglycemic conditions in the next section.  
 
3.4.1. Oxidative stress 
 
Oxidative stress – the result of an imbalance between reactive oxygen species 
(ROS) generation and the intrinsic antioxidant capacity of a cell – is implicated in the 
pathogenesis of multiple diseases (Bonnefont-Rousselot et al., 2000; Khullar et al., 
2010; King and Loeken, 2004). ROS production may be triggered by multiple stimuli, 
including elevations in metabolic fuel substrate influx (Catherwood et al., 2002; Finkel 
and Holbrook, 2000; Furukawa et al., 2004; King and Loeken, 2004; Lindsay, 1999). 
For example, hyperglycemia is associated with increased superoxide levels, while 
hyperlipidemia may elevate superoxide and peroxynitrite levels (Baynes and Thorpe, 
1999). The excess free radicals damage proteins, lipids and nucleic acids with 
detrimental outcomes.  
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Oxidative stress is also strongly implicated in the development of insulin 
resistance/diabetes and its complications, with diabetic patients and experimental 
models of diabetes (in vitro and in vivo) displaying increased oxidative stress 
compared to controls (Baynes and Thorpe, 1999; Brownlee, 2005, 2001; Catherwood 
et al., 2002; Giardino et al., 1996; King and Brownlee, 1996; Mapanga et al., 2012; 
Nourooz-Zadeh et al., 1997; Rösen et al., 2001, 1998; Szaleczky et al., 1999). 
Further evidence for this stems from studies which utilized antioxidants (e.g. vitamin 
E or C and α-lipoic acid) to attenuate diabetic complications (Jain et al., 2004; 
Paolisso et al., 1993; Ziegler et al., 1995), while the overexpression of manganese 
superoxide dismutase (MnSOD) reduced oxidative stress in experimentally-induced 
diabetes (Chen et al., 1998; Schwaiger et al., 1989). Oxidative stress is also 
prominently implicated in the etiology of insulin resistance, and may play a role in the 
attenuation of pancreatic β-cell function and insulin secretion (Futamura et al., 2012), 
as well as disruption of insulin signaling and glucose uptake in insulin responsive 
cells (Costford et al., 2009; Gao et al., 2010; Grimsrud et al., 2007; Messner et al., 
2013; reviewed in Eriksson, 2007; Ruskovska and Bernlohr, 2013). The specific ROS 
producing mechanisms, sources involved and its link to insulin resistance and cardio-
metabolic dysfunction are outlined below.   
 
3.4.1.1. ROS sources 
 
One of the primary sites for ROS generation is the mitochondrial electron transport 
chain. The metabolic utilization of glycolytic substrates and FA in mitochondria under 
physiological conditions was explained in Chapter 2. Briefly, the generation of 
electron donors (NADH and FADH2) from the citric acid cycle and FA β-oxidation, 
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drive the flux of electrons from complexes I and II of the electron transport chain 
through complexes III and IV to oxygen, forming water and resulting in protons being 
pumped across the mitochondrial inner membrane with ATP synthesis (Cecchini, 
2003; Hirst, 2005; Paradies et al., 2001). Mitochondria respond to various signals by 
controlling ATP production, calcium homeostasis, ROS production and membrane 
permeability. Under conditions of metabolic stress, mitochondria can contribute to 
increased production of oxidants (Grivennikova and Vinogradov, 2006; Paradies et 
al., 2001). This is evident from experimental studies demonstrating that mitochondrial 
damage is associated with diabetes (Ferreira et al., 2003; Fitzl et al., 2001; Shen et 
al., 2004). Here, electrons may leak from the respiratory chain and react with oxygen 
to form free radicals which are highly reactive because of unpaired electrons in their 
structure. ROS are generated if the membrane potential across the inner 
mitochondrial membrane rises above a certain threshold (Korshunov et al., 1997). 
Electrons mainly leak from complex I (Barja and Herrero, 1998; Barja, 1999; Chen et 
al., 2005; Genova et al., 2001; Herrero and Barja, 1997; Kudin et al., 2004; 
Kushnareva et al., 2002; Lambert and Brand, 2004; Ohnishi et al., 2005) and 
complex III (Boveris et al., 1976; Chen et al., 2003; St-Pierre et al., 2002). However, 
complex III is considered the major site of ROS production as a result of elevated 
substrate influx (e.g. hyperglycemia) (Brownlee 2001, 2005; Chen et al., 2003). This 
is evident by excess production of superoxide ions in diabetic rats in response to 
glycation of complex III proteins (Rosca et al., 2005).  
 
Hyperglycemia causes higher mitochondrial ROS production via increased electron 
transfer donors (NADH and FADH2), resulting in elevated electron flux through the 
mitochondrial ETC. This leads to a subsequent increase in the ATP/ADP ratio and 
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hyperpolarization of the mitochondrial membrane potential (Brand et al., 2004; 
Korshunov et al., 1997; Skulachev, 1999, 1996). The high electrochemical potential 
difference generated by the proton gradient leads to partial inhibition of the electron 
transport at complexes I and III. This results in accumulation of electrons at 
coenzyme Q, which in turn drives the partial reduction of oxygen to generate 
superoxide (Brownlee, 2001; Du et al., 2003, 2000). The continual accelerated 
reduction of coenzyme Q and subsequent ROS generation may be an important 
causative factor for mitochondrial dysfunction and diabetes-related metabolic 
disorders. Moreover, mitochondrial ROS production is associated with insulin 
resistance, with hydrogen peroxide (H2O2) implicated in the disruption of  insulin 
signaling intermediates (Anderson et al., 2009; Fisher-Wellman and Neufer, 2012). 
Mitochondrial dysfunction and defects in its morphology were found in muscle tissue 
of diabetic patients and animal models (reviewed in Cheng et al., 2010; Rabøl, 2011). 
Whether defects at the mitochondrial level are causative factors, or a consequence of 
insulin resistance, is not yet clear (reviewed in Rabøl, 2011).  
 
The mitochondrion is not the only site for intracellular ROS production. There is 
further evidence that elevated ROS generation from cytosolic sources may play 
central roles in pathogenic mechanisms (Garciarena et al., 2008; Zhou et al., 2010). 
Additional sources of ROS generation include; glucose autoxidation, NADPH oxidase 
(NOX), lipoxygenases, cyclo-oxygenases, peroxidases, heme proteins, xanthine 
oxidase, peroxisomes, or the hepatic P-450 microsomal detoxifying system 
(Brownlee, 2001; Ceriello et al., 2002; Desco et al., 2002; Nishikawa et al., 2000; 
Yamagishi et al., 2001).  
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The role of ROS production via NOX and its part in cardiovascular complications 
recently gained considerable attention. For example, NOX activity and superoxide 
production is high in vascular tissue from diabetic patients (Guzik et al., 2002), while 
it is a major producer of hyperglycemia-mediated ROS in cardiomyocytes (Brewer et 
al., 2011; Li et al., 2006; Santos et al., 2011). NOX-derived ROS can also participate 
in myocardial apoptosis under hyperglycemic conditions (Balteau et al., 2011), while 
NADPH from the pentose phosphate pathway (PPP) may be necessary to mediate 
NOX activity in obese and hyperglycemic rat hearts (Serpillon et al., 2009).  
Angiotensin II (ANG II)-induced NOX activation also induced insulin resistance in in 
vitro and in vivo studies (Ogihara et al., 2002; Sloniger et al., 2005; Wei et al., 2006). 
We are therefore particularly interested in NOX activation for the studies outlined in 
this thesis.  
 
In summary, both mitochondrial and non-mitochondrial ROS are key players in the 
manifestation of cardio-metabolic pathophysiologies. Here the initiating event is 
mitochondrial superoxide production that triggers further ROS generation (other 
sources) thereby creating a vicious cycle.  
 
3.4.1.2. Intracellular antioxidant systems 
 
Mitochondria together with the other intracellular antioxidant systems have the 
capability of maintaining oxidative stress homeostasis by a balance between ROS 
production and its elimination (Dhar et al., 2008). However, these endogenous 
oxidative stress defense mechanisms are overwhelmed during pathological 
conditions such as hyperglycemia and/or ischemia-induced oxidative stress. 
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Glutathione reductase and peroxidase play a key role in the recycling of glutathione 
between its reduced (GSH) and oxidized (GSSG) forms. Glutathione peroxidase 
removes H2O2 through the oxidation of GSH to GSSG, while glutathione reductase 
acts as an antioxidant by converting GSSG to GSH. Superoxide Dismutase (SOD) 
provides further defensive cover by conversion of superoxide to H202 that is then 
converted to water by catalase (another core antioxidant). SOD is present in three 
isoforms, i.e. SOD1; a dimer found in the cytoplasm, whereas SOD2 and SOD3 are 
tetramers found in the mitochondrion and extracellular matrix, respectively (McCord 
and Edeas, 2005).  
 
3.4.1.3. ROS and non-oxidative glucose pathways (NOGPs) – unifying 
hypothesis and its modifications 
 
The energy producing and fuel storage pathways of glucose metabolism are the chief 
avenues for glucose disposal in cells. However, small percentages of glucose-
derived intermediates enter alternative pathways under physiological conditions. 
These pathways are, however, significantly activated under conditions of fuel 
substrate excess (e.g. hyperglycemia), and oxidative stress may play a central role in 
mediating this. A currently favored model suggests that superoxide produced in 
mitochondria under hyperglycemic conditions may be a central unifying factor 
underlying the induction of NOGPs and their detrimental downstream effects 
(Brownlee, 2005). ROS produced here leads to DNA damage and the subsequent 
activation of the DNA repair enzyme poly (ADP)-ribose polymerase (PARP) (Beneke 
and Bürkle, 2007; Bürkle, 2005; Colussi et al., 2000; Diefenbach and Bürkle, 2005). 
PARP is recruited to catalyze the repair of single and double strand DNA breaks by 
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poly (ADP)-ribosylation. In addition to its DNA repair function, PARP activation results 
in the covalent linkage of ADP-ribose subunits to glutamate, aspartate and lysine 
residues of target proteins (Beneke and Bürkle, 2007; Bürkle, 2005). The glycolytic 
enzyme GAPDH is a PARP target, i.e. it can be inhibited by the action of PARP 
(Beneke and Bürkle, 2007; Bürkle, 2005; Du et al., 2003; Nishikawa et al., 2000). 
Subsequently, upstream glycolytic intermediates accumulate and are pushed into 
NOGPs, i.e. the pathways of advanced glycation end-product (AGE) formation and 
PKC activation, the polyol pathway and the hexosamine biosynthetic pathway (HBP) 
(Brownlee, 2005, 2001; Du et al., 2003, 2000; Giacco and Brownlee, 2010; King and 
Brownlee, 1996; Nishikawa et al., 2000). Elevated flux via these four pathways under 
hyperglycemic conditions is strongly implicated in a myriad of diabetic vascular 
complications. A fifth pathway, the pentose phosphate pathway (PPP) may also be 
altered under hyperglycemic conditions. However the fashion in which it is altered 
(increased or decreased with hyperglycemia/diabetes) remains controversial. 
However, a number of studies show that PPP activation  under 
hyperglycemic/diabetic conditions reduced flux via the other NOGPs and this was 
associated with positive outcomes (Balakumar et al., 2010; Beltramo et al., 2008; 
Cameron et al., 2005; Du et al., 2008; Katare et al., 2010a, 2010b; Mapanga et al., 
2013; Marchetti et al., 2006). A more detailed description of the NOGPs is provided 
below (also refer Fig 3.1). 
 
Although the unifying hypothesis gained strong experimental support and is a fairly 
widely accepted explanation for the vascular defects of hyperglycemia, recent studies 
show that additional factors may play more prominent roles in these mechanisms 
(reviewed in Schaffer et al., 2012). Here intracellular source(s) of ROS production at 
Stellenbosch University  http://scholar.sun.ac.za
93 
 
the center of hyperglycemia-induced detrimental effects, the contribution of other 
ROS species (not only mitochondrial superoxide), the role of antioxidant defense 
mechanisms and the regulation of glucose metabolism by these oxidative stress 
mechanisms, have been revisited. For example, decreased MnSOD activity and 
glutathione (GSH) levels may be the main mechanisms attributable to the elevated 
mitochondrial ROS observed  (Kanwar et al., 2007; Kowluru et al., 2006). 
Furthermore, the transport of superoxide to the nucleus (where it exerts DNA 
damage) is improbable due its relatively short half-life and reactivity (reviewed in 
Schaffer et al., 2012). It is thus plausible that other ROS species, e.g. cytosolic ROS 
sources may play more prominent roles in exerting damaging outcomes observed 
(Radi et al., 2002; reviewed in Schaffer et al., 2012). These concerns open up more 
possibilities for future work. In the case of this study, we considered the involvement 
of both mitochondrial- and NOX-derived ROS in activation of NOGPs, and the 
subsequent attenuation of insulin action. The next section provides a more in-depth 
discussion of the physiologic and pathophysiologic roles of the NOGPs. 
 
3.4.2. Non-oxidative glucose pathways 
 
As explained above, flux via the NOGPs is markedly upregulated when glucose fuel 
sources are in abundance and a number of these pathways are implicated in the 
pathogenesis of a wide array of diabetes-associated complications. Chronically 
elevated blood glucose levels under such conditions may contribute significantly to 
the observed adverse effects. Glucose metabolites may enter the pathways of 
advanced glycation-end products (AGE) formation, the polyol pathway, hexosamine 
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biosynthetic pathway (HBP), protein kinase C (PKC) activation and pentose 
phosphate (PPP) pathways (Fig 3.1). Each pathway will be described below.  
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Figure 3.1 Glycolysis and NOGP branch points. The pathways of glycolysis (red blocks), AGE 
formation (pink blocks), polyol pathway (green blocks), PKC (yellow blocks), HBP (brown blocks) and 
PPP (blue blocks) are shown. (Modified from Brownlee, 2005 and Bolanos et al., 2010) 
 
Stellenbosch University  http://scholar.sun.ac.za
96 
 
3.4.2.1. Advanced glycation end products  
 
The intracellular production of AGE precursors is an important mechanism of cellular 
stress. AGE molecules are formed during a non-enzymatic reaction between proteins 
and sugar residues, known as the Maillard reaction (Hartog et al., 2007). AGE 
accumulates with aging and with conditions like diabetes, renal failure and oxidative 
stress. AGEs are formed when sugar residues react with the amino group of a 
protein to form a Schiff-base (Hartog et al., 2007). This is a rapid and reversible 
reaction and the Schiff-base then forms a more stable Amadori product. Further 
steps result in the formation of irreversible and stable AGE compounds. High glucose 
levels may directly increase AGE precursors by accumulation of G-3-P in glycolysis, 
which is diverted to form methylglyoxal (Fig 3.2) 
 
AGEs are also implicated in the development of heart failure in both diabetic and 
non-diabetic patients, i.e. it can increase rigidity of heart tissue leading to diastolic 
and systolic dysfunction through coronary artery disease and vascular dysfunction 
(Hartog et al., 2007). AGE precursors may also exert cellular damage by modifying 
intracellular proteins (Giardino et al., 1994; Shinohara et al., 1998), extracellular 
matrix molecules (McLellan et al., 1994), and circulating proteins such as albumin 
(Doi et al., 1992). Modified circulating proteins can bind to and activate AGE 
receptors, hence causing an inflammatory response in the vasculature through the 
production of cytokines and growth factors (Abordo and Thornalley, 1997; Doi et al., 
1992; Kirstein et al., 1992; Li et al., 1996; Neeper et al., 1992; Schmidt et al., 1995; 
Skolnik et al., 1991; Smedsrød et al., 1997; Vlassara et al., 1995, 1988). Through 
their receptors (RAGEs), AGEs inactivate enzymes by altering their structures and 
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functions (McCarthy et al., 2001), promoting free radical formation (Baynes and 
Thorpe, 1999), and impair the anti- proliferative effects of nitric oxide (Vlassara, 
1997). Moreover, AGEs increase intracellular oxidative stress thereby activating the 
transcription factor nuclear factor κB (NF-κB) and promoting up-regulation of its target 
genes (Mohamed et al., 1999).  
 
 
Figure 3.2 AGE formation 
 
3.4.2.2. Polyol pathway 
 
Polyol pathway flux is elevated up to ~10 fold under hyperglycemic conditions 
(Dunlop, 2000; González et al., 1984; Sheetz and King, 2002; Travis et al., 1971; 
Yabe-Nishimura, 1998). The pathway is initiated by aldose reductase reducing 
glucose to sorbitol, that is later oxidized to fructose (Fig 3.3). The aldose reductase 
reaction uses up intracellular NADPH (Lee and Chung, 1999). Since NADPH is also 
needed for the regeneration of GSH, a decrease in reduced glutathione levels due to 
lesser availability of NADPH, increases susceptibility to intracellular oxidative stress 
(Brownlee, 2005) and subsequent ROS-mediated effects. Hyperglycemia-mediated 
induction of the polyol pathway may therefore increase intracellular oxidative stress 
by limiting the antioxidant defense mechanism usually exerted by GSH (Fig 3.3). 
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Figure 3.3 Polyol pathway 
 
3.4.2.3. Protein kinase C activation 
 
The PKC family consists of a diverse group of kinases that control the function of 
target proteins by phosphorylation of hydroxyl groups of serine and threonine 
residues. PKC enzymes are activated by upstream signals, e.g. diacylglycerol (DAG) 
(Koya et al., 1997). Accumulation of triosephosphates as a result of hyperglycemia, 
increases the production of DAG, which in turn actives classic isoforms of PKC (Fig 
3.4), i.e. β, δ, and α (Derubertis and Craven, 1994; Koya and King, 1998; Koya et al., 
1997; Xia et al., 1994). Upon activation, PKC enzymes are translocated to the 
sarcolemma by membrane-bound receptor for activated protein kinase C proteins 
(RACK). This is achieved by DAG production from phosphatidylinositol (by a 
phospholipase). Moreover, FA may also play a role in long-term activation of PKC 
isoforms (Koya et al., 1997). PKC activation exerts a number of downstream effects, 
including decreased endothelial nitric oxide synthase (eNOS), activation of NOX and 
subsequently increased ROS (Xia et al., 2006). Indeed, intermittent high glucose 
challenge in endothelial cells resulted in NOX activation that was reduced by PKC 
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inhibition (Quagliaro et al., 2003). Thus PKC activation may play an important role in 
the onset of insulin resistance (Davidoff et al., 2004; Ren et al., 2013). 
 
 
Figure 3.4 PKC activation 
 
3.4.2.4. Hexosamine biosynthetic pathway 
 
The HBP is regarded as an intracellular sensor of metabolic fuel substrates, resulting 
in partitioning of excess substrates to storage depots elsewhere in the body 
(reviewed in McClain, n.d.; Ravussin, 2002; Rossetti, 2000; Zachara and Hart, 2004). 
It utilizes approximately 3% of the total glucose available to the cell under normal 
circumstances, but is drastically increased by hyperglycemia (Hardie et al., 2003; 
Tang et al., 2000). Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the 
rate-limiting enzyme of the HBP and responsible for the catalytic conversion of 
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fructose-6-phosphate to glucosamine-6-phosphate (Daniels et al., 1996) (Fig 3.5). A 
series of successive reactions result in the post-translational modification of target 
proteins by addition of an O-GlcNAc moiety. During hyperglycemia increased O-
GlcNAcylation of target proteins is strongly associated with the onset of 
cardiovascular disease (CVD) and insulin resistance (Jacobsen et al., 1996). 
Moreover, the increased production of glucosamine-6-phosphate inhibits the activity 
of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP 
(McDaniel et al., 2002). This inhibition ultimately leads to a decrease in 
NADPH/NADP+ ratios since G6PD activity involves the reduction of NADP+ to 
NADPH (Li et al., 1996). The HBP therefore plays a role in mitigating the PPP and 
thereby reduces the intracellular NADPH levels. The decreased availability of 
NADPH attenuates intracellular antioxidant capacity and further contributes to ROS 
production (decreased GSH and catalase activity) (Li et al., 1996). 
 
 
Figure 3.5 Hexosamine biosynthetic pathway 
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3.4.2.5. Pentose phosphate pathway 
 
The pentose phosphate pathway (PPP) consists of two main branches, i.e. the 
oxidative and the non-oxidative branch, respectively. In addition to glucose oxidation, 
the PPP mainly generates reducing equivalents in the form of NADPH and pentoses 
(5-carbon sugars) such as ribose-5-phosphate and erythrose-4- phosphate used in 
the synthesis of nucleic acids and aromatic amino acids, respectively (Wamelink et 
al., 2008).  
 
For the oxidative PPP branch, glucose 6-phosphate is oxidized into 6-
phosphogluconolactone (6PG) by the rate-limiting enzyme, G6PD (Fig 3.6). This 
reaction results in the production of the first NADPH molecule in the pathway. The 
end product of this pathway, ribulose 5-phosphate, can then be converted into ribose 
5-phosphate in the non-oxidative pathway to yield nucleotides via the transketolase 
(TK) reaction. From these reactions it can be deduced that the main role of the 
oxidative PPP branch is to produce NADPH which functions in detoxification 
processes, i.e. reduced glutathione regeneration and lipid biosynthesis (Lonsdale, 
2006; Riganti et al., 2012) as well as provision of ribulose 5-phosphate for nucleotide 
synthesis. 
 
There are conflicting reports whether G6PD activity is increased, decreased or not 
changed with insulin resistance/ diabetes. Some found that G6PD activity increases 
(Gupte et al., 2009; Serpillon et al., 2009) while others reported decreased activity 
(Cappai et al., 2011; Carette et al., 2011; Katare et al., 2010a; Sudnikovich et al., 
2007; Yan et al., 1994). Such conflicting data further extends to NADPH produced by 
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this pathway, i.e. whether it contributes to or blunts oxidative stress. In fact, almost all 
the studies show that increased G6PD activity enhances NOX-induced ROS 
production via PKC activation. Similar findings were observed in various heart failure 
studies where G6PD activity is increased to provide more NADPH possibly as a 
compensation mechanism to counter oxidative stress (Gupte et al., 2007, 2006). 
However, the association of G6PD to increased NOX activity is disputed by Balteau 
et al. (2011) who suggested that this effect is independent of glucose metabolism but 
relies on glucose uptake via sodium glucose transporter 1 (SGLT1) (Balteau et al., 
2011). The differences observed may be attributed to variations of experimental 
approaches employed (in vivo and in vitro), species investigated (humans, rats and 
mice), and different tissues evaluated to measure G6PD (liver, cardiac, pancreas and 
neurons).  
 
TK catalyzes several reactions in the non-oxidative PPP, and serves as a bridge 
between the oxidative PPP and the oxidative decarboxyl metabolism of glucose. This 
therefore allows the cell to adapt to a variety of metabolic needs under different 
environmental conditions (Horecker, 2002). TK recognizes D-xylulose 5-phosphate, 
D-fructose 6-phosphate and D-sedoheptulose 7-phosphate as donors while D-ribose 
5-phosphate, D-erythrose 4-phosphate, D-glyceraldehyde 3-phosphate and 
glycoaldehyde as receptor substrates (Esakova et al., 2004). The main function of 
the non-oxidative PPP branch is to convert hexoses into pentoses, particularly 
glyceraldehyde 3-phosphate into ribose-5-phosphate that is required for nucleic acid 
synthesis. 
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TK relies on thiamine pyrophosphate (a thiamine pyrophosphate [TPP] ester) as 
cofactor for its function. Here the main source is from Vitamin B1 (thiamine) a water-
soluble compound that has been used for decades in the treatment of several 
disorders such as neurological, diabetic, and cardiovascular complications (Ang et 
al., 2008; Beltramo et al., 2009; Pomero et al., 2001). More recently, studies found 
that thiamine can prevent diabetes and its associated complications (Haupt et al., 
2005; Pomero et al., 2001; Stracke et al., 1996).  
 
The TK catalyzed reactions convert xylulose-5-phosphate and ribose-5-phosphate to 
glyceraldehyde-3-phosphate and sedoheptulose-7-phosphate, respectively. These 
are then converted to erythrose-4-phosphate and fructose-6-phosphate by 
transaldolase. In the second TK pathway, xylulose-5-phosphate and erythrose-4-
phosphate are converted to glyceraldehyde 3-phosphate and sedoheptulose-7-
phosphate. All the reactions are reversible and depend on substrate availability. 
Various studies reported reduced levels of thiamin, activity of transketolase (Babaei-
Jadidi et al., 2003; Havivi et al., 1991) and beneficial effects of benfotiamine 
treatment with diabetes (Babaei-Jadidi et al., 2003; Beltramo et al., 2009, 2008; 
Haupt et al., 2005; Katare et al., 2010a, 2010b).  
 
This section focused on the detrimental outcomes of hyperglycemia in terms of 
oxidative stress and NOGP induction. This analysis not only provides a sound 
foundation but also identifies current gaps and limited understanding regarding the 
role of acute hyperglycemia on insulin resistance in myocardial cells. We here 
employed a unique holistic approach by evaluating various aspects of ROS 
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production, scavenging mechanisms, sources and the relation to NOGP induction 
and insulin action.  
 
 
Figure 3.6 Oxidative and non-oxidative branches of the pentose phosphate pathway 
 
3.5. Summary 
 
In conclusion, elevated nutrient substrates play a significant role in the etiology of 
insulin resistance. Acute hyperglycemic episodes may be prominent in the pre-
diabetic state, and contributes to the pathophysiology of glucose homeostatic 
dysregulation. However, mechanistic links between acute hyperglycemia and insulin 
resistance in this crucial window in the pathogenesis of insulin resistance, remain to 
be fully understood. Lessons from the role of chronic hyperglycemia in the diabetic 
state show that oxidative stress and the induction of NOGPs are central mediators of 
downstream complications. Many of these mechanisms may be involved in the 
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disruption of insulin action. We therefore propose that acute hyperglycemic 
conditions may induce similar alterations in insulin responsive myocardial cells. Such 
mechanisms and inter-pathway cross talk may contribute to the dysregulation of 
insulin action.  In light of this, we therefore aim to investigate the role of oxidative 
stress (assessing sources and mechanisms of ROS production), NOGP activation, 
and the effect(s) of these events on insulin resistance using in vitro techniques to 
simulate acute hyperglycemia in a rat cardiac-derived cell line. The main objectives 
were to determine the insulin action (glucose uptake, GLUT4 translocation and Akt 
activity) in cells exposed to acute hyperglycemia, evaluate ROS levels and 
downstream effects on insulin action and assess the induction and role of each 
NOGP in mediating insulin resistance. The methodology is described in Chapter 4, 
while Chapters 5 and 6 describes our unique findings in this regard.    
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CHAPTER 4 
Materials and methods 
 
4.1. Study design and research chapter layout  
 
We aimed to evaluate the influence of acute hyperglycemia using an in vitro 
approach. Here, we simulated acute hyperglycemia in a cell culture model as this is a 
controllable experimental system. This approach allowed us to evaluate the role of 
acute hyperglycemia with minimal effect of other factors which may play a larger role 
in in vivo models. We could also manipulate various aspects of the experimental 
system through pharmacological intervention, while the measurement of certain 
parameters was accomplished by transfection experiments. 
 
We initially aimed to evaluate the role of oxidative stress and downstream effects on 
insulin action (discussed in Chapter 5). Here, we determined the potential major 
sources of ROS production and their mechanisms involved in establishment or 
maintenance of an oxidative stress milieu. Our next aim was to investigate the 
involvement of NOGPs pathways and their possible links to oxidative stress and 
downstream disruption of insulin action (discussed in Chapter 6). 
 
4.2. Cell culture and maintenance 
 
H9c2 rat-derived cardiomyoblasts (ECACC No. 8809294) were cultured as 
monolayers at 37°C in a humidified atmosphere of 95% air and 5% CO2. Cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing GlutaMAX™ 
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and 5.5 mM glucose (Invitrogen, Carlsbad CA) as previously described by our 
laboratory (Rajamani and Essop 2010; Mapanga et al., 2012). Media was 
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad CA) and 1% 
penicillin/streptomycin solution (Invitrogen, Carlsbad CA). Cells were cultured in T75 
flasks and sub-cultured when they were ~80% confluent. Splitting was achieved by 
washing the cell monolayer with warm (37°C) phosphate buffered saline (PBS) and 
incubation in 4 ml 0.25% trypsin-EDTA (Invitrogen, Carlsbad CA) at 37°C until all 
cells have dislodged or for a maximum of 4 min. Cells were then diluted in a 2:1 ratio 
of DMEM:trypsin and centrifuged for 3 min at 1,358 x g in a Digicen 20-R Ortoalresa 
centrifuge (United Scientific, Cape Town, South Africa). Cell numbers were 
determined by counting using a hemocytometer (LASEC, Cape Town, South Africa). 
Cell pellets were resuspended in fresh 37°C DMEM and seeded in suitable culture 
flasks, plates or dishes for experiments or further passaging.  Growth media were 
replaced every 48 h. 
 
4.3. Modulatory studies 
 
Cells were seeded at varying densities depending on the culture vessel for each 
experiment and allowed to plate and grow for 24 h prior to employment of 
modulators. Sub-confluent cells (~50%) were treated with high glucose (HG) DMEM 
(25 mM) (Invitrogen, Carlsbad CA) for 24 h to simulate acute hyperglycemia. The 
rationale for the high glucose (25 mM) concentration and time of exposure resulted 
from previous work in our laboratory, where high glucose (22 mM and 33 mM) were 
administered in a simulated chronic setting for 5 days (Mapanga et al., 2012; 
Rajamani and Essop, 2010). We therefore aimed to expose the cells to high glucose 
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for a much shorter period. This exposure time is also in accordance with similar 
studies (Davidoff et al., 2004; Park et al., 2005). We chose 25 mM glucose as this is 
already the end concentration in DMEM used for routine maintenance of various cell 
types, and addition of more glucose would not be required. This ensured a higher 
level of standardization between independent experiments and ruled out possibilities 
of contamination associated with exogenously added glucose. The 25 mM 
concentration is also often used in similar studies (Davidoff et al., 2004; Park et al., 
2005).   
 
In separate treatment groups, cells were administered with pharmacological 
compounds (described below) ± high glucose for the final hour of the simulated acute 
hyperglycemic period (i.e. 23 h HG + 1 h compounds with high glucose).  A timeline 
for the experimental plan is illustrated in Fig 3.1. In order to assess the role of 
mitochondrial and NOX- derived ROS in our system, we employed 250 µM α-cyano-
4-hydroxycinnamic acid (4-OHCA, Sigma Aldrich, St Louis MO; inhibits mitochondrial 
ROS production) and 100 µM diphenylene iodonium chloride (DPI, Sigma Aldrich, St 
Louis MO; NADPH oxidase inhibitor) (Fig 4.2). These ROS modulators were used for 
studies outlined in Chapter 4. The involvement of the four NOGPs was assessed 
using pharmacological inhibitors to target key mediators of each respective pathway. 
Here we employed 100 µM aminoguanidine (AMG; inhibits AGE precursors), 5 µM 
chelerythrine (CHE; PKC inhibitor), 40 µM 6-diazo 5-oxo-L-norleucine (DON; HBP 
inhibitor), and 10 µM zopolrestat (ZOP; polyol pathway inhibitor) (all from Sigma 
Aldrich, St. Louis MO). The transketolase co-factor and activator benfotiamine (BFT; 
Sigma Aldrich, St. Louis MO) was employed to evaluate the influence of the pentose 
phosphate pathway (PPP) (Fig. 4.2). The NOGP modulators were used for studies in 
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Chapter 5. Low glucose and high glucose controls were administered without any 
modulators. Acute high glucose treatments and modulatory studies were followed by 
molecular analyses for insulin action, oxidative stress and NOGPs using various 
experimental systems.  
 
 
Figure 4.1 Timeline of experimental plan. Cells were seeded and allowed to plate and grow for 48 h 
prior to high glucose treatment for additional 24 h. Modulators were added (separate experimental 
groups) for the final hour prior to analysis. 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
128 
 
 
Figure 4.2 Target sites for pharmacological modulators employed in this study. Hyperglycemia 
leads to increased glycolytic flux and higher mitochondrial ROS production. PARP is released to repair 
the resulting DNA damage, but inhibits GAPDH in the process. This leads to accumulation of 
upstream metabolites (refer red arrows). Subsequently, non-oxidative glucose pathways (NOGPs) are 
activated: polyol pathway, PPP, HBP, AGE and PKC (refer blue arrows). This may result in NOX 
activation and further increased ROS production (refer green arrows). The following inhibitors were 
used: (1) α-cyano-4-hydroxycinnamic acid (4-OHCA) - mitochondrial ROS, (2) diphenylene iodonium 
(DPI) – NOX, (3) zopolrestat (ZOP) – polyol, (4) 6-diazo-5-oxo-L-norleucine (DON) – HBP, (5) 
aminoguanidine (AMG) – AGE, and (6) chelerythrine (CHE) – PKC. We also employed the 
transketolase activator benfotiamine (BFT) (7) to assess PPP involvement. AR: aldose reductase, 
SDH: sorbitol dehydrogenase, G6PD: glucose-6-phosphate dehydrogenase, 6-PGL: 6-
phosphoglucono-1-5-lactone, TK: transketolase, GFAT: glutamine:fructose-6-phosphate 
amidotransferase, Gln-6-P: glucosamine-6-phosphate, DHAP: dihydroxy acetone phosphate, DAG: 
diacylglycerol, PARP: poly(ADP)ribose polymerase.    
  
 
4.4. Otsuka Long-Evans Tokushima Fatty (OLETF) rat model of thiamine 
treatment 
 
Previously collected heart tissues were kindly provided by Dr. Takao Tanaka (Osaka 
University of Pharmaceutical Sciences, Osaka, Japan). Here, four week old male 
OLETF rats (a model of obesity and insulin resistance) were randomly divided into 
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untreated and thiamine treated groups (n=16 per group) with the latter group 
receiving thiamine (2 g/L) in their drinking water (refer Tanaka et al., 2010). 
Experimental groups were further divided according to treatment time, with one group 
sacrificed at 25 weeks (i.e. 21 weeks of thiamine) and the other at 55 weeks (i.e. 51 
weeks thiamine). There were thus four groups of n=8 per group in total. Control 
OLETF rats displayed higher body and organ weights versus thiamine treated 
counterparts. Although control  Long-Evans Tokoshima Otsuka (LETO) rats (non-
diabetic/lean counterparts to OLETF rats) were not assessed in the study by Tanaka 
et al. (2010), OLETF rats from the study and from breeder colonies exhibited obesity 
and insulin resistance phenotypes when compared to LETO breeders. Here, the 
researchers reported higher body weights and plasma glucose levels in the OLETF 
breeders and experimental animals. Thiamine administration reversed plasma 
glucose, insulin, triglycerides and HbA1c levels. Of note, the levels of plasma glucose 
and insulin were both higher in the 25 week OLETF controls relative to the thiamine 
treated group, while glucose levels remained high but insulin levels were reduced at 
55 weeks in both untreated and treated groups. This was accompanied by enlarged 
pancreatic islets at 25 weeks, but severe morphologically altered islets at 55 weeks. 
The researchers suggested that these data may point to a 
hyperinsulinemic/hyperglycemic (pre-diabetic phenotype) state at 25 weeks, but a full 
blown diabetic state at 55 weeks. Thiamine treatment prevented development of 
insulin resistance and diabetes. Furthermore, echocardiographic assessment of 55 
week-old OLETF rats showed reduced heart function which was attenuated by 
thiamine treatment (Tanaka et al., 2010)  
For the purposes of this thesis, we aimed to assess the role of in vivo hyperglycemia 
in the two different states of glucose metabolic dysregulation (i.e. 25 weeks - “pre-
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diabetes” and 55 weeks – “overt diabetes”) and evaluate the molecular mechanisms 
underlying the thiamine-induced reversal of metabolic dysfunction in collected heart 
tissues. Here, we assessed the involvement of NOGPs (discussed in Section 6.4.3).   
 
4.5. Measurement of insulin action 
 
We employed different experimental approaches to evaluate insulin action. Here, we 
aimed to assess glucose uptake, GLUT4 translocation and activity of the proximal 
insulin signaling cascade. These events occur in a sequential manner upon insulin 
stimulation and directly results in the uptake of glucose.  
    
4.5.1. Glucose uptake assay 
 
Insulin-mediated glucose uptake was assessed by labeling cells with the fluorescent 
glucose analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-
NBDG; Invitrogen, Carlsbad CA).  Cells were seeded in T25 culture flasks at 300,000 
cells per flask and treated as described in Section 4.3. Serum free DMEM was 
employed for 3 h prior to preparation for analysis to achieve a basal condition. This is 
routinely done in similar experiments to evaluate the effect of insulin per se on 
downstream mechanisms such as glucose uptake (Bogan et al., 2001; Gonzales et 
al., 2011; Welsh et al., 2007; Zeigerer et al., 2004). Cells were trypsinized and 
centrifuged at 1,358 x g for 3 min. The pellets were washed in warm PBS (1 ml) and 
the resulting suspension divided into two separate tubes (i.e. two tubes per treatment 
condition). Here, one tube would serve as a basal control while the other would be 
exposed to insulin. The following working solutions were prepared - reaction buffer A: 
Stellenbosch University  http://scholar.sun.ac.za
131 
 
100 µM 2-NBDG and 10 µg/ml propidium iodide (PI; Invitrogen, Carlsbad CA); and 
reaction buffer B: 100 µM 2-NBDG, 10 µg/ml PI and 100 nM insulin (Sigma Aldrich, 
St. Louis MO). Aliquots of 500 µl of the appropriate buffer (A for basal and B for 
insulin groups) were added to respective cell pellets for 20 min prior to analysis by 
flow cytometry (BD FACSAria, Becton Dickinson, San Jose CA). A minimum of 
10,000 events were analyzed per sample using the 488 nm laser. PI and 2-NBDG 
fluorescence intensities were detected using the PE-Texas Red and FITC emission 
filters, respectively. Four independent experiments were performed.  
 
PI-positive (non-viable) cells were identified in order to be excluded from analysis for 
glucose uptake. Initial optimization experiments were performed to determine the 
scatter characteristics of PI-positive cells (Fig. 4.3). Here, a positive control sample 
tube containing cells with compromised membranes (methanol treated) were 
analyzed for both PI and 2-NBDG uptake (Fig. 4.3 A-D). Population P1 (A) 
represents all cells analyzed. Sub-population P2 is a daughter population of P1 and 
is gated from the intensity histogram (B) which represents PI fluorescence intensity. 
The large peak to the right of the gate P2 (indicated by the arrow) represents PI 
positive cells, allowing gate P2 to be set to the left of the base of this peak. All cells 
falling in gate P2 would thus be considered PI-negative and viable. Sub-population 
P3 (C) is a daughter population of P2 and represents the 2-NBDG fluorescence 
intensity of (only) the viable cell population. Figure 3.3 (D) represents the 
fluorescence intensities of PI-PE-Texas Red (y-axis) and 2-NBDG-FITC (x-axis), and 
shows the large PI-positive population (red dots indicated with black arrow) with a 
small PI-negative (blue dots) population. Figure 3.3 (E-H) represents a normal 
experimental sample. The gating parameters set up using the positive control sample 
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were applied to identify and exclude PI positive cells in experimental samples. Here, 
a large population of PI-negative cells fall inside gate P2 (F) and is included in the 
analysis of 2-NBDG uptake (the peak inside gate P3 at G and population of blue dots 
in H). The smaller peak in F and small population of red dots in H (indicated by the 
arrows) are the PI-positive cells excluded from analysis. The appropriate timepoint for 
incubation in reaction buffer was also optimized during an initial set of experiments 
(refer Fig 5.5). 
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Figure 4.3 Flow cytometry analysis of 2-NBDG uptake in H9c2 cells – gating characteristics 
used to exclude non-viable cells. Cells were stained with 100 µM 2-NBDG and 10ng/ml PI. Non-
viable (PI-positive) cells were identified by inclusion of a positive control sample containing cells with 
comprised membranes (A-D). Parameters from a normal experimental sample are indicated (E-F). A 
and E: Parent populations falling in gate P1 with side scatter (SSC-A) on the y-axis and forward 
scatter (FSC-A) on the x-axis. B and F: PI intensity histograms indicated by PE-Texas Red-A showing 
PI-negative populations in gate P2. C and G: 2-NBDG intensity histograms indicated by FITC-A. D and 
H: Scatter plots of PI-PE-Texas Red (y-axis) and 2-NBDG-FITC (x-axis) showing PI-positive cells (red 
dots) and 2-NBDG-positive cells (blue dots).  Arrows indicate PI-positive cells B, D, F and H.  
     . 
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4.5.2. GLUT4 translocation assay 
 
Insulin-stimulated translocation of GLUT4 transporters was determined by expressing 
the HA-GLUT4-GFP fusion protein (a kind gift from Drs. G. Welsh and J.M. Tavarè, 
University of Bristol, UK) in H9c2 cells. 
 
4.5.2.1. Transfection of HA-GLUT4-GFP 
 
H9c2 cells were seeded in 8-chamber coverslides (Nalge Nunc, Roschester NY) at 
10,000 cells per well and allowed to plate for 24 h. Transfection of HA-GLUT4-GFP 
was achieved using Lipofectamine LTX™ transfection reagent (Invitrogen, Carlsbad 
CA). Per sample well, 3 µl of Lipofectamine transfection reagent was diluted in 50 µl 
serum and antibiotic free DMEM in a sterile microcentrifuge tube. A second solution, 
800 ng DNA in 50 µl serum and antibiotic free DMEM was prepared in separate 
tubes. The two solutions were gently vortexed and mixed together to form 100 µl of 
DNA-Lipofectamine complexes. The solution was incubated at room temperature for 
15 min and added in a drop wise manner to each well. The plates were gently rocked 
and cells were incubated for 24 h at 37°C and 5% CO2. Expression of GLUT4 was 
determined in cells exhibiting positive GFP fluorescence. After establishing 
successful transfection and expression of HA-GLUT4-GFP, cells were exposed to 
treatment protocols as described above and the effect of insulin was determined by 
labeling HA tags using immunofluorescence.  
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4.5.2.2. Treatment and preparation for fluorescence microscopy 
 
After 24 h, cells were treated with pharmacological compounds (4-OHCA, DPI), 
serum starved for 3 h and treated with 100 nM insulin for 10 min. Cell monolayers 
were then washed with cold PBS and fixed in 4% paraformaldehyde followed by 
immunostaining with 10 µg/ml anti-HA mouse monoclonal antibody (Cell Signaling, 
Danvers MA) and anti-mouse Texas Red secondary antibody (Invitrogen, Carlsbad 
CA). This approach allows the detection of HA tags which would be exposed on the 
outer face of the sarcolemma when HA-GLUT4-GFP molecules have translocated, 
docked and fused. Fluorescence microscopy was performed using an Olympus 
Cell^R IX-81 fluorescence inverted microscope (Olympus Biosystems, Germany). All 
images were acquired using a 60X oil immersion objective. Multicolor images were 
acquired for both the Texas Red (HA) and GFP channels. Fluorescence in each 
channel was corrected for background by subtracting the fluorescence from 
untransfected cells. 
 
4.5.2.3. Evaluation of HA: GFP ratio 
 
The HA:GFP ratio was calculated for each cell to determine the membrane-to-total 
GLUT4 (the relative amount of GLUT4 at the membrane as a measure of GLUT4 
translocation), as done before (Welsh et al., 2007). This also served to normalize for 
differences in expression levels between cells. Results were derived from at least 
150 cells per treatment group from five independent experiments.  
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4.5.3. Protein kinase B (PKB/Akt) activity assay 
 
The activity of protein kinase B (PKB), also known as Akt, was determined by 
employing an Akt kinase activity assay kit (Abcam, Cambridge MA). Akt was isolated 
by immunoprecipitation from lysates of treated cells and incubated with a mixture of 
recombinant glycogen synthase kinase (GSK) 3α (a known Akt substrate) and ATP. 
Akt activity was determined by the degree of GSK3α phosphorylation as detected by 
Western blotting. The kit components included: kinase extraction buffer, kinase assay 
buffer, anti-Akt antibody, protein-A sepharose beads, GSK3α peptide-ATP mixture 
and phospho-GSK3α specific antibody. The protocol consisted of the following steps: 
preparation of cell lysate, immunoprecipitation of Akt, kinase assay and Western 
blotting. A detailed description is outlined below. 
 
4.5.3.1. Preparation of cell lysate 
 
Cells were grown in T25 flasks and treated according to the protocols described in 
Section 3.3. Monolayers were then washed with warm PBS, trypsinized and 
centrifuged (1,358 x g, 3 min). Pellets were washed with cold (4°C) PBS and 
subsequently lysed in 200 µl cold kinase extraction buffer for 5 min on ice. The lysed 
cells were centrifuged (5,000 x g, 10 min at 4°C) and supernatant (cell lysate) 
transferred to new pre-chilled microcentrifuge tubes. Protein content was assayed 
using the Bradford protein determination method (Appendix B). Cell lysates were 
kept on ice and immunoprecipitation carried out immediately. 
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4.5.3.2. Immunoprecipitation of Akt 
 
Akt was immunoprecipitated from cell lysates by incubation of 200 µl lysate 
(containing 400 µg total protein) with 2 µl anti-Akt antibody per reaction for 45 min at 
room temperature while gently rotating. Protein A sepharose beads were gently 
resuspended and 50 µl of the slurry was added to each sample. Rotation of tubes 
was continued at room temperature for 1 h. Samples were then centrifuged at 8,000 
x g for 2 min and the supernatant removed. Protein A beads were washed twice with 
500 µl kinase extraction buffer and once with 500 µl kinase assay buffer.  
 
4.5.3.3. Kinase assay 
 
Kinase assay buffer (50 µl) was added to the washed beads, followed by 2 µl of the 
GSK3α-ATP mixture per sample and incubated at 30°C for 4 h. Samples were then 
centrifuged to pellet beads and 30 µl supernatant collected into new microcentrifuge 
tubes. Next, 15 µl Laemmli sample buffer (3X concentrated) was added and samples 
boiled at 95°C for 3 min. Samples were microcentrifuged to pellet any remaining 
beads and 20 µl aliquots of the supernatant were transferred to new tubes for 
Western blot analysis.   
 
4.5.3.4. Western blot analysis of phosphorylated GSK3α 
 
Samples were subjected to 12% SDS-PAGE and semi-dry transfer onto PVDF 
membranes (a full Western blotting protocol is described in Appendix C). Membranes 
were blocked with 5% non-fat milk in TBS-T and incubated with the rabbit anti-
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phospho-GSK3α antibody (1:1,000) overnight at 4°C. This was followed by 
incubation with anti-rabbit HRP-conjugated secondary antibody (1:10,000) for 1 h at 
room temperature and detection using ECL (Bio-Rad, Hercules CA).  
 
4.6. Evaluation of oxidative stress mechanisms 
 
We aimed to evaluate the role of oxidative stress mechanisms under acute 
hyperglycemic conditions. Here, we employed various techniques to determine the 
levels of total intracellular ROS, mitochondrial-derived ROS and activity of NADPH 
oxidase. We further assessed intracellular damage associated with oxidative stress 
by evaluation of aconitase activity and malondialdehyde (MDA) adduct formation. 
Finally, we also determined the intracellular antioxidant systems by evaluation of 
superoxide dismutase (SOD) activity, formation of reduced glutathione (GSH) and 
catalase activity. As the replenishment of GSH pools require NADPH, we also 
assessed its levels and turnover (NADP+:NADPH ratio), and the activity of glucose-6-
phosphate dehydrogenase (G6PD), a major supplier of intracellular NADPH.  
 
4.6.1. Total intracellular ROS levels – DCF fluorescence 
 
We employed the cell permeant ROS indicator 2´,7´-dichlorodihydrofluorescein 
diacetate stain (H2DCFDA or DCF; Molecular Probes, Eugene OR) for detection of 
relative changes in intracellular ROS. These dyes are non-fluorescent, chemically 
reduced and acetylated compounds which become fluorescent when the acetate 
groups are removed upon oxidation. An increase in fluorescein (FITC) fluorescence 
is observed, which in turn can be related to ROS levels within the cell.  
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DCF stock solutions were prepared by dissolving lyophilized reagent in DMSO to a 
concentration of 10 mM. Single use aliquots were stored at -20°C protected from light 
and air. Fresh working solutions were prepared for every experiment by diluting 
stocks in warm (37°C) PBS to a final concentration of 50 µM (1:200 dilution). We 
employed fluorescence microscopy to qualitatively evaluate intracellular localization 
and fluorescence intensity of DCF in single cells, while flow cytometry was employed 
to quantitatively evaluate relative changes of cell populations per treatment group.  
 
4.6.1.1. Fluorescence microscopy analysis of DCF staining 
 
Cells were seeded in 8-well chambered coverslides (Nalgene Nunc, Rochester NY) 
at 15,000 cells per well in 400 µl DMEM for fluorescence microscopy experiments. 
High glucose and modulator treatments were performed as described in Section 4.2. 
After treatments, cell monolayers were washed with warm (37°C) PBS and incubated 
in 100 µl of freshly prepared dye solution (50 µM DCF) for 10 min at 37°C in the dark. 
Cells were also stained with 1:200 dilution of DAPI (Molecular Probes, Eugene OR) 
to detect nuclei. After 10 min, dye solutions were removed and cells washed with 
warm PBS. The cell layers were covered with 100 µl warm PBS, followed by 
fluorescence microscopy using an Olympus Cell^R IX-81 fluorescence inverted 
microscope (Olympus Biosystems, Germany) equipped with an F-view-II cooled CCD 
camera.  All images were acquired using a 60X oil immersion objective. Cells were 
maintained at 37°C using the heating chamber while images were acquired. 
Multicolor images were acquired for both the DAPI and FITC channels. At least three 
random fields of view were acquired per treatment group per experiment and four 
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independent experiments were performed. Images were used for qualitative data 
while flow cytometry analysis served as a quantitative measure of DCF fluorescence.    
 
4.6.1.2. Flow cytometry analysis of DCF staining  
 
For flow cytometry experiments, cells were seeded in T25 flasks and treated as 
described in Section 3.2. Cells were washed with warm PBS and trypsinized using 2 
ml warm Trypsin-EDTA (Invitrogen, Carlsbad CA) and incubated at 37°C until cells 
have dislodged. Cell suspensions were diluted with 4 ml warm DMEM, collected in 15 
ml centrifuge tubes and centrifuged at 1,358 x g for 3 min in a Digicen 20-R 
Ortoalresa centrifuge (United Scientific, Cape Town, South Africa). Cells were 
incubated for 10 min at 37°C with the freshly prepared dye working solution, 
centrifuged (1,358 x g, 2 min) and pellets washed with warm PBS before flow 
cytometry analysis (BD FACSAria™, Becton Dickinson, San Jose CA). Positive 
control samples were treated with 100 µM H2O2. A 488 nm laser and 502LP, 530/30 
BP emission filters were used. Fluorescence intensity was determined using the 
geometric mean. A minimum of 10 000 events were analyzed per sample tube. 
Experiments were repeated at least nine times and population data for treatment 
groups were normalized to relative control population data. 
 
4.6.2. Mitochondrial ROS levels 
 
In separate experiments, MitoTracker Red™ carboxy-methyl dihydro-X-rosamine 
(CM-H2XRos) dye (Molecular Probes, Eugene OR) was employed to detect 
mitochondrial ROS sources. As with DCF, this dye is chemically reduced and non-
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fluorescent. It readily diffuses across cell membranes and accumulates in 
mitochondria of live and actively respiring cells. It becomes fluorescent when it is 
oxidized in the mitochondria, with Ex/Em wavelengths at 579/599 nm.  
 
Stock solutions were prepared by dissolving the lyophilized product in DMSO to a 
concentration of 1 mM. Single use aliquots were stored at -20°C protected from light 
and air. Fresh working solutions were prepared for every experiment by diluting 
stocks in warm (37°C) PBS to a final concentration of 20 nM (1:500 dilution). We 
employed fluorescence microscopy to qualitatively evaluate intracellular localization 
and fluorescence intensity of MitoTracker in single cells, while flow cytometry was 
employed to quantitatively evaluate relative changes of cell populations per treatment 
group.  
 
4.6.2.1. Fluorescence microscopy analysis of MitoTracker CM-H2XRos staining 
 
Cell treatment, staining and microscopy analysis were performed as described in 
Section 4.6.1.1, with the following exceptions: cells were stained with 20 nM 
MitoTracker and 1:200 DAPI (Molecular Probes, Eugene OR) and images were 
acquired for the Texas Red and DAPI channels.  
 
4.6.2.2. Flow cytometry analysis of MitoTracker CM-H2XRos staining  
 
Flow cytometry protocols for MitoTracker detection were as described in Section 
4.6.1.2, with the following exceptions: cells were incubated for 10 min at 37°C with 20 
nM MitoTracker and a minimum of 10,000 events were analyzed per sample tube 
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using a 488 nm laser and 610LP, 616/23 BP emission filters. Experiments were 
repeated at least twelve times and population data for treatment groups were 
normalized to relative control population data. 
 
4.6.3. NADPH oxidase activation 
 
The activity of NADPH oxidase was evaluated using a modified assay (Abid et. Al., 
2007). Lucigenin emits photons upon acceptance of electrons generated by the 
NADPH oxidase complex. Briefly, lysates of treated cells were prepared and protein 
content determined using the Bradford method. Assay buffer containing 250 mM 
HEPES (pH 7.4), 120 mM NaCl, 5.9 mM KCl, 1.2 mM MgSO4(7H2O), 1.75 mM 
CaCl2(2H2O), 11 mM glucose, 0.5 mM EDTA, 100 µM NADH and 5 µM lucigenin was 
added to the samples and light emission measured over a 20 min period using a 
Glomax-96 luminometer (Promega, Madison WI). Data was converted to relative light 
units/min/µg protein and expressed as percentage (%) of control cells. 
 
4.6.4. Aconitase activity 
 
Aconitase is a citric acid cycle intermediate that catalyzes the stereospecific 
isomerization of citrate to isocitrate. We employed a colorimetric aconitase activity 
assay kit (Abcam, Cambridge MA) to monitor relative changes in cytosolic aconitase 
activity in our cell system. In the assay, aconitase converts citrate to isocitrate and a 
subsequent reaction results in a product that converts a colorless probe into a 
colored form with λmax at 450 nm.  
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Cells were cultured in T25 flasks and treated as described in Section 4.3. Cell 
monolayers were washed with cold PBS and scraped in 100 µl cold assay buffer, 
followed by sonication and centrifugation at 800 x g for 10 min at 4°C. The 
supernatant was transferred to new tubes, followed by addition of 10 µl activation 
solution and kept on ice for 1 h to activate aconitase. Fifty microliters of activated 
samples were added to duplicate wells of a 96-well plate. A 2 mM isocitrate standard 
solution was prepared and 0, 2, 4, 6, 8 and 10 µl added to triplicate wells to 
respectively generate 0, 4, 8, 12, 16 and 20 nmol/well standard curve. The volumes 
in each well were adjusted to 50 µl with assay buffer. Reaction mixture containing 
assay buffer, enzyme mixture and substrate were prepared and 50 µl added to each 
well and the contents mixed well. Plates were incubated at 25°C for 60 min followed 
by addition of 10 µl developer and further incubation at 25°C for 10 min. Optical 
density (OD) was measured at 450 nm in a microplate reader (EL 800 KC Junior 
Universal Microplate reader, Bio-Tek Instruments, Winooski VT). OD values from 
blank wells were subtracted from sample and standard curve wells and isocitrate 
content per well determined from the standard curve. Aconitase activity was 
calculated as follows: Aconitase activity = B/(T x V) x sample dilution factor, where B 
= nmol isocitrate per well; T = time incubated (60 min) and V = final sample volume 
assayed. Data was calculated as nmol/min/ml and expressed as percentage (%) of 
control. An n=3 was generated.        
 
4.6.5. Malondialdehyde (MDA) assay 
 
Lipid peroxidation is a detrimental modification of lipids exerted by oxidative stress. 
Malondialdehyde (MDA) adducts are among the products of lipid peroxidation and a 
Stellenbosch University  http://scholar.sun.ac.za
144 
 
measure of MDA adduct formation can serve as an indication of oxidative stress. We 
employed the Oxyselect MDA adduct ELISA kit (Cell Biolabs, San Diego CA) to 
assess levels of MDA adducts. Briefly, cells treated as described in Section 4.3 were 
lysed using cold modified RIPA buffer and protein concentrations determined using 
the Bradford method. Protein samples were diluted to10 µg/ml in 1X PBS and kept 
on ice. MDA-BSA standards were prepared according to kit instructions and serial 
dilutions were prepared in duplicate to create a range of standards. Protein samples 
(triplicates) and standards with blank controls (duplicates) were pipetted into wells of 
a 96-well protein binding plate (included in the kit) and incubated at 4°C overnight. 
Wells were washed with 250 µl 1X PBS the next day, followed by addition of 200 µl 
assay diluent and incubated for 2 h at room temperature. This was followed by 
washing with 1X wash buffer and addition of 100 µl 1:1,000 anti-MDA antibody for 1 h 
at room temperature. Wells were thoroughly washed and incubated with 100 µl 
1:1,000 secondary HRP-conjugated antibody for 1 hour at room temperature. This 
was followed by thorough washing as before and addition of 100 µl substrate solution 
to all wells and incubation for 30 min at room temperature. The enzyme reaction was 
terminated by adding 100 µl stop solution to each well and absorbance was 
immediately read at 450 nm using a microplate reader (EL 800 KC Junior Universal 
Microplate reader, Bio-Tek Instruments, Winooski VT). MDA adduct levels were 
determined by calculating sample values from the standard curve after subtracting 
blank OD values.  
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4.6.6. Superoxide dismutase (SOD) activity assay 
 
Total SOD activity was assessed by using the Biovision SOD activity assay kit 
(Biovision, Mountain View CA). The kit utilizes a water-soluble tetrazolium salt (WST-
1) which is reduced by superoxide radicals to a water soluble and colored WST1-
formazan product. The reaction is inhibited by SOD and the inhibition activity of SOD 
can therefore be determined colorimetrically. Protein samples were prepared from 
treated cells using cold modified RIPA buffer and protein concentration determined 
by the Bradford method. Protein samples, controls and blanks were pipetted into 
wells of a 96-well plate, 20 µl per well, followed by addition of 200 µl WST working 
solution and 20 µl SOD enzyme working solution  to all wells. Plates were incubated 
at 37°C for 20 min. Absorbance was read at 450 nm using a microplate reader (EL 
800 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski VT). SOD 
activity was calculated by determining the % inhibition as follows: % inhibition = 
(Acontrol – Asample)/Acontrol x 100. 
 
4.6.7. Glutathione levels 
 
Intracellular glutathione (GSH) levels were determined by employing the DetectX 
glutathione colorimetric detection kit (Arbor Assays, Ann Arbor MI). A colorimetric 
substrate provided with the kit reacts with free thiol groups on GSH, resulting in a 
colored product. Samples were prepared by lysing cells in cold 100 mM phosphate 
buffer, pH 7. An aliquot of the cell lysate was used for protein determination, while a 
second aliquot was treated with an equal volume of cold 5% sulfosalicylic acid and 
incubated at 4°C for 10 min to deproteinize the sample. Samples were centrifuged for 
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10 min at 10,000 x g at 4°C to remove precipitated protein. Supernatants were 
collected in new microcentrifuge tubes and diluted 1:5 with assay buffer. A serial 
dilution of the supplied GSH standard was prepared in sample diluent. Prepared 
samples and standards were pipetted into duplicate wells of a 96-well plate (50 µl 
each) and sample diluent served as a reaction blank. Colorimetric detection reagent 
(25 µl per well) was added to all wells followed by the addition of 25 µl reaction 
mixture (NADPH concentrate and glutathione reductase concentrate diluted in assay 
buffer). Plates were tapped gently to mix the contents and incubated for 20 min at 
room temperature. Absorbance was measured at 405 nm using a microplate reader 
(EL 800 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski VT). 
GSH levels in samples were calculated from the standard curve.         
 
4.6.8. NADPH levels and NADP+: NADPH ratio calculation 
 
We employed a NADP/NADPH assay kit (Abcam, Cambridge MA) to determine the 
levels of NADPH and the ratio of NADP: NADPH in treated cells. Samples were 
prepared by washing cell monolayers (cells grown in T25 flasks) with PBS followed 
by tripsinization. Cell pellets were treated with 400 µl NADP/NADPH extraction buffer 
and exposed to two freeze-thaw cycles (20 min on dry ice followed by 10 min at room 
temperature. Extractions were vortexed for 10 sec and centrifuged at 10,000 x g for 5 
min. Supernatants were transferred to new tubes and kept on ice – this contained 
total NADP (NADPH and NADP). In order to determine NADPH levels, an aliquot of 
the extracted samples was decomposed by heating at 60°C for 30 min. A serial 
dilution was prepared using the supplied NADPH standard to generate a standard 
curve. Samples and standards (50 µl) were added to duplicate wells of a 96-well 
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plate followed by addition of 100 µl NADP cycling mix (NADP cycling enzyme diluted 
in NADP cycling buffer). Plates were gently rocked and incubated for 5 min at room 
temperature. This was followed by addition of 10 µl NADPH developer to each well 
and incubation for 4 h at room temperature. Absorbance was read at 450 nm using a 
microplate reader (EL 800 KC Junior Universal Microplate reader, Bio-Tek 
Instruments, Winooski VT), before and after the addition of 10 µl stop solution. Total 
NADP and NADPH values were calculated from the standard curve using blanked 
absorbance values. The ratio of NADP: NADPH was calculated as follows: Ratio = 
(NADPt – NADPH)/NADPH, where NADPt is the total NADP (i.e. NADP and NADPH 
combined. 
 
4.6.9. Glucose-6-phosphate dehydrogenase (G6PD) activity assay 
 
We employed a commercially obtained colorimetric assay kit to determine the activity 
of G6PD (Biovision, Mountain View CA). In the assay, the oxidation of glucose-6-
phosphate is accompanied by the conversion of a colorless probe into a colored 
product. Protein samples were prepared from treated cells using cold modified RIPA 
buffer (Appendix A) and protein concentrations determined using the Bradford 
method. Fifty microliters of the prepared protein samples, a G6PD positive control 
and serial dilution of NADH standards were pipetted in duplicate wells of a 96-well 
plate. This was followed by addition of 50 µl reaction mix (G6PD substrate and 
developer diluted in assay buffer). The plate was immediately read at 450 nm using a 
microplate reader (EL 800 KC Junior Universal Microplate reader, Bio-Tek 
Instruments, Winooski VT) at timepoint T1, followed by incubation at 37°C for 30 min. 
Thereafter, the plate was read again at 450 nm (timepoint T2). The change in 
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absorbance (ΔA450) was determined by subtracting OD values of T1 from that of T2. 
After correcting for background by subtracting blank OD values, the NADH amount 
between T1 and T2 (B) was calculated from the standard curve by applying ΔA450. 
G6PD activity was calculated as follows: G6PD activity = [B/(T2 – T1) x V] x sample 
dilution; V is the pre-teated sample volume added to wells.  
 
4.7. Evaluation of metabolic alterations 
 
We aimed to evaluate metabolic alterations by measuring intracellular ATP levels 
and several markers of the NOGPs. 
 
4.7.1. Measurement of intracellular ATP levels 
 
Intracellular ATP levels were determined using the ENLITEN® ATP bioluminescent 
assay kit (Promega, Madison WI). Here, the ATP-dependent oxidation of luciferin by 
luciferase results in light emission, which could be quantitatively measured using a 
luminometer.  The assay includes recombinant luciferase which is used to catalyze 
the reaction:  
Luciferin + ATP + O2 → Oxyluciferin + AMP + PPi + light (560 nm) 
The light emission is directly proportional to the ATP amount since ATP is the limiting 
factor.  
 
Cells were grown in T25 flasks and treated as outlined in Section 4.2. Monolayers 
were washed and trypsinized (4 ml Trypsin-EDTA, 37°C) until cells detached. Cells 
were collected, centrifuged (1,350 x g, 3 min at 4°C) and pellets washed in sterile 
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PBS. The suspension was centrifuged again and resulting pellets were resuspended 
in 50 µl ice cold lysis buffer (100 mM Tris-HCl, 4 mM EDTA, pH 7.75) (Essmann et 
al., 2003). This was immediately followed by the addition of 150 µl boiling lysis buffer 
and incubation at 99°C for 2 min. Samples were then centrifuged at 8,000 x g, 4°C 
for 1 min and supernatant collected for ATP assay and protein determination. 
 
A volume of 50 µl samples were added to duplicate wells of a white 96-well 
luminometer plate (Glomax Promega, Madison WI). ATP-free water served as a 
negative control and ATP standard as a positive control. These reagents were added 
to triplicate wells (50 µl). The luciferase reagent was prepared as per the kit 
instructions, and 50 µl added to samples followed by immediate analysis using a 
Glomax-96 luminometer (Promega, Madison WI).  
 
4.7.2. Evaluation of non-oxidative glucose metabolic pathways 
 
We employed commercial kits to evaluate markers of NOGPs as follows: polyol 
pathway using a D-sorbitol colorimetric detection kit (Biovision, Mountain View CA), 
PKC kinase activity (Enzo Life Sciences, Farmingdale NY), AGE precursors using the 
OxiSelect™ Methylglyoxal ELISA kit (Cell Biolabs, San Diego CA) and oxidative PPP 
using the G6PD assay kit (Biovision, Mountain View CA).  O-GlcNAc levels (HBP 
marker) were determined by immunofluorescence microscopy and Western blotting. 
Transketolase activity (non-oxidative PPP) was assessed by using a modified 
enzyme assay. These procedures were as described by us before (Mapanga et al., 
2012). 
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4.7.2.1. Sample preparation for NOGP analysis  
 
Cells were grown and treated in T25 flasks as described in Section 4.3. Monolayers 
were washed with cold PBS followed by the addition of 500 µl cold freshly prepared 
modified RIPA buffer (see Appendix) and scraped using a pre-chilled sterile cell 
scraper. The suspension was transferred to pre-chilled microcentrifuge tubes, 
sonicated and centrifuged at 4,300 x g at 4°C for 10 min. The supernatant (cell 
lysate) was transferred to new tubes and kept on ice. Protein concentrations were 
determined using the Bradford method (refer Appendix B). 
 
4.7.2.2. Methylglyoxal levels (AGE) 
 
Methylglyoxal-BSA (MG-BSA) standards and a blank (triplicate wells) and 100 µl of 
10 µg/ml protein samples (duplicate wells) were pipetted into a pre-adsorbed 96-well 
ELISA plate (component of the kit), and incubated overnight at 4°C with gentle 
agitation. Wells were washed with 1X PBS the following day and 250 µl assay diluent 
added for 2 h at room temperature. The plate was subsequently washed with wash 
buffer and probed with 100 µl of anti-MG monoclonal antibody (1:1,000 dilution) for 
60 min at room temperature. Primary antibody was then removed, wells washed and 
100 µl of secondary HRP-conjugated antibody (1:1,000 dilution) added and incubated 
for 60 min at room temperature. After an additional series of wash steps, 100 µl of 
substrate solution was added to each well and the plate incubated for 20 min at room 
temperature. The enzyme reaction was stopped by adding 100 µl of stop solution to 
each well. Absorbance was read immediately at 450 nm using a microplate reader 
(EL 800 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski VT). 
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Optical densities were normalized by subtracting values of the blank from those of 
samples and standards. MG levels were calculcated from the standard curve as 
nmol/µg protein and data normalized to relevant controls. A minimum of six 
independent sample preparations were performed and each assayed in duplicate.   
 
4.7.2.3. Sorbitol levels (Polyol) 
 
A working solution of sorbitol standards (1 mM) was prepared using the stock 
solution provided in the kit. Standards (including reaction blanks) were pipetted into 
triplicate wells of a 96-well microtitre plate to generate 0, 2, 4, 6, 8 and 10 nmol/well 
by dilution in assay buffer. A volume of 50 µl protein samples was pipetted into 
duplicate wells. This was followed by addition of 50 µl reaction mix (enzyme mix, 
developer and probe diluted in assay buffer) to all wells and incubation at 37°C for 30 
min. Absorbance was read at 560 nm using a microplate reader (EL 800 KC Junior 
Universal Microplate reader, Bio-Tek Instruments, Winooski VT). Sorbitol 
concentration (C) was calculated by using the sample amount from the standard 
curve (Sa) in nmol, sample volume (Sv) and dilution factor (D) in the following 
equation: C=Sa/Sv*D.    
 
4.7.2.4. PKC activity 
 
Duplicates of prepared protein samples (refer Section 4.6.2.2) and triplicates of 
serially diluted PKC standards were pipetted (30 µl per well) into wells of the PKC 
substrate microtitre plate provided with the kit. The kinase reaction was initiated by 
addition of 10 µl ATP to each well and incubation at 30°C for 90 min. The reaction 
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was stopped by emptying the wells, followed by addition of 40 µl phospho-specific 
substrate antibody to each well and incubation for 60 min at room temperature. Wells 
were then emptied and, after a series of wash steps using 100 µl wash buffer, 
secondary HRP-conjugated anti-rabbit antibody (40 µl) added to each well. Plates 
were incubated at room temperature for a further 30 min. Wells were again emptied 
and washed as before. The assay was developed by adding 60 µl of 
tetramethylbenzidine (TMZ) substrate and incubation for 60 min at room temperature. 
Twenty microliters of acid stop solution was then added to each well and absorbance 
measured at 450 nm using a microplate reader (EL 800 KC Junior Universal 
Microplate reader, Bio-Tek Instruments, Winooski VT). The relative PKC kinase 
activity was calculated from the standard curve and expressed per µg protein for 
each well. Values were normalized to relative controls.    
 
4.7.2.5. PKC isoform expression 
 
Western blots were performed to investigate the expression levels of PKCβII in total 
cell lysate after treatment. Membranes were probed with an antibody against PKCβII 
(Abcam, Cambridge MA) and quantified by densitometric analysis - values 
normalized to β-actin. 
 
4.7.2.6. O-GlcNAc levels (HBP) 
 
O-GlcNAc levels were determined using immunofluorescence microscopy as 
described by us before (Rajamani and Essop, 2010) (Rajamani and Essop.,2010). 
Briefly, treated cells were fixed and permeabilized in cold (-20°C) methanol, blocked 
Stellenbosch University  http://scholar.sun.ac.za
153 
 
in 5% donkey serum (Sigma Aldrich, St. Louis MO) and probed overnight at 4°C with 
the anti-O-GlcNAc CTD110.6 monoclonal antibody (Santa Cruz Biotechnology, Santa 
Cruz CA). This was followed by staining with a donkey anti-mouse Texas Red 
secondary antibody (Invitrogen, Carlsbad CA) and imaging done by fluorescence 
microscopy (Olympus Biosystems, Germany) using the Texas Red filter.  
 
Cells were grown and treated in T25 flasks as described. Monolayers were washed 
with cold PBS followed by addition of 500 µl cold freshly prepared modified RIPA 
buffer (see Appendix A) and scraped using a pre-chilled sterile cell scraper. The 
suspension was transferred to pre-chilled microcentrifuge tubes, sonicated and 
centrifuged at 4,300 x g at 4°C for 10 min. The supernatant (cell lysate) was 
transferred to new tubes and kept on ice. Protein concentrations were determined 
using the Bradford method (refer Appendix B). 
 
4.7.2.7. Co-localization analysis of O-GlcNAc modifications 
 
Co-localization allows the visualization of proteins in close proximity using 
immunocytochemistry and fluorescence microscopy techniques. Using this approach, 
molecular interactions e.g. protein dimerization, post-translational modifications, 
intracellular localization, etc. may be determined and quantified by calculating the 
area of co-localization, as previously done by us (Rajamani and Essop, 2010). We 
aimed to determine the O-GlcNAc modification of insulin signaling intermediates Akt 
and AS160 by using double antibody staining and determining co-localization of O-
GlcNAc with each of these intermediates in separate experiments. 
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H9c2 cells were seeded in 8-well chambered coverslides (Nalgene Nunc, Rochester 
NY) at 10,000 cells per well and allowed to proliferate. High glucose and 
pharmacological treatments were administered as described in Section 3.2. Upon 
completion of the treatment protocols, media was removed and wells were washed 
with 300 µl cold (4°C) PBS. Cells were then fixed by adding cold 1:1 
methanol:acetone solution (100 µl per well) for 10 min at 4°C. Non-specific sites were 
blocked by incubating the cells in 50 µl 5% donkey serum solution (Sigma, St. Louis 
MO) for 20 min at 4°C. This was followed by addition of a primary antibody cocktail 
(100 µl per well) at 4°C overnight. The primary antibody cocktails consisted of the 
following combinations: a) 1:50 anti-O-GlcNAc CTD110.6 mouse monoclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz CA) and 1:200 anti-Akt rabbit 
polyclonal primary antibody (Cell Signaling, Danvers MA); or b) 1:50 anti-O-GlcNAc 
CTD110.6 mouse monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz CA) 
and 1:200 anti-AS160 rabbit primary antibody (Cell Signaling, Danvers MA).  
Antibody solutions were removed the following day and wells thoroughly washed with 
300 µl cold PBS. A cocktail of secondary antibodies was then added (1:200 anti-
mouse Texas Red conjugated – for O-GlcNAc detection; and 1:200 anti-rabbit FITC 
conjugated – for Akt or AS160 detection) and plates incubated for a further 30 min at 
4°C in the dark. We also included DAPI to stain the nuclei. The anti-mouse Texas 
Red conjugated antibody and DAPI were from Invitrogen (Carlsbad CA) and the anti-
rabbit FITC conjugated secondary antibody was from Santa Cruz Biotechnology 
(Santa Cruz CA). Wells were subsequently washed up to six times with cold PBS to 
remove excess antibodies, and coated with layer of fluorescence mounting medium 
(DAKO, Glostrup, Denmark) followed by analysis using an Olympus Cell^R 
fluorescence IX-81 inverted microscope (Olympus Biosystems, Germany) equipped 
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with an F-view-II cooled CCD camera.  All images were acquired using a 60X oil 
immersion objective. Multicolor images were acquired for the DAPI, Texas Red and 
FITC channels. Images were acquired through z-stacks with the top and bottom 
dimensions selected beforehand and a step width of 0.26 µm between image frames 
were used for all experiments. At least four random fields of view were acquired per 
treatment group per experiment and four independent experiments were performed. 
Images were processed for background subtraction and maximum intensity 
projections used for co-localization analysis using the Cell^R software (Olympus 
Biosystems, Germany). The area of co-localization was determined and data 
expressed relative to control values per experiment. 
    
4.7.2.8. Transketolase activity (PPP) 
 
Transketolase activity (non-oxidative PPP) was measured using a modified protocol 
(EC 2.2.1.1) from Sigma Aldrich (St. Louis MO). All chemicals used were of analytical 
grade and from Sigma Aldrich (St. Louis MO). An assay buffer containing 216 mM 
glycylglycine buffer, 3.3 mmol/l xylulose 5-phosphate (X-5-P), 1.7 mmol/l ribose 5-
phosphate (R-5-P), 0.002% (w/v) cocarboxylase (thiamine pyrophosphate solution) 
(TPP), 0.14 mmol/l reduced β-nicotinamide adenine dinucleotide (β-NADH), 15 
mmol/l MgCl2, 20 units a-glycerophosphate dehydrogenase/triophosphate isomerase 
enzyme solution (a-GDH/TPI) were added to a 96-well plate. Absorbance was 
monitored until constant using a microplate reader (EL 800 KC Junior Universal 
Microplate reader, Bio-Tek Instruments, Winooski VT), whereafter cell samples and 
transketolase enzyme solution (positive control) were added to triplicate wells and 
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the relative decrease in absorbance monitored for 10 min. Transketolase activity was 
calculated as follows:   
 
 
 
4.8. Statistical analysis 
 
Data are presented as mean ± standard error of the mean (SEM). Two-way ANOVA 
was used to determine changes between basal and insulin stimulated groups for the 
glucose uptake and GLUT4 translocation experiments. One-way ANOVA was used 
to assess differences between more than two groups. A Bonferroni post hoc test was 
performed when significant differences were observed. All statistical analyses were 
performed using Graphpad Prism version 5.01 (Graphpad Software Inc., San Diego 
CA). Values were considered significant when p<0.05. 
 
  
Units/ml of enzyme =   (∆ A340nm / min test - ∆ A 340nm / min blank) (0.3) (df) 
(6.22) (0.01) 
The values were presented as units/mg protein =  units / ml enzyme 
       mg protein / ml enzyme 
(∆- change increment; A-absorbance; df-dilution factor; ml-milliliter; mg-milligram) 
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CHAPTER 5 
Study I: Acute hyperglycemia induces oxidative stress-related 
insulin resistance in vitro. 
 
5.1. Introduction 
 
Cardiovascular complications constitute a major cause of death and disability among 
individuals burdened with diabetes mellitus.  Here myocardial insulin resistance may play an 
important role in the progression of diabetic cardiomyopathy and heart failure (Chavali et al., 
2013; Chiha et al., 2012; Gustafsson et al., 2004). Chronic hyperglycemia, a hallmark of 
diabetes, is strongly correlated with higher incidence of myocardial infarction and markers of 
cardiac damage in humans (Barr et al., 2007; Rubin et al., 2012). Furthermore, effective 
glucose uptake and metabolism is particularly important in the ischemic heart (Tian and Abel, 
2001), and also in preventing cardiac dysfunction associated with heart failure (Liao et al., 
2002).  However, optimal glucose lowering interventions for the treatment of diabetic 
complications pose unique challenges within the clinical setting (Radke and Schunkert, 
2008).  Thus prevention of insulin resistance at an early stage is of utmost importance to help 
curb the growing global burden of cardio-metabolic complications.  
 
Chronically elevated nutrients (hyperglycemia, hyperlipidemia) can initiate detrimental 
metabolic and molecular events. For example, increased hyperglycemia-induced production 
of reactive oxygen species (ROS) is considered a central factor in mediating damaging 
outcomes (Brownlee, 2005; Giacco and Brownlee, 2010). Here, the current paradigm is that 
elevation of mitochondrial-derived ROS causes DNA damage and the subsequent release of 
poly-ADP-ribose polymerase (PARP) as a restorative mechanism (Nishikawa et al., 2000).  
However, PARP can also inhibit glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
thereby reducing glycolytic flux (Du et al., 2003). Glucose metabolites are subsequently 
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diverted into non-oxidative glucose metabolic pathways (NOGP) – the formation of advanced 
glycation end products (AGE), activation of protein kinase C (PKC), polyol pathway and 
hexosamine biosynthetic pathway (HBP) - resulting in harmful vascular complications 
associated with diabetes (Giaccari et al., 2009).  
 
It is plausible that oxidative stress also plays a prominent part in the etiology of insulin 
resistance, i.e. not only does it attenuate pancreatic β-cell function and insulin secretion 
(Futamura et al., 2012), but it can also disrupt insulin signaling and glucose uptake in skeletal 
muscle, adipose tissue and the liver (Costford et al., 2009; Gao et al., 2010; Grimsrud et al., 
2007; Messner et al., 2013; reviewed in Eriksson, 2007; Ruskovska and Bernlohr, 2013). 
Although mitochondrial-derived ROS are generally considered chief participants in exerting 
such detrimental effects, the impact of additional sources of ROS production and 
downstream mechanisms needs further elucidation. For example, the NADPH oxidase 
(NOX) complex is emerging as an important producer of hyperglycemia-mediated ROS in 
cardiomyocytes (Brewer et al., 2011; Li et al., 2006; Santos et al., 2011). Furthermore, 
hyperglycemia-mediated NOX-derived ROS can participate in myocardial apoptosis (Balteau 
et al., 2011), while NADPH from the pentose phosphate pathway (PPP) may be a crucial 
mediator of NOX activity in obese/hyperglycemic rat hearts (Serpillon et al., 2009).  
Angiotensin II (ANG II)-induced NOX activation also induced insulin resistance in in vitro and 
in vivo studies, including the TG(mRen-2)27 rat model of ANG II overexpression (Ogihara et 
al., 2002; Sloniger et al., 2005; Wei et al., 2006).  
 
Poor lifestyle and dietary habits can give rise to the prevalence of acute hyperglycemic 
episodes (e.g. high postprandial excursions and impaired glucose tolerance) in diabetic and 
non-diabetic individuals. However, the role of ROS and associated activation of NOGPs 
under acute hyperglycemic conditions in insulin-responsive cells remains poorly understood. 
In light of this, we investigated the effects of ROS on NOGP activation and insulin-mediated 
glucose uptake within the setting of in vitro acute hyperglycemia. We hypothesized that 
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mitochondria and NOX are major sources of ROS production and function in tandem to 
modulate NOGPs, resulting in reduced cardiac glucose uptake with acute hyperglycemia. 
The first study (this chapter) focuses on oxidative stress mechanisms and the effect of 
elevated intracellular ROS on insulin-mediated glucose uptake. NOGP activation and their 
downstream effects are described in Chapter 6. 
 
5.2. Aims 
 
We aimed to evaluate the effect of simulated acute hyperglycemia on intracellular 
ROS production in vitro. Here specific emphasis was placed on ROS sources, 
focusing on mitochondrial and NOX-derived ROS. We also aimed to elucidate 
mechanisms of oxidative stress by evaluating intracellular antioxidant systems and 
markers of oxidative damage. More importantly, we aimed to assess the impact of 
ROS from both sources on insulin action and glucose uptake by employing inhibitors 
to reduce mitochondrial ROS output and NOX activation.  
 
5.3. Modulators and brief description of methodology 
 
The first phase of experiments focused on elucidating the effect of high glucose on 
ROS production and insulin action. This was followed by phase two – assessing the 
role of mitochondrial and NOX-derived ROS in insulin action. In order to achieve this, 
we employed 250 µM α-cyano-4-hydroxycinnamic acid (4-OHCA, inhibits 
mitochondrial ROS production) and 100 µM diphenylene iodonium chloride (DPI; 
NOX inhibitor) (Fig 5.1 refer Section 4.3 and Figs 4.1 and 4.2 for description of the 
methodology employed) (Cross and Jones, 1986; Halestrap and Denton, 1975; 
O’Donnell et al., 1993; Rajamani and Essop, 2010).  We utilized fluorescent markers 
Stellenbosch University  http://scholar.sun.ac.za
161 
 
to detect total intracellular ROS (CM-H2DCF) and mitochondrial ROS levels 
(MitoTracker Red CMH2XRos), and a luminescence assay to evaluate NOX activity. 
Insulin action was assessed by 1) glucose uptake using the fluorescent glucose 
analog 2-NBDG; 2) GLUT4 translocation in cells expressing the HA-GLUT4-GFP 
construct and 3) Akt kinase activity.  Oxidative stress mechanisms were further 
evaluated by ascertaining the intracellular antioxidant capacity (superoxide 
dismutase activity, replenishment of glutathione) and assessing markers of oxidative 
damage (aconitase activity and malondialdehyde levels). The detailed methodology 
is described in Chapter 4. 
 
 
Figure 5.1 Modulators used to inhibit ROS from the mitochondria and NOX. 4-OHCA: α-cyano-4-
hydroxy cinnamic acid; DPI: diphenylene iodonium chloride; NOX: NADPH oxidase. 
 
 
5.4. Results 
 
5.4.1. Acute high glucose exposure upregulates ROS and reduces glucose 
transport capacity 
 
Total intracellular ROS levels were determined by DCF fluorescence. Qualitative analysis by 
fluorescence microscopy revealed a dispersed cytoplasmic signal which increased in 
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intensity in the high glucose group compared to controls (Fig 5.2A). Flow cytometric analysis 
showed that DCF fluorescence was markedly upregulated (~58%) with high glucose 
treatment (P<0.001 vs. control) (Fig 5.2 B and C). MitoTracker Red CMH2XRos fluorescence 
signal was localized within mitochondria, with increased intensity in the high glucose group 
(Fig 5.3A). Flow cytometry data showed a moderate increase of mitochondrial ROS levels by 
9.6 ± 2.6% (P<0.05 vs. control) in the high glucose group (Fig 5.3 B and C). NOX activity 
was robustly upregulated by high glucose treatment (by ~49%) (P<0.001 vs. control) 
(Fig 5.4). 
 
 
Figure 5.2 Total intracellular ROS levels determined by CM-H2DCFDA (DCF) fluorescence. H9c2 
cells were subjected to 24 h high glucose conditions vs. controls. (A) Qualitative analysis of DCF 
fluorescence (FITC-green, top panel) by microscopy with nuclei stained with DAPI (blue fluorescence, 
bottom panel); (B) Fluorescence intensity histogram indicating DCF signal (FITC channel) as 
measured by flow cytometry with controls indicated in the red peak, high glucose treated cells in the 
blue peak and a positive control (50 µM H2O2) in green; (C) Statistical analysis of flow cytometry 
population data (10,000 events analyzed per treatment condition), expressed as percentage (%) of 
control. Values are expressed as mean ± SEM (n=3 for microscopy; n=9 for flow cytometry analysis). 
***P<0.001 vs. control.  
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Figure 5.3 MitoTracker Red CMH2XROS staining of cells to indicate mitochondrial ROS 
sources. H9c2 cells were subjected to 24 h high glucose conditions vs. controls. (A) Fluorescence 
microscopy analysis of MitoTracker fluorescence intensity (Texas Red, top panel) with nuclei stained 
with DAPI (blue fluorescence, bottom panel); (B) Fluorescence intensity histogram indicating PE-
Texas Red signal as measured by flow cytometry with controls indicated in the red peak, high glucose 
treated cells in the blue peak and a positive control (50 µM H2O2) in green; (C) Statistical analysis of 
flow cytometry population data (10,000 events analyzed per treatment condition),, expressed as 
percentage (%) of control. Values are expressed as mean ± SEM (n=3 for microscopy, n=9 for flow 
cytometry). *P<0.05 vs. control.   
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Figure 5.4 NADPH oxidase activity increased under high glucose conditions. H9c2 cells were 
subjected to 24 h high glucose conditions vs. controls. Values are expressed as mean ± SEM (n=6). 
***P<0.001 vs. controls.  
 
The insulin-mediated uptake of glucose was determined by flow cytometry using the 
fluorescent glucose analog 2-NBDG. Here low glucose control cells rapidly 
upregulated glucose uptake upon insulin stimulation (red line on graph) from 10 – 30 
min (P<0.001 vs. respective basal control indicated by the black line) (Fig 5.5A).  
Inhibition of insulin signaling by 100 nM wortmannin, a PI3K inhibitor (blue dotted 
line), blunted the stimulatory effect of insulin (P<0.05 vs. control insulin). Twenty 
minutes insulin stimulation was chosen to evaluate glucose uptake in subsequent 
experiments (Fig 5.5B). The insulin stimulatory effect on glucose uptake could be 
reproduced in control cells, however, this was markedly inhibited in cells treated with 
high glucose.    
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Figure 5.5 Impaired glucose uptake in response to high glucose conditions. H9c2 cells were 
subjected to 24 h high glucose conditions vs. controls. Flow cytometry analysis of 2-NBDG 
fluorescence intensity in viable cells. (A) Preliminary optimization to evaluate insulin-mediated glucose 
uptake over time (basal controls – black line; insulin treated groups – red line; 100 nM wortmannin 
treated groups – blue dotted line). (B) H9c2 cells were subjected to 24 h high glucose conditions vs. 
controls and glucose uptake evaluated after 20 min insulin exposure vs. basal controls. Values are 
expressed as mean ± SEM (n=8). ***P<0.001 vs. basal control; #P<0.05 vs. 20 min insulin.  
 
 
To confirm our findings, we repeated these experiments in the presence of a HA-
GLUT4-GFP construct.  Assessment of GLUT4 translocation revealed similar findings 
to the glucose uptake data (Fig 5.6), i.e. inhibited insulin stimulation in the HG group, 
while insulin increased GLUT4 translocation in the control condition (P<0.001 vs. 
basal)  
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Figure 5.6 High glucose treatment suppressed the translocation of HA-GLUT4-GFP to the 
sarcolemma. H9c2 cells were subjected to 24 h high glucose conditions vs. controls. (A) 
Fluorescence microscopy analysis of H9c2 cells expressing GFP (green fluorescence, top panel) 
stained with Texas Red-conjugated anti-HA antibody (red fluorescence, bottom panel). The anti-HA 
antibody binds to an HA target sequence in the first exofacial loop, which is exposed upon 
translocation and fusion at the sarcolemma in response to insulin. (B) Quantification of the HA:GFP 
ratio as a measure of GLUT4 translocation. Values are expressed as mean ± SEM (n≥150 cells from 
five independent experiments) ***P<0.001 vs. unstimulated (basal) control.    
 
 
Further analysis of insulin action revealed downregulation of Akt activity under high 
glucose conditions (P<0.001 vs.control) (Fig 5.7). 
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Figure 5.7 Acute hyperglycemia downregulated the kinase activity of Akt. Cell free in vitro kinase 
activity of Akt was assessed by immunoprecipitation of Akt from H9c2 cells that were subjected to 24 h 
high glucose conditions vs. controls. Equal concentrations of the isolated Akt was exposed to the Akt 
substrate GSK3α and ATP at 30°C, resulting in the Akt-catalyzed formation of phosphorylated GSK3α 
and analysis of pGSK3α by Western blotting (refer Section 4.5.3 for methodology). Values are 
expressed as mean ± SEM (n=3). ***P<0.001 vs. control. 
 
 
5.4.2. Mitochondrial and NOX-derived ROS mediates insulin resistance 
 
Our next aim was to determine whether the higher ROS levels produced by the 
mitochondria and NOX play a role in the induction of insulin resistance under high 
glucose conditions. We employed the modulators of mitochondrial and NOX-derived 
ROS (discussed in Section 5.3). The elevated intracellular ROS levels as determined 
by DCF fluorescence were markedly reduced by 4-OHCA (63.1 ± 13.9%) (P<0.01 vs. 
HG), while NOX inhibition (by DPI) attenuated it by 78.6 ± 16% (P<0.01 vs. HG) (Fig 
5.8A).   Mitochondrial ROS levels were reduced with 4-OHCA treatment (P<0.001 vs. 
HG). However, DPI treatment did not result in any significant changes (Fig 5.8B). As 
expected, treatment with DPI markedly decreased NOX activity (by 124.6 ± 8.4%) 
(P<0.001 vs. HG) (Fig 5.8C). Surprisingly, 4-OHCA administration also lowered NOX 
activity (33.1 ± 8.6%, P<0.05 vs. HG).  The difference between 4-OHCA and DPI 
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(~91%) was statistically significant (P<0.001), indicating that DPI more specifically 
inhibited NOX activity 
 
 
Figure 5.8 Pharmacological attenuation of mitochondrial- and NOX-derived ROS. H9c2 cells 
were subjected to 24 h high glucose conditions vs. controls ± 1 h treatment with a) 250 µM 4-OHCA 
(inhibits mitochondrial ROS),  and b) DPI (NOX inhibitor). Flow cytometry analysis of (A) DCF 
fluorescence and (B) MitoTracker Red fluorescence. C) Assay of NOX activity. Values are expressed 
as mean ± SEM (n=6-9). *P<0.05, ***P<0.001 vs. control; ##P<0.01, ###P<0.001 vs. high glucose; 
^^^P<0.001 vs. indicated treatment.  
 
We next employed the ROS modulators in the analysis of insulin action. Both 
antioxidant treatments (4-OHCA and DPI) restored glucose uptake (P<0.05 and 
P<0.01 vs. basal, respectively) after insulin stimulation (Fig 5.9). The respective 4-
OHCA and DPI treatments also significantly increased the recruitment of HA-GLUT4-
GFP to the sarcolemma (P<0.001 vs. basal) (Fig 5.10). Furthermore, 4-OHCA and 
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DPI treatment reversed the inhibitory effect of high glucose on Akt activity (Fig 5.11). 
Together, these data point toward the involvement of both mitochondrial and NOX-
derived ROS in the hyperglycemia-induced attenuation of insulin action and 
consequently, glucose uptake.  
 
 
Figure 5.9 Enhanced glucose uptake upon inhibition of mitochondrial and NOX-derived ROS. 
H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± 1 h treatment with a) 250 µM 
4-OHCA (inhibits mitochondrial ROS),  and b) DPI (NOX inhibitor). Flow cytometry analysis of 2-NBDG 
fluorescence. Values are expressed as mean ± SEM (n=4). *P<0.05; **P<0.01; ***P<0.001 vs. 
indicated basal controls. 
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Figure 5.10 Attenuation of ROS (mitochondrial and NOX-derived) restored GLUT4 
translocation. H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± 1 h treatment 
with a) 250 µM 4-OHCA (inhibits mitochondrial ROS),  and b) DPI (NOX inhibitor). (A) Fluorescence 
microscopy images of cells expressing HA-GLUT4-GFP with and without insulin stimulation. (B) 
Quantification of HA:GFP ratios. Values are expressed as mean ± SEM (n≥150 cells from five 
independent experiments). ***P<0.001 vs. respective basal control.  
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Figure 5.11 Regulation of Akt activity by mitochondrial and NOX-derived ROS. Cell free in vitro 
kinase activity of Akt was assessed by immunoprecipitation of Akt from H9c2 cells that were subjected 
to 24 h high glucose conditions vs. controls ± 1 h treatment with a) 250 µM 4-OHCA (inhibits 
mitochondrial ROS), and b) DPI (NOX inhibitor). Equal concentrations of the isolated Akt was exposed 
to the Akt substrate GSK3α and ATP at 30°C, resulting in the Akt-catalyzed formation of 
phosphorylated GSK3α and analysis of pGSK3α by Western blotting (refer Section 4.5.3 for 
methodology). Values are expressed as mean ± SEM (n=3). ***P<0.001 vs. control; ###P<0.001 vs. 
high glucose. 
 
 
5.4.3. Attenuation of endogenous antioxidant systems under hyperglycemic 
conditions 
 
To gain further understanding of the intracellular redox status, we next investigated 
the activity of intrinsic antioxidant defense systems. Superoxide dismutase (SOD) 
activity was reduced by high glucose by 42.4 ± 6.7% (P<0.001 vs. control), but this 
effect was markedly reversed by 4-OHCA (~2.6 fold) and DPI (~2.4 fold), respectively 
(P<0.001 vs. HG) (Fig 5.12).    
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Figure 5.12 High glucose attenuated superoxide dismutase (SOD) activity. H9c2 cells were 
subjected to 24 h high glucose conditions vs. controls ± 1 h treatment with a) 250 µM 4-OHCA (inhibits 
mitochondrial ROS),  and b) DPI (NOX inhibitor). Values are expressed as mean ± SEM (n=6). 
**P<0.01, ***P<0.001 vs. control; ###P<0.001 vs. high glucose.  
 
Total GSH levels were also lowered by high glucose (P<0.01 vs. control) (Fig 5.13B). 
The 4-OHCA treatment failed to increase GSH levels, while it was upregulated by 
DPI (P<0.001 vs. high glucose and P<0.001 vs. 4-OHCA). NADPH is an essential 
substrate to NOX (to produce ROS), and to the glutathione system (to replenish GSH 
pools and increase antioxidant defenses) (Fig 5.13A). The fate of intracellular 
NADPH and its role in the cell’s redox status is a subject of much controversy. In light 
of our NOX and GSH data, we next determined the effects of high glucose ± 4-OHCA 
± DPI on G6PD (a major producer of intracellular NADPH) activity, NADPH levels 
and the ratio of NADP+:NADPH. G6PD activity remained unaltered by high glucose 
and 4-OHCA treatment, while DPI increased it modestly (P<0.01 vs. 4-OHCA) (Fig 
5.13C). Furthermore, inhibition of G6PD activity by treatment with 6-
aminonicotinamide (6-AN, 100 µM) mirrored the effect of high glucose on GSH levels 
(Fig 5.13D). In parallel, NADPH levels (Fig 5.13E) and the NADP+:NADPH ratio (Fig 
5.13F) were unchanged by high glucose and 4-OHCA treatment, while DPI 
decreased NADPH levels (P<0.01 vs. HG).  DPI treatment also increased the 
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NADP+:NADPH ratio (P<0.01 vs. 4-OHCA), indicative of higher NADPH turnover (Fig 
5.13F).  
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Figure 5.13 Attenuation of the glutathione replenishment system under high glucose conditions. H9c2 cells were subjected to 24 h high glucose 
conditions vs. controls ± 1 h treatment with a) 250 µM 4-OHCA (inhibits mitochondrial ROS), b) DPI (NOX inhibitor), 100 µM 6-aminonicotinamide (6-AN: 
G6PD inhibitor employed to test relevance of G6PD-mediated NADPH production) . (A) Schematic representation of the reactions of NOX (leading to ROS 
formation) and replenishment of reduced glutathione (GSH; an intrinsic antioxidant), both requiring NADPH; (B and D) Glutathione levels; (C) G6PD activity; 
(E) NADPH levels; (F) NADP
+
:NADPH ratio. Values are expressed as mean ± SEM (n=6-9). *P<0.05, **P<0.01, ***P<0.001 vs. control; ##P<0.01, ##P<0.001 
vs. high glucose; ^^P<0.01, ^^^P<0.001 vs. indicated treatment.   
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Interestingly, markers of intracellular damage resulting from oxidative stress 
evaluated here, i.e. aconitase activity and the levels of malondialdehyde adducts, 
were unaltered in all experimental conditions (Fig 5.14). 
 
 
Figure 5.14 Intracellular markers of oxidative damage were unaltered. A: Aconitase acitivity; B: 
Malondialdehyde adducts. 
 
 
5.5. Discussion 
 
Excess nutrients (e.g. hyperglycemia) are key features of the metabolic syndrome 
and can play a significant part in the etiology of insulin resistance (de Moura et al., 
2009; Sharma et al., 2007). Furthermore, myocardial insulin resistance can elicit 
detrimental consequences that eventually impact on cardiac metabolism and function 
(Barr et al., 2007; Liao et al., 2002; Rubin et al., 2012; Tian and Abel, 2001).  Acute 
hyperglycemic episodes per se may also contribute significantly to unfavorable 
outcomes after stroke and to impaired endothelial function in humans (Parsons et al., 
2002; Williams et al., 1998). Furthermore, acute hyperglycemia may induce apoptosis 
in perfused rat hearts (Ceriello et al., 2002; Mapanga et al., 2013), while it is 
correlated with mortality in patients undergoing cardiac surgery (Doenst et al., 2005). 
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However, a mechanistic link between acute hyperglycemic episodes and the etiology 
of insulin resistance is an important consideration that indeed warrants further 
attention.  
 
Although oxidative stress is implicated in the etiology of insulin resistance, the 
mechanisms involved and its role in the acute hyperglycemic setting remain poorly 
understood. The current paradigm suggests that mitochondrial ROS function as a 
central mediator to link hyperglycemia-mediated defects to diabetic complications 
(Brownlee, 2005). This notion has, however, recently been revisited and new 
information raise additional questions regarding its validity (reviewed in Schaffer et 
al., 2012). In light of this, we undertook to further investigate these concepts in an in 
vitro model of acute hyperglycemia. We used a novel, holistic approach to interrogate 
various pathways and mechanisms at one time point and under the same condition. 
The major finding of study I (outlined in this Chapter) is that both mitochondrial- and 
NOX-derived ROS are upregulated and may act in tandem to blunt cardiac insulin-
mediated glucose uptake in response to acute hyperglycemia. Our findings therefore 
support a modification of the classic ‘’unifying hypothesis’’ and sheds novel insights 
into the onset of acute hyperglycemia-mediated insulin resistance. 
 
We initially set up an in vitro model of acute hyperglycemia where cardiomyoblasts 
displayed elevated ROS levels (total, mitochondrial and NOX-derived), and defective 
insulin action (glucose uptake, GLUT4 translocation and Akt kinase activity).  These 
findings are in agreement with previous research, e.g. optimization of in vitro glucose 
levels reversed insulin resistance in skeletal muscle and adipose cells isolated from 
type 2 diabetic patients, demonstrating that hyperglycemia itself or in the presence of 
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high insulin levels is a potent initiator of insulin resistance (Burén et al., 2003; Zierath 
et al., 1994).  Moreover, others established decreased glucose uptake accompanied 
by lower insulin receptor substrate 1 (IRS1) protein levels in adipocytes exposed to 
high glucose and insulin levels (Renström et al., 2007).  Isolated rat ventricular 
cardiomyocytes exposed to high glucose also displayed decreased glucose uptake 
and impaired insulin signaling and contractile function in vitro (Ren et al., 1996, 
2003).   
 
Our data are also in agreement with studies done in our laboratory that showed 
increased ROS levels under hyperglycemic conditions (Mapanga et al., 2012; 
Rajamani and Essop, 2010), while oxidative stress is associated with metabolic 
dysfunction in animals and humans in vivo (Furukawa et al., 2004). Furthermore, 
previous studies determined that increased ROS production due to chronic 
hyperglycemia can lead to damaging cardio-metabolic complications. For example, 
elevated levels of 4-hydroxy-2-nonenal and protein/lipid peroxidation were found in 
patients and animal models of diabetes, while micro- and macrovascular 
complications can also arise from oxidative stress-induced alterations in vascular 
endothelial cells (Kawahito et al., 2009; King and Loeken, 2004; Stentz et al., 2004).  
Recent studies from our laboratory also showed higher levels of myocardial 
apoptosis and reduced cardiac function associated with hyperglycemia-mediated 
oxidative stress (Mapanga et al., 2012; 2013, Rajamani and Essop, 2010; Rajamani 
et al., 2011).  
 
Oxidative stress is also implicated in the induction of insulin resistance in target 
tissues (e.g. adipose, skeletal muscle and liver) (Costford et al., 2009; Gao et al., 
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2010; Grimsrud et al., 2007; Messner et al., 2013; Ruskovska and Bernlohr, 2013). 
Here hyperglycemia-induced ROS can reduce GLUT4 translocation in 3T3-L1 
adipocytes (Grimsrud et al., 2007; Ruskovska and Bernlohr, 2013), and decrease 
insulin synthesis and secretion in pancreatic β-cells (Futamura et al., 2012). Meigs 
and colleagues (2007 recently showed an association between oxidative stress and 
insulin resistance in participants at risk for diabetes in the Framingham offspring 
study (Meigs et al., 2007). Tissue levels of oxidative stress markers were upregulated 
prior to the development of insulin resistance in rodents exposed to high fat feeding 
(Matsuzawa-Nagata et al., 2008). Furthermore, employment of antioxidants N-acetyl 
cysteine, taurine and α-lipoic acid resulted in protection against oxidative stress-
mediated insulin resistance and sensitized tissues and L6 myocytes to insulin action 
(Haber et al., 2003; Maddux et al., 2001). 
 
The intracellular source(s) of ROS production - at the center of hyperglycemia-
induced detrimental effects - is gaining considerable attention (as recently reviewed 
in Schaffer et al., 2012).  Hyperglycemia-mediated ROS production is generally 
proposed to have strong mitochondrial origins, i.e. the inhibition of mitochondrial 
respiratory complexes triggers excess superoxide generation, with deleterious 
downstream outcomes (known as the unifying hypothesis of hyperglycemic damage) 
(Brownlee, 2005; Giacco and Brownlee, 2010). Indeed, mitochondrial ROS 
production is associated with insulin resistance, with hydrogen peroxide playing a 
major role in disrupting several key mediators of insulin action (Anderson et al., 2009; 
Fisher-Wellman and Neufer, 2012). Mitochondrial dysfunction and defects in its 
morphology were reported in muscle tissue of diabetic patients and animal models 
(reviewed in Cheng et al., 2010; Rabøl, 2011). Whether defects at the mitochondrial 
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level are causative factors, or a consequence of insulin resistance, is not yet clear 
(reviewed in Rabøl, 2011). Furthermore, additional sources of ROS may also play a 
significant role in the etiology of insulin resistance. 
 
Since the NOX complex also acts as a key source of ROS production in 
cardiomyocytes (Balteau et al., 2011; Brewer et al., 2011; Li et al., 2006; Santos et 
al., 2011; Serpillon et al., 2009), it emerges as another important regulator that may 
also orchestrate the detrimental effects of acute hyperglycemia. Our findings 
revealed that 4-OHCA and DPI treatment reversed the inhibitory effect of high 
glucose on insulin-stimulated glucose uptake, GLUT4 translocation and Akt activity, 
suggesting involvement of both mitochondrial and NOX-derived ROS. Intriguingly, 
NOX-derived ROS constituted the overwhelming majority of overall ROS generated 
by acute hyperglycemia. Furthermore, the mitochondrial ROS inhibitor (4-OHCA) also 
blunted NOX activity suggesting that the relatively low mitochondrial ROS levels can 
cross-talk with, and activate the NOX system in response to acute high glucose 
exposure. We propose that the initial modest increase in mitochondrial ROS may act 
as a trigger for downstream activation of NOX. This is further evident in the relatively 
equal effects of 4-OHCA and DPI treatment on total ROS, glucose uptake, GLUT4 
translocation and Akt activity, despite the modest contribution of mitochondrial ROS. 
In support, a recent study determined that mitochondrial ROS (superoxide, hydrogen 
peroxide, peroxynitrite) can trigger NOX activation in phagocytic cells and 
vascular/cardiac tissues (Kröller-Schön et al., 2013). NOX-mediated ROS can 
subsequently mediate detrimental effects, e.g. playing a role in cardiac contractile 
dysfunction leading to heart failure, while also promoting myocardial apoptosis 
(Balteau et al., 2011; Serpillon et al., 2009). Further investigation is warranted to 
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evaluate the validity of such a mechanism and to ascertain the molecular basis. 
Nevertheless, NOX activation alone may also play a significant role in the etiology of 
insulin resistance. For example, others found that Ang II- and high glucose-mediated 
NOX activation may play a role in diminishing insulin signaling events and reduce 
insulin-mediated glucose uptake and GLUT4 translocation (Ogihara et al., 2002; 
Sloniger et al., 2005; Wei et al., 2006) 
 
Since the overall degree of intracellular oxidative stress depends on both the 
production and removal of ROS, we next assessed intracellular antioxidant defense 
systems and found diminished SOD activity and GSH levels following high glucose 
treatment.  Inhibition of both mitochondrial- and NOX-derived ROS markedly 
upregulated SOD activity, while only DPI (NOX inhibitor) increased GSH levels. We 
are unclear how exactly high glucose levels attenuate SOD activity.  We propose that 
this may be the result of oxidative damage to the SOD enzyme, but further studies 
are required to confirm this.  
 
Although replenishment of GSH pools (anti-oxidative) and NOX activity (pro-
oxidative) are processes with opposite effects, both require NADPH as substrate 
(Serpillon et al., 2009).  However, the fate of intracellular NADPH with hyperglycemia 
is a subject of contention.  Our data show higher NOX activity, oxidative stress and 
decreased GSH while activity of G6PD (a major source of NADPH), NADPH levels 
and the NADP+:NADPH ratio remained unaltered in response to acute high glucose 
exposure.  However, NOX inhibition increased G6PD activity and GSH levels, while 
concomitantly attenuating NADPH levels.  Thus our findings indicate that acute high 
glucose exposure drives NOX activation (and NADPH consumption) over 
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replenishment of GSH pools by G6PD and the PPP. Indeed, NOX-derived 
superoxide production is fueled by G6PD-mediated NAPDH in Zucker fa/fa rats, a 
model of severe hyperglycemia and hyperlipidemia (Serpillon et al., 2009). Although 
our data showed unchanged G6PD levels with acute hyperglycemia, previous studies 
found reduced G6PD, NADPH and GSH levels accompanied by oxidative stress in 
kidneys of streptozotocin-induced diabetic rats (Xu et al., 2005). Furthermore, G6PD 
deficient (G6PDx) mice exposed to different obesogenic diets displayed metabolic 
dysfunction, however this was coupled to reduced oxidative stress (Hecker et al., 
2012).  
 
We therefore postulate that the acute hyperglycemia in our system may reduce 
G6PD-mediated NADPH production, however, the limited NADPH levels may be 
utilized exclusively for NOX activation versus GSH formation. This mechanism may 
act as important cycle to promote oxidative stress, along with reduced SOD activity 
and increased ROS output by mitochondria and NOX. The markers of oxidative 
damage analyzed in this study (aconitase activity and MDA levels) were unchanged. 
This is in contrast to data showing its dysregulation with acute hyperglycemia (33 mM 
glucose) in ex vivo rat heart perfusion experiments (Mapanga et al., 2013). We 
suggest that the ROS levels induced by high glucose (25 mM) in our in vitro system 
may be less severe to induce the reduction in aconitase activity and elevation in MDA 
levels indicative of damage by oxidative stress. The differences may also be 
attributable to the distinct models utilized to assess such markers. Together our 
findings demonstrate that greater oxidative stress with acute high glucose exposure 
occurs due to both higher ROS generation (mitochondrial- and NOX-derived) and an 
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impairment of defense mechanisms, that ultimately blunts insulin-mediated glucose 
uptake.    
 
In conclusion, our data support the hypothesis that oxidative stress related to acute 
hyperglycemia may play a significant role in the dysregulation of insulin action in 
cardiac-derived cells. We propose that both mitochondrial and NOX-derived ROS 
play a role here. Furthermore we describe two mechanisms that may considerably 
contribute to the observed levels of intracellular ROS. Firstly, a modest increase in 
mitochondrial ROS may act as a triggering mechanism leading to the activation of 
downstream events, including NOX activation which may result in further 
upregulation of ROS levels. Secondly, the increased activation of NOX may favor 
NADPH utilization, leading to decreased replenishment of GSH pools. This 
mechanism together with decreased SOD activity will further promote intracellular 
oxidative stress. The molecular link(s) between hyperglycemia-mediated ROS 
production and diminished insulin action are beyond the scope of this chapter, but 
will be addressed in the next chapter. 
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CHAPTER 6 
Study II: Metabolic alterations of acute hyperglycemia – role of non-
oxidative glucose pathways in insulin resistance. 
 
6.1. Introduction 
 
Insulin resistance has a complex and multifactorial etiology with many factors 
contributing to its induction (Petersen and Shulman, 2006). Dietary fuel 
overabundance and excess lipid and glucose availability associated with metabolic 
dysfunction, may all play a role in its onset (Kawahito et al., 2009; Sharma et al., 
2007a, 2007b; Tappy and Lê, 2010). The impact of chronic diabetes-associated 
hyperglycemia in the long term is known to have far reaching pathophysiologic 
effects (Brownlee, 2005; Du et al., 2001; Kawahito et al., 2009; King and Brownlee, 
1996; King and Loeken, 2004; Rösen et al., 2001). Of particular importance here are 
the adverse cardio-metabolic defects associated with diabetes. The mechanisms of 
myocardial insulin resistance and its impact on cardiac function is not completely 
understood. Moreover, it is important to consider the mechanisms at the center of 
insulin resistance onset in order to assess and implement preventative therapeutic 
strategies before too much damage is done.  On a broader scale, metabolic 
dysregulation in obesity, metabolic syndrome, pre-diabetes and poor dietary and 
lifestyle habits may all contribute to the etiology of insulin resistance (Stumvoll et al., 
2005). It is our opinion, that acute hyperglycemia is a common downstream factor at 
the center of detrimental outcomes in this case. In light of this, we therefore 
undertook to investigate the effects of acute hyperglycemia on insulin resistance in 
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cardiac-derived cells, and to elucidate metabolic mechanisms that may orchestrate 
this.  
 
In Chapter 5 we described an important role for both mitochondrial- and NOX-derived 
ROS production, along with mechanisms contributing to overall oxidative stress, in 
the impairment of glucose uptake under acute hyperglycemic conditions. We now 
aimed to further evaluate downstream mechanisms that may play important roles in 
mediating the damaging outcomes of high glucose. A widely held model is that 
elevation of mitochondrial-derived ROS causes DNA damage, and the subsequent 
release of PARP (as a restorative mechanism) can also inhibit GAPDH, thereby 
reducing glycolytic flux (Du et al., 2003; Nishikawa et al., 2000). Glucose metabolites 
are subsequently diverted into NOGPs (AGE, PKC, polyol pathway and HBP). This 
unifying hypothesis is proposed as a central mediator of harmful vascular 
complications associated with diabetes (reviewed in Brownlee, 2005; Giaccari et al., 
2009; Giacco and Brownlee, 2010). The contribution of additional mechanisms can, 
however, not be overlooked. Indeed, the unifying hypothesis is currently under the 
spotlight and alternative mechanisms also put forward (reviewed in Schaffer et al., 
2012). In agreement, our data from Chapter 5 show the importance of both 
mitochondrial- and NOX-derived ROS in exerting high glucose-mediated insulin 
resistance. In this chapter we aim to evaluate the contribution of ROS (from the 
sources identified before) in the induction of NOGPs and its downstream effects. We 
hypothesized that ROS from mitochondria and NOX, and specifically the cross-talk 
mechanisms identified in Chapter 5, contribute significantly to NOGP induction. 
Furthermore, this may serve as a molecular link to the diminished insulin action 
observed under acute hyperglycemic conditions.    
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6.2. Aims 
 
The aims for this study were to determine the effect of hyperglycemia-induced ROS 
production (both mitochondrial- and NOX-derived) on NOGP induction and to assess 
possible links between NOGP induction and insulin resistance. Furthermore, we 
aimed to evaluate mechanisms of pathway cross-talk, the role of NOGP induction, 
and possible downstream molecular events linking ROS, NOGP induction and 
diminished insulin action.   
 
6.3. Modulators 
 
The involvement of the four NOGPs was assessed using pharmacological inhibitors 
to target key mediators of each respective pathway (Fig 6.1). Here we employed 100 
µM aminoguanidine (AMG; inhibits AGE precursors), 5 µM chelerythrine (CHE; PKC 
inhibitor), 40 µM 6-diazo 5-oxo-L-norleucine (DON; HBP inhibitor), and 10 µM 
zopolrestat (ZOP; polyol pathway inhibitor) (refer Section 4.3 and Figs 4.1 and 4.2 for 
description of the methodology employed). The transketolase co-factor and activator 
benfotiamine (BFT) was employed to evaluate the influence of the pentose 
phosphate pathway (PPP) (Hammes et al., 2003). This served as an additional 
means of collectively diminishing NOGP induction as shown in previous studies 
(Babaei-Jadidi et al., 2003; Balakumar et al., 2010; Beltramo et al., 2008; Berrone et 
al., 2006; Ceylan-Isik et al., 2006; Hammes et al., 2003; Katare et al., 2010a, 2010b; 
Lin et al., 1998; Wu and Ren, 2006).  Inhibitor concentrations were selected based 
on previous studies (Chmura et al., 2000; Davidoff et al., 2004; Kador et al., 2009; 
Rajamani and Essop, 2010; Rohr et al., 1999; Wang et al., 2010).   
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Figure 6.1 Modulators used to inhibit NOGPs. Zopolrestat (ZOP) – polyol pathway inhibitor, 
benfotiamine (BFT) – activates PPP, 6-diazo-5-oxo-L-norleucine (DON) – inhibits HBP, 
aminoguanidine (AMG) – AGE inhibitor, chelerythrine (CHE) – PKC inhibitor.    
 
 
6.4. Results 
 
6.4.1. Glucose metabolic alterations are mediated by mitochondrial and NOX-
derived ROS 
 
To gain an understanding regarding the intracellular metabolic milieu, we first set out 
to determine intracellular ATP levels as a measure of the cell’s ability to couple fuel 
availability to energy production. High glucose treatment had no significant effect on 
total intracellular ATP levels (Fig 6.2). On the other hand, inhibition of both 
mitochondrial ROS (4-OHCA) and NOX activity (DPI) significantly reduced ATP 
levels by 82.7 ± 2.7% (P<0.001 vs. high glucose) and 39.4 ± 2.7% (P<0.001 vs. high 
glucose) respectively. These effects were also lower than the control values 
(P<0.001 for 4-OHCA and P<0.05 for DPI), while the more pronounced inhibitory 
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effect of 4-OHCA treatment resulted in a ~43% difference compared to DPI treatment 
(P<0.001). 
 
 
Figure 6.2 Intracellular ATP levels were reduced by ROS modulation. H9c2 cells were treated 
acutely with a) 4-OHCA and b) DPI under acute high glucose conditions. Values are expressed as 
mean ± SEM (n=6). *P<0.05, ***P<0.001 vs. control; ###P<0.001 vs. high glucose; ^^^P<0.001 vs. 
indicated treatment. 
 
We next determined the effects of acute high glucose on NOGP activation. Acute 
high glucose treatment increased NOGP markers, i.e. methylglyoxal and sorbitol 
levels (P<0.001 vs. controls, Fig 6.3A and B), and PKC activity (P<0.01 vs. control, 
Fig 6.3C).  However, transketolase activity remained unchanged under high glucose 
conditions, but was reduced following 4-OHCA (P<0.01 vs. control, P<0.05 vs. high 
glucose) and DPI administration (P<0.001 vs. control, P<0.001 vs. high glucose) (Fig 
6.3D).  We also found higher levels of intracellular O-GlcNAc modification [P<0.01 vs. 
control, Fig 6.3E (ii and iv)]. Here, we employed fluorescence microscopy analysis of 
O-GlcNAc stained cells [Fig 6.3E (i and ii)], and Western blot analysis of total O-
GlcNAc moieties from crude cell lysates [Fig 6.3E (iii and iv)]. Both 4-OHCA and DPI 
reduced methylglyoxal levels, PKC activity (P<0.001 vs. high glucose), sorbitol levels 
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(P<0.01 vs. control, P<0.001 vs. high glucose) and O-GlcNAc modification (P<0.001 
vs. high glucose – fluorescence microcopy; P<0.01 vs. high glucose – Western 
blots).  
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Figure 6.3 Metabolic alterations under acute high glucose conditions were mediated by ROS. H9c2 cells were subjected to 24 h high glucose conditions 
vs. controls ± a) 250 µM 4-OHCA (inhibits mitochondrial ROS), and b) DPI (NOX inhibitor).  (A) Methylglyoxal levels (AGE pathway), (B) Sorbitol levels (polyol 
pathway), (C) PKC activity, (D) Transketolase activity (non-oxidative PPP), (Ei and ii) Immunofluorescence microscopy and quantification of total intracellular 
O-GlcNAc-modified proteins, (Eiii and iv) Western blot and quantification of O-GlcNAc-modified proteins (HBP), with densitometry values normalized to 
respective β-actin. Values are expressed as mean ± SEM (n=4-6). **P<0.01, ***P<0.001 vs. control; #P<0.05, ##P<0.01, ###P<0.001 vs. high glucose. 
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In an effort to understand the relative pathway induction under high glucose 
conditions, we next calculated the mean difference between controls and high 
glucose treated groups for each NOGP marker analyzed above (Fig. 6.4). The 
approximate percentage induction of each pathway according to the markers 
evaluated is expressed. Here, the polyol, PKC and HBP were more rigorously 
upregulated, with approximately 67%, 63% and 57% induction, respectively. AGE 
induction was increased by approximately 19%, while PPP (transketolase activity) 
was unaltered. 
 
 
 
Figure 6.4 Relative percentage induction of NOGP markers by high glucose treatment. The 
mean difference (Δ) between control and high glucose treated samples were analyzed for each NOGP 
marker tested above (refer Fig. 6.3). Values are expressed as the approximate mean percentage Δ 
between high glucose and controls.     
 
6.4.2. The role of NOGP modulation on insulin and ROS signaling events 
 
In light of the previous data indicating ROS-mediated NOGP induction under high 
glucose conditions, we next set out to determine the influence of each NOGP on 
insulin action. We employed the individual pathway inhibitors as earlier described. 
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Our first aim was to evaluate the effect of each inhibitor on its respective pathway. 
Each individual inhibitor significantly blunted the hyperglycemia-mediated induction of 
its respective NOGP (Fig 6.5). Treatment with AMG significantly reduced 
methylglyoxal levels by 35.4 ± 2.2% (P<0.001 vs. high glucose) (Fig 6.5A).  ZOP and 
CHE respectively blunted sorbitol levels (122.4 ± 15.1%) and PKC activity (102.2 ± 
9.8%) (P<0.001 vs. high glucose) (Fig 6.5B and C). Fluorescence microscopy 
analysis of intact cells (P<0.001 vs. high glucose) (Fig 6.5 Di) and Western blot 
analysis of cell lysate (P<0.05 vs. high glucose) (Fig 6.5 Dii) both showed significant 
downregulation of O-GlcNAc moieties with DON treatment.    
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Figure 6.5 Inhibitory effect of NOGP inhibitors used in this study. H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± respective 
NOGP inhibitors as follows: 100 µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM DON (for HBP), 10 µM ZOP (for polyol pathway). (A) 
Methylglyoxal levels (AGE pathway), (B) Sorbitol levels (polyol pathway), (C) PKC activity, (Di) Immunofluorescence microscopy data of total intracellular O-
GlcNAc-modified proteins, (Bii) Western blot quantification of O-GlcNAc-modified proteins (HBP), with densitometry values normalized to respective β-actin. 
Values are expressed as mean ± SEM (n=4-6). *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, ###P<0.001 vs. high glucose. 
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We next evaluated the effect of each NOGP on glucose uptake by employing the 
respective inhibitors in separate experiments (Fig 6.6). All four modulator treatments 
significantly reversed the inhibitory effect of high glucose on insulin-stimulated 
glucose uptake. Cells treated with AMG, ZOP and DON increased insulin-stimulated 
glucose uptake by ~39, 40 and 49% under high glucose conditions, respectively 
(P<0.05 vs. respective basal controls) (Fig 6.6A, B and D). On the other hand, CHE 
treatment had a more pronounced effect, i.e. it elevated glucose uptake by ~84% 
(P<0.001 vs. basal control) (Fig 6.6C).  
 
 
Figure 6.6 NOGP inhibition reversed high glucose-mediated inhibition of glucose uptake. H9c2 
cells were subjected to 24 h high glucose conditions vs. controls ± respective NOGP inhibitors as 
follows: (A) 100 µM AMG (for AGE pathway), (B) 10 µM ZOP (for polyol pathway), (C) 5 µM CHE (for 
PKC pathway), (D) 40 µM DON (for HBP). Values are expressed as mean ± SEM (n=4). *P<0.05, 
***P<0.001 vs. respective basal control. 
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In order to determine the relative contribution of each NOGP to glucose uptake, and 
to draw a statistical comparison between the pathways, we evaluated the effect of 
individual NOGP inhibitors on glucose uptake within the same experiment (Fig 6.7). 
Glucose uptake in cells treated with AMG, DON and ZOP were not significantly 
changed when comparing the four NOGP inhibitors together.  However, PKC 
inhibition markedly increased glucose uptake upon insulin stimulation (P<0.01 vs. 
respective basal control).  These results mirrored the individual inhibitory studies 
showing PKC inhibition resulted in a more pronounced increase of glucose uptake. 
Although the AGE, polyol and hexosamine pathways may contribute to the observed 
insulin resistance associated with high glucose, the data suggest that PKC activation 
may outweigh that of the other pathways in this regard. 
 
 
Figure 6.7 PKC inhibition outweighs that of the other NOGP inhibitors – upregulation of 
glucose uptake. H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± respective 
NOGP inhibitors as follows: 100 µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM 
DON (for HBP), 10 µM ZOP (for polyol pathway). Values are expressed as mean ± SEM (n=4). 
**P<0.01 vs. respective controls.  
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In the earlier part of this thesis (Chapter 5), we determined that oxidative stress plays 
a significant role in the modulation of high glucose-induced insulin resistance. These 
data demonstrate that imbalanced intracellular redox status plays a major role in 
driving high glucose-induced alterations and that altered NOGP flux and ROS 
production may act in concert to reduce glucose uptake. Since ROS-dependent 
changes resulted from both higher ROS levels (total; mitochondrial and NOX-
derived) and attenuated antioxidant defenses, we further pursued molecular events 
that may be implicated in this process. In light of this, we employed the NOGP 
inhibitors to determine the impact of NOGP induction on mitochondrial and total 
intracellular ROS levels, as well as NOX activity under high glucose conditions (Fig 
6.8). Mitochondrial ROS was attenuated by AMG, DON (P<0.05 vs. high glucose) 
and CHE (P<0.001 vs. high glucose), while ZOP treatment had no significant effect 
(Fig 6.8A). NOX activity was significantly downregulated by AMG (P<0.01 vs. high 
glucose) (Fig 6.8B). Moreover, CHE treatment dramatically reduced NOX activity by 
~4 fold (P<0.001 vs. high glucose), resulting in significantly lower NOX activity 
compared to AMG (P<0.01) and DON (P<0.001). ZOP treatment also had a 
pronounced inhibitory effect (by ~86%) on NOX activity (P<0.01 vs. high glucose). 
DON administration resulted in no significant difference. Total intracellular ROS 
levels were reduced by AMG, CHE, DON (P<0.01 vs. high glucose) and ZOP 
(P<0.05 vs. high glucose) (Fig 6.8C).       
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Figure 6.8 NOGP modulation attenuated high glucose–induced ROS production. H9c2 cells were 
subjected to 24 h high glucose conditions vs. controls ± respective NOGP inhibitors as follows: 100 
µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM DON (for HBP), 10 µM ZOP (for 
polyol pathway). (A) MitoTracker Red analysis by flow cytometry; (B) NOX activity; (C) total 
intracellular ROS analyzed by DCF fluorescence using flow cytometry. Values are expressed as mean 
± SEM (n=6-9). *P<0.05, **P<0.01, ***P<0.001 vs. non-treated high glucose (NT); ^^P<0.01, 
^^^P<0.001 vs. indicated treatment.  
 
 
The NOGP inhibitor treatments significantly reversed the downregulation of SOD 
under high glucose conditions (Fig 6.9). AMG (P<0.01 vs. control; P<0.001 vs. high 
glucose; P<0.05 vs. DON; P<0.01 vs. ZOP) and CHE (P<0.01 vs. control; P<0.001 
vs. high glucose; P<0.05 vs DON; P<0.05 vs. ZOP) induced a more pronounced 
effect compared to DON (P<0.001 vs. high glucose) and ZOP (P<0.01 vs. high 
glucose) treatments.  
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Figure 6.9 High glucose-mediated inhibition of SOD activity was reversed by NOGP inhibition. 
H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± respective NOGP inhibitors 
as follows: 100 µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM DON (for HBP), 10 
µM ZOP (for polyol pathway). Values are expressed as mean ± SEM (n=6). **P<0.01, vs. control; 
##P<0.01, ###P<0.001 vs. high glucose; ^P<0.05, ^^P<0.01 vs. indicated treatment.  
  
 
 
In the previous chapter we showed that dysregulation of the replenishment of GSH 
under high glucose conditions may be an important mechanism contributing to the 
overall increase in ROS levels. We next aimed to assess the influence of NOGPs on 
this mechanism. GSH levels were increased by AMG (P<0.01 vs. HG), CHE 
(P<0.001 vs. HG) and ZOP (P<0.001 vs. HG) treatment, while DON had no 
significant effects (Fig 6.10A). ZOP increased G6PD activity (P<0.001 vs. control) 
while the other modulators elicited no significant effects (Fig 6.10B). NADPH levels 
were significantly lowered by CHE treatment (P<0.05 vs. control), while ZOP 
treatment upregulated it (P<0.05 vs. HG, P<0.05 vs. DON and P<0.001 vs. CHE) 
(Fig. 6.10C). The ratio of NADP+:NADPH was markedly upregulated by CHE 
treatment (P<0.01 vs. control, high glucose, AMG and DON; P<0.001 vs. ZOP). The 
other NOGP inhibitors had no significant effects. 
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Figure 6.10 Regulation of the glutathione system by NOGP modulation. H9c2 cells were 
subjected to 24 h high glucose conditions vs. controls ± respective NOGP inhibitors as follows: 100 
µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM DON (for HBP), 10 µM ZOP (for 
polyol pathway). (A) GSH levels, (B) G6PD activity, (C) NADPH levels, (D) NADP
+
:NADPH ratio. 
Values are expressed as mean ± SEM (n=6-9). *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, 
##P<0.01, ###P<0.001 vs. high glucose; ^P<0.05, ^^P<0.01, ^^^P<0.001 vs. indicated treatment.  
 
In an effort to assess the possible interplay between NOGPs, we investigated the 
effects of the NOGP inhibitors on all the other respective pathway markers under 
hyperglycemic conditions (Fig 6.11). Methylglyoxal levels (the AGE marker) were 
significantly decreased by CHE, ZOP (P<0.01 vs. high glucose) and DON (P<0.001 
vs. high glucose). Sorbitol levels were markedly reduced by AMG, CHE and DON 
treatment (P<0.001 vs. high glucose) (Fig 6.11B). AMG treatment did not exert a 
significant effect on O-GlcNAc levels, however it was decreased by CHE (P<0.05 vs 
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high glucose) and ZOP (P<0.01 vs. high glucose) administration (Fig 6.11C). PKC 
activity was markedly reduced by AMG, DON and ZOP treatment (P<0.001 vs. high 
glucose).    
 
 
Figure 6.11 Levels of NOGP markers in high glucose treated cells subjected to pathway 
inhibition. H9c2 cells were subjected to 24 h high glucose conditions ± respective NOGP inhibitors as 
follows: 100 µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM DON (for HBP), 10 µM 
ZOP (for polyol pathway). (A) Methylglyoxal levels (AGE pathway), (B) Sorbitol levels (polyol 
pathway), (C) O-GlcNAc modified proteins (HBP), (D) PKC activity. Values are expressed as mean ± 
SEM (n=6-9). *P<0.05, **P<0.01, ***P<0.001 vs. non-treated high glucose (NT).  
 
These data point toward NOGP interplay and their involvement in eliciting oxidative 
stress mechanisms and reduced glucose uptake. PKC activation may play a 
prominent role here. Our data further show no difference in PPP activity upon high 
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glucose treatment. The regulation of transketolase may, however, increase PPP flux 
and result in improved glucose metabolism. Indeed, thiamine or benfotiamine (BFT) 
administration (an important co-factor of transketolase) may have beneficial 
outcomes on dysreglulated glucose metabolism (Katare et al., 2010a; Mapanga et 
al., 2013; Marchetti et al., 2006; Schupp et al., 2008; Stirban et al., 2006; Winkler et 
al., 1999; Wu and Ren, 2006). Thiamine and BFT are proposed to redirect flux away 
from the NOGPs by upregulating glycolytic intermediates and enzymes (Hammes et 
al., 2003; Nishikawa et al., 2000). We therefore aimed to further assess the role of 
NOGPs in our system by employing BFT in vitro and thiamine in vivo. The rationale 
here is that the reversal of NOGP induction by BFT or thiamine would confirm our 
inhibitor data and shed more light on the importance and impact of NOGPs and their 
role in oxidative stress-mediated insulin resistance under acute high glucose 
conditions.  
 
6.4.3. Modulation of PPP diverts flux away from NOGPs – the role benfotiamine 
in vitro and thiamine in vivo 
 
H9c2 cells were exposed to 24 h high glucose ± two concentrations of BFT (50 and 
100 µM) for the final hour of the hyperglycemic period. Both concentrations of BFT 
robustly increased insulin stimulated glucose uptake – 50 µM (P<0.05 vs. basal) and 
100 µM (P<0.01 vs. basal), with the 100 µM concentration exerting a greater effect 
(Fig 6.12). 
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Figure 6.12 Benfotiamine administration increased glucose uptake.  H9c2 cells were subjected to 
24 h high glucose conditions ± 50 and 100 µM BFT. Values are expressed as mean ± SEM (n=4). 
*P<0.05, **P<0.01 vs. respective basal control. 
 
Compared to the other NOGP inhibitors, BFT (100 µM) had a similar pronounced 
effect on glucose uptake as CHE treatment (P<0.01 vs. basal control). This suggests 
that PPP induction and PKC inhibition represents two major mechanisms resulting in 
the reversal of hyperglycemia-mediated insulin resistance.     
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Figure 6.13 Comparison of BFT versus the other NOGP inhibitors – effect on glucose uptake. 
H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± respective NOGP inhibitors 
as follows: 100 µM AMG (for AGE pathway), 5 µM CHE (for PKC pathway), 40 µM DON (for HBP), 10 
µM ZOP (for polyol pathway) and 50 and 100 µM BFT (activates transketolase, non-oxidative PPP). 
Values are expressed as mean ± SEM (n=4). **P<0.01 vs. respective controls.  
  
Treatment of H9c2 cells exposed to acute high glucose and 100 µM BFT increased 
transketolase activity (P<0.01 vs. control, P<0.01 vs. high glucose) (Fig 6.14A). On 
the contrary, BFT had no significant effect on G6PD activity (Fig 6.14B). 
 
 
Figure 6.14 BFT increased transketolase activity. H9c2 cells were subjected to 24 h high glucose 
conditions vs. controls ± 100 µM BFT (activates transketolase, non-oxidative PPP). (A) Transketolase 
activity, (B) G6PD activity. Values are expressed as mean ± SEM (n=6). **P<0.01 vs. control, 
##P<0.01 vs. high glucose.  
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Since BFT promotes glucose metabolic flux (glucose oxidation) and may shift flux 
away from the detrimental NOGPs (Nishikawa et al., 2000), we next endeavored to 
assess NOGP markers and ATP levels (as a marker of metabolic flux coupled to 
energy production) in cells treated with 100 µM BFT during the last hour of 
hyperglycemia. BFT treatment markedly reduced methylglyoxal (P<0.01 vs. control, 
P<0.001 vs. high glucose) (Fig 6.15A) and sorbitol levels (P<0.01 vs. high glucose) 
(Fig 6.15B). PKC activity was also significantly decreased (P<0.01 vs. high glucose) 
(Fig 6.15C), along with O-GlcNAc levels (P<0.01 vs. high glucose) (Fig 6.15D). 
Surprisingly, ATP levels were also diminished upon BFT treatment (P<0.05 vs. 
control, P<0.01 vs. high glucose) (Fig 6.15D). 
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Figure 6.15 BFT treatment reduced NOGP markers and ATP levels. H9c2 cells were subjected to 24 h high glucose conditions vs. controls ± 100 µM BFT 
(activates transketolase, non-oxidative PPP). (A) Methylglyoxal levels (AGE pathway), (B) Sorbitol levels (polyol pathway), (C) PKC activity, (D) O-GlcNAc-
modified proteins (HBP), (E) ATP levels. Values are expressed as mean ± SEM (n=4-6). Values are expressed as mean ± SEM (n=6). *P<0.05, **P<0.01 vs. 
control, ##P<0.01, ###P<0.001 vs. high glucose.  
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The relative NOGP induction under high glucose ± BFT treatment conditions is 
depicted in Fig 6.16 below. This represents the mean difference in NOGP markers 
between BFT treated samples and high glucose treatments. BFT reduced markers of 
the AGE (~44%), polyol (~77%), PKC (~59%) and HBP pathways (~68%), and 
increased transketolase activity (PPP marker (~58%) compared to high glucose 
treatments.  
 
 
Figure 6.16 Relative NOGP induction with BFT treatment compared to high glucose. The mean 
difference (Δ) between high glucose and BFT treated samples were analyzed for each NOGP marker 
tested above (refer Fig. 6.15). Values are expressed as the approximate percentage Δ between high 
glucose and controls.     
 
Our next aim was to evaluate the role of BFT treatment on ROS production 
(mitochondrial- and NOX-derived) and to elucidate whether it plays a role in the 
regulation of antioxidant defense systems under high glucose conditions. BFT 
treatment mitigated mitochondrial ROS (P<0.01 vs. high glucose) (Fig 6.17A), NOX 
activity (P<0.05 vs. control, P<0.01 vs. high glucose) (Fig 6.17B) and total 
intracellular ROS (P<0.05 vs. high glucose) (Fig 6.17 C). 
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Figure 6.17 BFT attenuated ROS production. H9c2 cells were subjected to 24 h high glucose 
conditions vs. controls ± 100 µM BFT (activates transketolase, non-oxidative PPP). (A) MitoTracker 
Red analysis by flow cytometry; (B) NOX activity; (C) total intracellular ROS analyzed by DCF 
fluorescence using flow cytometry. Values are expressed as mean ± SEM (n=6-9). *P<0.05, **P<0.01, 
vs. control; #P<0.05, ###P<0.001 vs. high glucose. 
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SOD activity was also markedly upregulated by BFT treatment (P<0.01 vs. high 
glucose) (Fig 6.18).  
 
Figure 6.18: BFT administration increased SOD activity. H9c2 cells were subjected to 24 h high 
glucose conditions vs. controls ± 100 µM BFT (activates transketolase, non-oxidative PPP). Values 
are expressed as mean ± SEM (n=6). *P<0.05 vs. control; ##P<0.01 vs. high glucose. 
 
Our data further show that BFT treatment increased GSH levels (P<0.05 vs. high 
glucose) (Fig 6.19A). Although such treatment had no effect on NADPH levels (Fig 
6.19B), it resulted in a marked increase in the NADP+:NADPH ratio (P<0.01 vs. 
control, P<0.01 vs. high glucose) (Fig 6.19C). This suggests increased NADPH 
utilization by processes that are activated with BFT treatment. 
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Figure 6.19 BFT upregulated GSH levels and increased NADPH utilization. H9c2 cells were 
subjected to 24 h high glucose conditions vs. controls ± 100 µM BFT (activates transketolase, non-
oxidative PPP). (A) GSH levels; (B) NADPH levels; (C) NADP
+
:NADPH ratio. Values are expressed as 
mean ± SEM (n=6-9). **P<0.01 vs. control; #P<0.05, ###P<0.001 vs. high glucose. 
 
 
Since our previous data point toward interplay between NOGPs under high glucose 
conditions (refer Fig 6.11), we therefore postulated that transketolase activity may be 
regulated by NOGPs under high glucose conditions. We found that DON treated cells 
drastically decreased transketolase activity (P<0.001 vs. control, P<0.05 vs. high 
glucose; P<0.01 vs. CHE) (Fig 6.20). Although AMG and ZOP decreased 
transketolase activity by ~17 and ~24% (compared to high glucose) respectively, 
these effects were not significant. CHE resulted in an opposite effect to the other 
NOGPs, i.e. ~16% upregulation compared to high glucose; however this effect was 
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also not significant. Of note, CHE triggered a different effect compared to the other 
NOGPs.   
 
 
Figure 6.20 DON administration downregulated transketolase activity. H9c2 cells were subjected 
to 24 h high glucose conditions vs. controls ± 100 µM BFT (activates transketolase, non-oxidative 
PPP). (A) GSH levels; (B) NADPH levels; (C) NADP
+
:NADPH ratio. Values are expressed as mean ± 
SEM (n=6-9). *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, ###P<0.001 vs. high glucose. 
 
 
Our in vitro BFT studies in a simulated acute hyperglycemic setting showed that 
upregulation of the PPP may play an important role in diminishing high glucose-
mediated insulin resistance. We now turned our attention to evaluating the effects of 
thiamine in an in vivo model of metabolic dysregulation – the OLETF rat. Previously 
collected heart tissues were kindly provided by Dr. Takao Tanaka (Osaka University 
of Pharmaceutical Sciences, Osaka, Japan). A description of the model and 
experimental protocol is provided in Section 4.4 (also refer Tanaka et al., 2010). For 
this study, 25-week old OLETF rats displayed a “pre-diabetic” phenotype 
characterized by high glucose and high insulin levels, while 55-week old rats 
exhibited a diabetic phenotype (diminished plasma insulin levels accompanied by β-
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cell damage and severe hyperglycemia). Moreover, thiamine treatment reversed the 
detrimental metabolic effects in this model.  
 
We next aimed to assess the role of in vivo hyperglycemia in the two different states 
of glucose metabolic dysregulation (i.e. 25 weeks “pre-diabetes” and 55 weeks “overt 
diabetes”) and to evaluate the molecular mechanisms underlying the thiamine-
induced reversal of metabolic dysfunction in collected heart tissues. More 
specifically, we aimed to evaluate the role of NOGPs and their regulation by thiamine 
treatment in each condition. We initially aimed to gain an understanding of insulin 
signaling. This was achieved by employing an ELISA-based Akt kinase activity 
assay. Akt activity was ~2.4 fold increased by thiamine treatment in the 25 week 
group (P<0.001 vs. 25 week control) (Fig 6.21). Conversely, the 55 week old control 
animals displayed markedly reduced myocardial Akt activity (P<0.05 vs. 25 week 
control, P<0.001 vs. 25 week thiamine) at baseline and in response to thiamine 
treatment.  
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Figure 6.21 Myocardial Akt activity is upregulated by thiamine in 25 week old OLETF rats. Four 
week old OLETF rats were subjected to 2 g/L thiamine for 21 and 51 weeks, respectively. Animals 
were sacrificed at 25 and 55 weeks and heart tissues collected for Akt activity analysis. Values are 
expressed as mean ± SEM (n=8). *P<0.05, ***P<0.001 vs. 25 week control; ###P<0.001 vs. 25 week 
thiamine.  
 
We next aimed to determine NOGP activity in the pre-diabetic and diabetic states, as 
well as the effect of thiamine administration on NOGP activity. We started by 
assessing the activity of two key regulatory PPP enzymes, G6PD and transketolase 
(Fig 6.22). Thiamine treatment had no effect on G6PD activity compared to the 
respective controls in the 25 week or the 55 week groups (Fig 6.22A). It was, 
however, markedly reduced in the 55 week controls (P<0.01 vs. 25 week control, 
P<0.001 vs. 25 week thiamine). G6PD activity was also significantly lower with 
thiamine treatment in the 55 week old animals compared to thiamine treatment in the 
25 week group. Transketolase activity was markedly upregulated with thiamine 
treatment in both the pre-diabetic (P<0.001 vs. 25 week control) and the diabetic 
groups (P<0.001 vs. 55 week control) (Fig 6.22B). Moreover, transketolase activity 
was reduced in heart tissue of the 55 week old animals (P<0.001 vs. 25 week 
control). 
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Figure 6.22 PPP enzymes are reduced in the 55 week old (diabetic) hearts and transketolase 
upregulated by thiamine in vivo. Four week old OLETF rats were subjected to 2 g/L thiamine for 21 
and 51 week respectively. Animals were sacrificed at 25 and 55 week and heart tissues collected for 
analysis of (A) G6PD and (B) transketolase enzyme activity. Values are expressed as mean ± SEM 
(n=8). **P<0.01, ***P<0.001 vs. 25 week control; #P<0.05, ###P<0.001 vs. 25 week thiamine; 
^^^P<0.001 vs. indicated treatment.  
 
Myocardial methylglyoxal levels were decreased with thiamine treatment in the pre-
diabetic state (P<0.001 vs. 25 week control) (Fig 6.23). Furthermore, the older 
OLETF rats displayed lower methylglyoxal levels compared to the 25 week old rats 
(P<0.001 vs. 25 week control). However, thiamine treatment in the 55 week old 
diabetic animals did not have a significant effect compared to the controls, but 
remained lower vs. the 25 week controls (P<0.001).  
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Figure 6.23 Methylglyoxal levels (marker of the AGE pathway) were decreased by thiamine 
treatment in pre-diabetic hearts in vivo. Four week old OLETF rats were subjected to 2 g/L thiamine 
for 21 and 51 week respectively. Animals were sacrificed at 25 and 55 week and heart tissues 
collected for analysis of methylglyoxal levels. Values are expressed as mean ± SEM (n=8). ***P<0.001 
vs. 25 week control.  
 
Sorbitol levels were markedly reduced by thiamine administration in the pre-diabetic 
state (P<0.001 vs. 25 week control), while it was also lower in the older diabetic 
animals (P<0.01 vs. 25 week control). Thiamine treatment did not significantly alter 
sorbitol levels in the 55 week old group. 
 
 
Figure 6.24 Sorbitol levels were decreased in the 25 week old animals. Four week old OLETF rats 
were subjected to 2 g/L thiamine for 21 and 51 week respectively. Animals were sacrificed at 25 and 
55 week and heart tissues collected for analysis of sorbitol levels. Values are expressed as mean ± 
SEM (n=8). **P<0.01, ***P<0.001 vs. 25 week control; ###P<0.001 vs. 25 week thiamine. 
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Similar trends were observed for PKC activity in heart tissues compared to the 
markers for the AGE and polyol pathways, i.e. reduced PKC activity in the 25 week 
thiamine-treated and 55 week control and thiamine groups vs. the 25 week controls 
(P<0.001) (Fig 6.25). Thiamine treatment did not significantly change PKC activity in 
the 55 week old animals compared to controls, but resulted in a modest reduction 
compared to the 25 week old control (P<0.001) and thiamine-treated animals 
(P<0.05). 
 
 
Figure 6.25 Thiamine treatment decreased PKC activity in the pre-diabetic OLETF rats. Four 
week old OLETF rats were subjected to 2 g/L thiamine for 21 and 51 week respectively. Animals were 
sacrificed at 25 and 55 week and heart tissues collected for PKC kinase activity assay. Values are 
expressed as mean ± SEM (n=8). ***P<0.001 vs. 25 week control; #P<0.05 vs. 25 week thiamine. 
 
Myocardial O-GlcNAc levels were assessed by Western blotting (Fig 6.26). Thiamine 
treatment decreased O-GlcNAc levels in the 25 week (P<0.001 vs. 25 week control) 
and 55 week (P<0.001 vs. 55 week control) heart samples. It was also modestly 
decreased in the diabetic control groups compared to the pre-diabetic control groups 
(P<0.001).  
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Figure 6.26 Thiamine treatment diminished O-GlcNAc levels in the pre-diabetic and diabetic 
OLETF rat hearts. Four week old OLETF rats were subjected to 2 g/L thiamine for 21 and 51 week 
respectively. Animals were sacrificed at 25 and 55 week and heart tissues collected for O-GlcNAc 
analysis by Western blotting. (A) Representative Western blots of O-GlcNAc and corresponding β-
actin. (B) Quantification of Western blotting data with values normalized to respective β-actin. Values 
are expressed as mean ± SEM (n=8). ***P<0.001 vs. 25 week control; ###P<0.001 vs. 25 week 
thiamine; ^^P<0.01 vs. indicated treatment. 
 
6.4.4. Molecular events downstream of NOGP activation in in vitro simulated 
hyperglycemia 
 
Collectively our data provides a strong metabolic link between high glucose-induced 
ROS production, activation of NOGPs and subsequent dysregulation of insulin 
action, including decreased insulin-mediated glucose uptake. Our next aim was to 
explore possible molecular mechanisms to link the observed upstream detrimental 
events to decreased insulin responsiveness. Upregulation of PKC isoforms may play 
an important role in regulation of insulin signaling mechanisms (Bandyopadhyay et 
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al., 1999a, 1999b; Hennige et al., 2010; Itani et al., 2000; Quagliaro et al., 2003; 
Ragheb et al., 2009). PKCβII may be a central effector of various detrimental 
outcomes under hyperglycemic conditions (Amadio et al., 2010; Geraldes and King, 
2010; Voris et al., 2010), while it may also regulate NOX activity and the resultant 
ROS production (Quagliaro et al., 2003). We therefore evaluated the protein levels of 
this isoform in our in vitro model of acute hyperglycemia, and assessed the role of 
mitochondrial and NOX-derived ROS by employing 4-OHCA and DPI treatments. 
Here PKCβII protein levels were upregulated by acute high glucose when compared 
to controls (P<0.001) (Fig 6.27), and downregulated by both 4-OHCA and DPI 
treatment. 
 
 
Figure 6.27 Upregulation of PKCβII by acute hyperglycemia was reduced by 4-OHCA and DPI 
treatment. H9c2 cells were treated acutely with a) 4-OHCA and b) DPI under high glucose conditions. 
Values are expressed as mean ± SEM (n=6). *P<0.05, ***P<0.001 vs. control; #P<0.05 vs. high 
glucose. 
  
The post-translational modification of kinases involved in insulin signaling is key to 
their regulation. Phosphorylation is a major modification resulting in effective insulin 
action. However, several signals lead to downregulation of insulin signaling 
intermediates. O-GlcNAcylation of several insulin signaling intermediates, including 
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Akt, is proposed to effect downregulaation of insulin action and may be involved in 
insulin resistance when HBP flux is elevated (Gandy et al., 2006; Kang et al., 2008; 
Park et al., 2005; Vosseller et al., 2002). Our data showed that Akt and O-GlcNAc co-
localized in H9c2 cells, and this was increased ~3.3 fold in the high glucose treated 
group (P<0.05 vs. control) (Fig 6.28). Treatment with 4-OHCA and DPI reduced this.      
 
 
Figure 6.28 Co-localization of Akt and O-GlcNAc was elevated under high glucose conditions 
and reduced by inhibition of mitochondrial and NOX-derived ROS. H9c2 cells were treated 
acutely with a) 4-OHCA and b) DPI under high glucose conditions. (A) Fluorescence microscopy 
analysis of H9c2 cells co-stained with antibodies to detect Akt (FITC-green) and O-GlcNAc (Texas 
Red) with nuclei stained with DAPI (blue). (B) Co-localization of Akt and O-GlcNAc indicated in the 
yellow color. (C) Quantification of the area of co-localization expressed in arbitrary units (AU). Values 
are expressed as mean ± SEM (n=4). *P<0.05 vs. control; #P<0.05 vs. high glucose. 
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Similar trends were observed when we analyzed AS160 and O-GlcNAc co-
localization, i.e. a ~2.7 fold increase under hyperglycemic conditions (P<0.05 vs. 
control) which was blunted by 4-OHCA (P<0.01 vs. high glucose) and DPI treatment 
(P<0.05 and vs. high glucose), respectively. Although further analysisis warranted to 
confirm the co-locailization results (e.g. co-immunoprecipitation experiments),  our 
preliminary data suggest that increased modification of Akt and AS160 under acute 
hyperglycemic conditions is regulated by mitochondrial and NOX-derived ROS. 
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Figure 6.29 Co-localization of AS160 and O-GlcNAc was elevated under high glucose 
conditions and reduced by inhibition of mitochondrial and NOX-derived ROS. H9c2 cells were 
treated acutely with a) 4-OHCA and b) DPI under high glucose conditions. (A) Fluorescence 
microscopy analysis of H9c2 cells co-stained with antibodies to detect AS160 (FITC-green) and O-
GlcNAc (Texas Red) with nuclei stained with DAPI (blue). (B) Co-localization of AS160 and O-GlcNAc 
indicated in the yellow color. (C) Quantification of the area of co-localization expressed in arbitrary 
units (AU). Values are expressed as mean ± SEM (n=4). *P<0.05 vs. control; #P<0.05 vs. high 
glucose. 
 
 
6.5. Discussion 
 
The etiology of insulin resistance is complex and multifaceted.  For example, it may 
result from metabolic alterations associated with multiple conditions of metabolic 
dysregulation (e.g. obesity and the metabolic syndrome), while increased 
consumption of energy rich food coupled to sedentary lifestyle may also fuel this 
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process (Petersen and Shulman, 2006; Stumvoll et al., 2005). We are of the opinion 
that nutrient excess may be at the core of the detrimental causal effects of insulin 
resistance.  More specifically, excursions of acute hyperglycemia - associated with 
excess nutrient intake or elevated postprandial glycemic spikes in non-diabetic, pre-
diabetic or diabetic individuals - can play a significant role in insulin resistance and its 
complications (Ceriello et al., 2002; Kawahito et al., 2009; Mapanga et al., 2013, 
2012; Williams et al., 1998; Wisneski et al., 1990; Yang et al., 2009).  The detrimental 
link between acute hyperglycemic episodes and the etiology of insulin resistance is 
thus an important factor to consider and explore. In Chapter 5 we identified a role for 
both mitochondrial- and NOX-derived ROS in the setting of acute hyperglycemia in 
vitro. Our data showed a link between oxidative stress and downstream disruption of 
insulin action with high glucose treatment. Furthermore, we proposed that 
mitochondrial ROS (although only modestly increased) may participate in cross-talk 
mechanisms and even trigger downstream activity of NOX and other molecular 
events. As a result we next turned our attention to investigate possible molecular 
events linking mitochondrial- and NOX-derived ROS production to the observed 
downregulation of glucose uptake. 
 
Our first aim was to evaluate metabolic function under high glucose conditions and to 
assess the possible role(s) of mitochondrial- and NOX-derived ROS in this process. 
The first step was to measure ATP levels as an indicator of metabolic flux coupled to 
energy production. High glucose treatment had no significant effect on intracellular 
ATP levels. This is in accordance with the data showing lower glucose uptake (refer 
Fig 5.5), as one would expect a strong increase in ATP production when the glucose 
transport machinery would be functional and in the context of elevated extracellular 
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glucose availability. Conversely, it may also point towards alternate utilization of 
glucose metabolic intermediates, e.g. diversion into NOGPs (discussed below). 
Glucose uptake by alterative means (other than via GLUT4) may indeed be 
upregulated when extracellular glucose is high. For example, Balteau and colleagues 
recently showed increased glucose uptake via SGLT1 with damaging downstream 
effects (Balteau et al., 2011). Administration of 4-OHCA inhibits the mitochondrial 
uptake of pyruvate (Halestrap, 1975),  thereby limiting reducing equivalent production 
by the citric acid cycle,  decreasing electron flow via the electron transport chain, and 
hence limiting mitochondrial ROS production.  Thus a 4-OHCA-mediated reduction of 
mitochondrial pyruvate uptake may translate into lower mitochondrial ATP 
production. We are unclear how DPI treatment reduced ATP levels, but speculate 
that the inhibition of NOX may lead to activation of ATP consuming processes. These 
processes may be particularly increased in the period following acute DPI 
administration. Additional studies are required to further delineate a molecular basis 
for our observations. It may also be useful to determine the exact role on glucose-
derived (glycolytic/glucose oxidation) ATP production.      
 
To further evaluate the downstream effects of hyperglycemia-induced ROS, we 
subsequently determined the degree of NOGP activation in our experimental system.   
Exposure to acute high glucose coordinately induced the NOGP markers (AGE, 
polyol pathway, PKC, HBP) evaluated. These elevations were reduced by acute 
treatment with 4-OHCA and DPI. Our findings are in agreement (in part) with the 
unifying hypothesis that proposes that hyperglycemia-mediated oxidative stress may 
be a common upstream factor that elevates NOGP flux (Brownlee, 2005). Here 
mitochondrial-derived superoxide results in GAPDH inhibition and subsequent PARP 
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activation, leading to the diversion of upstream glycolytic intermediates into the 
NOGPs (Du et al., 2003).   
 
The current study now extends this paradigm since the data demonstrate that both 
mitochondrial and NOX-derived ROS coordinately upregulated all four NOGPs.  
Moreover, inhibition of both mitochondrial- and NOX-derived ROS generation 
lowered NOGP activation to the same extent, despite NOX-derived ROS constituting 
the bulk of ROS generated by acute high glucose exposure. These findings therefore 
support cross-talk between mitochondrial ROS and the downstream activation of the 
NOX system in our model (discussed in Chapter 5).  The activity of transketolase 
(non-oxidative PPP) was, however, unaltered by high glucose conditions. 
Surprisingly, inhibition of ROS production (both mitochondrial- and NOX-derived) 
resulted in diminished transketolase activity. This suggests that transketolase 
activation may be linked to mitochondrial and NOX signaling events.  However, 
further studies are needed to investigate this intriguing observation. It is also 
important to consider the contribution of attenuated antioxidant defense mechanisms 
to the overall intracellular oxidative stress as it forms another part of the extension to 
the original unifying hypothesis. Pharmacological studies aiming to delineate the role 
of oxidative stress should take these factors into account. 
 
To ascertain the functional effects of NOGP activation, we employed various NOGP 
inhibitors. Initial optimization experiments showed that each individual inhibitor 
markedly reduced the hyperglycemia-mediated induction of their respective 
pathways. Furthermore, insulin-mediated glucose uptake was improved to varying 
degrees by each inhibitor. For example, PKC inhibition (CHE) resulted in the most 
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substantial reversal of high glucose effects compared to the other NOGP inhibitors. 
This indicates that PKC is the major downstream target of hyperglycemia-induced 
ROS that impairs insulin-stimulated glucose uptake with acute hyperglycemia. 
Indeed, PKC activation may exert a negative regulatory effect on insulin signaling 
(Bollag et al., 1986; Takayama et al., 1988). In support, Davidoff and colleagues 
(2004) found that high glucose-induced insulin resistance and diminished in vitro 
contractile function could be reversed by CHE treatment in rat ventricular 
cardiomyocytes isolated from diabetic animals. They concluded that PKC is a central 
modulator of hyperglycemic damage (Davidoff et al., 2004).  
 
The PKC family is composed of numerous isoforms with different subcellular 
localizations (reviewed in Cosentino-Gomes et al., 2012).  Oxidative stress can result 
in direct PKC activation that is usually associated with its translocation to the 
sarcolemma (Konishi et al., 1997).  The PKC enzyme family also plays an important 
role in the activation of NOX isoforms, e.g. the plasma-localized NOX2 (reviewed by 
Fisher, 2009).  Since PKCβII is strongly implicated in the onset of insulin resistance 
(Hennige et al., 2010), we next assessed its expression in our experimental system.  
Here PKCβII was upregulated by acute hyperglycemia and this induction was ROS-
dependent (mitochondrial- and NOX-derived), indicating that it is a downstream 
target of mitochondrial and NOX signaling, respectively. Together, we show that 
acute hypergycemia-induced ROS triggers coordinate NOGP activation, but that 
PKCβII is the key regulator responsible for attenuation of insulin-mediated glucose 
uptake in this instance.  However, we cannot rule out the possibility that other PKC 
isoforms (not evaluated in this study) may also contribute to this effect.   
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Increased HBP flux may impair insulin-mediated glucose transport by acting as an 
upstream activator of PKC activation under high glucose conditions (Filippis et al., 
1997). Indeed, high glucose-mediated activation of the HBP is implicated as an 
important mechanism in the downregulation of insulin sensitivity (Chen et al., 1997; 
Cooksey et al., 1999; Marshall et al., 1991; Robinson et al., 1995), and insulin 
signaling intermediates (e.g. IRS1 and Akt) may be post-translationally modified by 
O-GlcNAc, resulting in reduced phosphorylation and activity (Arias et al., 2004; 
Gandy et al., 2006; Nelson et al., 2002; Park et al., 2005; Vosseller et al., 2002). Our 
laboratory previously established that impaired cardiac function, increased infarct 
size and myocardial apoptosis were associated with oxidative stress and elevated 
HBP activation in various in vitro, ex vivo and in vivo models of experimental 
hyperglycemia (Mapanga et al., 2012; Rajamani and Essop, 2010; Rajamani et al., 
2011). However, others found that acute elevation of HBP flux may be 
cardioprotective against ischemia-reperfusion damage and that this may be 
attributable to an adaptive response (reviewed in Chatham and Marchase, 2010; 
Fülöp et al., 2007; McLarty et al., 2013).  Data from the current study suggest that 
HBP flux may not play a prominent role under our experimental conditions.  We 
cannot, however, rule out pathway cross-talk as our preliminary data indicate 
reducing effects of each pathway inhibitor on markers of the other pathways, while 
co-localization studies revealed that Akt and its downstream substrate AS160, may 
both be modified by O-GlcNAcylation. Mitochondrial- and NOX-derived ROS may 
both be effectors of the O-GlcNAcylation of these intermediates, as 4-OHCA and DPI 
treatments markedly reduced the co-localization effect of high glucose. The 
prominence of such mechanisms deserves further attention.    
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We further aimed to elucidate whether any cross-talk exists between NOGP activity 
and oxidative stress mechanisms. NOX activity was markedly reduced and GSH 
levels enhanced by inhibition of the PKC (CHE) and polyol (ZOP) pathways. 
Inhibition of the AGE pathway (AMG) also increased GSH levels.  Furthermore, PKC 
inhibition (CHE) lowered NADPH supply, while the latter was elevated with polyol 
pathway inhibition (ZOP). Polyol pathway inhibition also led to increased G6PD 
activity. These data indicate that there is cross-talk between the NOGPs but 
especially between the polyol and PKC pathways, with NADPH availability a key 
common metabolite determining which pathway will predominate under specific 
circumstances. Our data show that acute high glucose conditions increased polyol 
pathway flux, a process that utilizes NADPH (Asbun and Villarreal, 2006; King and 
Loeken, 2004; Sato et al., 1999; Tracey et al., 2000). The concomitant upregulation 
of PKC and subsequent activation of NOX further diminishes intracellular NADPH 
levels, while the activity of G6PD (a chief NADPH producing enzyme) is not altered. 
This results in attenuation of the glutathione replenishment reactions. The 
concomitant reduction in SOD activity, NOX activation and increased mitochondrial 
ROS production results in a global intracellular oxidative stress milieu. We propose 
that this may result in a vicious cycle of further NOGP activation and ROS production, 
all contributing to reduced insulin action. Others found that the elevation of AGEs 
may directly induce oxidative stress (Li et al., 2007). In agreement, our data show 
involvement of AGEs in NOX activation and upregulation of mitochondrial ROS, as 
well as disruption of SOD activity and GSH levels. The precise mechanisms and 
possible interplay is not clear and needs further evaluation.   
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Upregulation of the PPP by BFT treatment may divert flux from the four NOGPs into 
the PPP and is associated with beneficial outcomes in the setting of 
hyperglycemia/diabetes (Hammes et al., 2003). We therefore employed BFT to 
further evaluate the validity of our NOGP inhibitor data. Our data showed that BFT 
administration markedly reduced each of the NOGPs evaluated, and increased the 
activity of transketolase. BFT treatment (100 µM) also prominently increased insulin-
stimulated glucose uptake, and generally reversed the effects of acute hyperglycemia 
here described. This likely represents an attenuation of effects largely exerted by 
PKC, and to a lesser extent the polyol pathway. We were surprised that  DON 
treatment reduced transketolase activity and it is our opinion that this may represent 
additional regulation of the PPP by HBP activation. We speculate that transketolase 
may be O-GlcNAc modified, however, this has not been shown before. The 
regulatory mechanism(s) and downstream outcome(s) need to be further evaluated. 
 
We also evaluated NOGP activation in the setting of in vivo pre-diabetes and overt 
diabetes by employing the OLETF rat model of metabolic dysfunction (Tanaka et al., 
2010). This model develops mild obesity and insulin resistance associated with late 
onset hyperglycemia (Kawano et al., 1992, 1994). We analyzed molecular 
derangements in heart tissues from rats treated with thiamine from the age of 4 week 
and rats developed hallmarks of a pre-diabetic state at the age of 25 week (elevated 
blood glucose accompanied by high insulin levels).  By 55 week of age the rats were 
diabetic, displaying low insulin and chronic hyperglycemia accompanied by β-cell 
destruction and associated diabetic complications (Tanaka et al., 2010). We 
evaluated Akt kinase activity as a marker of insulin action and found it was reduced 
over time.  However, thiamine treatment markedly upregulated it in the pre-diabetic 
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rat heart. This is in accordance with our in vitro data showing normalized glucose 
uptake by BFT treatment in an acute hyperglycemic setting. Thiamine treatment also 
markedly increased transketolase activity in both age groups (25 and 55 weeks).  
However, G6PD activity (reduced in the diabetic vs. pre-diabetic tissues) could only 
be increased by thiamine in the 55 week group. These data further support our in 
vitro results showing that G6PD activity is relatively unaltered by BFT, but that 
transketolase is markedly increased during acute hyperglycemic conditions. NOGP 
markers (AGE, polyol pathway, PKC activity) were generally reduced in the diabetic 
tissues. This is in contrast to studies showing drastically elevated NOGP markers 
associated with diabetes (Brownlee, 2005; Giacco and Brownlee, 2010; Hammes et 
al., 2003; King and Brownlee, 1996). However, these studies focused on tissues and 
cell types that are not insulin dependent (e.g. pancreatic β-cells and endothelial 
cells). We therefore conclude that overt diabetes, specifically the reduced insulin 
levels accompanied by severe insulin resistance, may result in decreased 
intracellular glucose in insulin responsive cells (e.g. cardiomyocytes) resulting in 
reduced glycolytic and NOGP flux. This is, however, not the case in the pre-
diabetic/acute hyperglycemic phase, and the elevated intracellular glucose 
concentrations may in fact drive insulin resistance via the mechanisms described in 
this study. The original study by Tanaka and colleagues (Tanaka et al., 2010), did 
unfortunately not include a LETO group (control for OLETF) meaning that 
conclusions regarding the effects observed in untreated OLETF rats vs. a normal 
metabolic state cannot be readily made. Nonetheless, their study showed differences 
in the metabolic parameters between OLETF rats included and from the breeder 
colony vs. LETO breeders (refer Tanaka et al., 2010).  In accordance with the in vitro 
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BFT data, thiamine administration reduced markers of all four NOGPs, mainly in the 
25 wk group.  
 
In summary, this study demonstrates that acute hyperglycemia triggers an 
‘unfortunate series of events’ that contribute to decreased insulin-mediated cardiac 
glucose uptake (Fig. 6.30).  We propose that acute hyperglycemia generates a 
relatively small amount of mitochondrial ROS (as a trigger event) that results in the 
direct activation of PKC isoforms in proximity and/or localized to the mitochondrion. 
Interestingly, others found that PKCβII was localized to mitochondria in melanomas 
(Voris et al., 2010) making it an ideal candidate in this instance. However, further 
studies are required to determine whether this is indeed the case in the heart.  
PKCβII in turn can activate NOX that will result in substantially higher ROS 
production, thus amplifying the initial mitochondrial ROS trigger effect. Increased 
ROS levels can decrease antioxidant defenses (e.g. lower SOD activity) and its 
activation of the polyol pathway will lower GSH availability. Subsequently, 
intracellular oxidative stress triggers activation of the NOGPs, particularly PKCβII, 
leading to impaired insulin-mediated glucose uptake. We also propose that high 
glucose availability may increase these effects in a more direct fashion (i.e. high 
substrate supply, direct NOX activation).  Thus repeated, acute hyperglycemic 
episodes may contribute to the onset of insulin resistance and subsequent 
detrimental effects on the heart. 
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Figure 6.30 Our proposed model for acute hyperglycemia-induced myocardial insulin 
resistance. 
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CHAPTER 7 
Concluding remarks 
 
7.1. Summary of findings 
 
So far, treatment of diabetes and its associated complications does not always 
achieve optimal results. This does not bode well for the alarming future projections 
regarding diabetes and similar metabolic diseases. Further fueling this is the strong 
association with cardio-metabolic complications, together contributing to the most 
significant percentage of non-communicable diseases. These complications affect 
young, working age adults from both developed and developing nations, resulting in 
a significant socio-economic burden.  Obesity, metabolic syndrome and diabetes 
(undiagnosed, newly diagnosed or frank diabetes) are also highly prevalent in South 
Africa. A call for urgent measures to help curtail the growing disease burden is a 
global priority, however, the complex molecular mechanisms underlying the etiology 
of insulin resistance is not yet fully understood.  
 
We are of the opinion that a thorough understanding of the pathophysiological 
mechanisms driving insulin resistance is of utmost importance to curb the disease 
progression at an early stage. Our study therefore evaluated the effects of acute 
hyperglycemia on insulin resistance in cardiac-derived cells. Our data reveal that 
acute hyperglycemia elicits oxidative stress mechanisms that are strongly implicated 
in mediating insulin resistance. We further describe cross-talk mechanisms between 
mitochondrial ROS and NOX activation with downstream induction of NOGPs. Here, 
PKCβII may play a central role in exerting downstream damaging effects. Such 
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pathway interplay can also amplify downstream activation of further detrimental 
effects. Collectively our data extend current hypotheses describing hyperglycemia-
mediated derangements, specifically in the setting of insulin resistance. The findings 
of this study also point to ways how to confront the problem of insulin resistance and 
its complications, and lay a robust foundation for future work. Delineating the etiology 
of insulin resistance in more certain terms can greatly benefit identification of new 
pharmaceutical targets and the design of improved, more affordable medication 
and/or implementation of lifestyle intervention.   
 
7.2. Limitations 
 
Although we evaluated NOX activation in this study, we cannot comment on the 
specific NOX isoforms involved. Furthermore, we acknowledge that additional 
sources of ROS production (other than mitochondria and NOX) may also play a role 
and deserve further attention. The fluorescent probes used to detect ROS are not 
specific to any type, thus an analysis of specific ROS and reactive nitrogen species, 
and its impact on insulin action may provide additional insights. Additional methods to 
inhibit and enhance mitochondrial ROS, NOX and NOGPs (e.g. siRNA knockdown 
and/or overexpression of key regulatory enzymes) may also provide more specific 
means of controlling NOGP induction compared to the pharmacological inhibitors 
utilized here. For the current study, we focused on the expression levels of PKCβII in 
the hyperglycemic setting and its regulation by ROS. The role of additional PKC 
isoforms may also be important, and warrants further investigation. Furthermore, 
close attention should also be paid to the activity and intracellular localization of PKC 
isoforms, while specific means of isoform inhibition/activation should provide valuable 
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information. The use of H9c2 cells provides valuable model for the analysis of a wide 
variety of experimental assays. The cell line is easily maintained and can be 
experimentally manipulated by transfection or pharmacological treatments. The cells 
are, however, neonatal myoblasts and therefor prefer glucose as substrate versus 
the adult cardiomyocyte, which favors fatty acids. H9c2 cells also do not possess the 
ability to contract. These features mean that conclusions drawn from studies using 
H9c2 cells should be interpreted with caution when comparing to effects in the adult 
heart or cardiomyocyte. The lack of a LETO control in the OLETF study of thiamine 
treatment hampered our ability to draw firm conclusions and future in vivo studies 
should take this into account. 
 
7.3. Future directions 
 
For future studies we plan to further evaluate and clarify the molecular mechanisms 
involved in hyperglycemia-induced insulin resistance and perform additional studies 
to prove the unique model we here propose (refer Figure 6.30).  We aim to employ 
more sophisticated in vitro techniques (including overexpression and siRNA 
transfections) and ‘cause-and-effect’ studies to rigorously evaluate the validity of this 
model. To further confirm these findings, we will also test our hypothesis in an in vivo 
context.  Here we plan to perform additional studies on a genetically obese/insulin 
resistant (db/db) mouse model to evaluate the interplay between hyperglycemia, 
oxidative stress, NOGP activation and the onset of insulin resistance. Such 
investigations will be performed in a temporal manner to more precisely determine 
the sequence of events that lead to the development of insulin resistance, and 
related cardiac dysfunction in db/db mice. Successful completion of this study should 
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allow us to make valuable contributions toward understanding the etiology of insulin 
resistance/Type 2 diabetes and help identify novel therapeutic interventions to curb 
its onset.  Moreover, our investigations in the heart should also contribute to an 
improved mechanistic understanding of the damaging link between insulin resistance 
and the onset of CVD, and point the way(s) ahead to disrupt this.  
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Appendix A – Modified radio-immunoprecipitation assay (RIPA) buffer 
Modified radioimmunoprecipitation (RIPA) buffer) – 100 ml 
50 mM Tris-HCl, pH 7.4 (790 mg Tris dissolved in 75 ml dH2O, add 900 mg NaCl, pH to 7.4 with HCl) 
1% Nonidet-P40 (NP-40) – from 10% stock solution 
0.25% sodium deoxycholate – from 10% stock solution 
1 mM EDTA, pH 7.4 – from 100 mM stock solution 
1 mM phenylmethylsulfonyl fluoride (PMSF) – from 200 mM stock solution (add just prior to use) 
1 µg/ml leupeptin 
4 µg/ml soybean trypsin inhibitor (SBTI) 
1 mM benzamidine 
1 mM sodium orthovanadate (Na3VO4) 
1 mM sodium fluoride (NaF) 
1 mM PUGNAc* 
1% Triton X-100 
 All constituents, except PMSF, are added to a final volume of 100 ml, aliquoted and stored at -20°C 
*PUGNAc is an O-GlcNAcase inhibitor an is added to blunt removal of O-GlcNAc moieties during the protein extraction 
procedure 
  
Stellenbosch University  http://scholar.sun.ac.za
247 
 
Appendix B – Bradford protein determination 
Bradford stock solution (5X conc.) 
Dilute 500 mg Coomassie Brilliant blue G250 in 250 ml 95% ethanol 
Add 500 ml phosphoric acid, mix thoroughly 
Adjust volume to 1 L with dH2O 
Filter solution and store at 4°C 
 
Bradford working solution 
Dilute stock in a 1:5 ratio with dH2O 
Filter with 2 filter papers 
The filtered working solution should be a light-brown color – light sensitive! 
 
Materials 
1 mg/ml BSA stock solution (stored in freezer) 
Microcentrifuge tubes (7 for standards, 1 for each sample) 
dH2O 
Ice 
Bradford working reagent 
Cuvettes 
Spectrophotometer 
 
Protein determination: 
1. Thaw the BSA stock solution 
2. Thaw protein samples on ice if stored – keep on ice at all times 
3. Make up a BSA working solution by diluting 100 µl BSA stock in 400 µl dH20, vortex 
thoroughly 
4. Mark tubes – 7 for standards and 1 each for samples 
5. Add BSA and dH2O to standard tubes as indicated in the table below: 
Protein standard (µg protein) BSA (µl) dH2O (µl) 
Blank 
2 
4 
8 
12 
16 
20 
0 
10 
20 
40 
60 
80 
100 
100 
90 
80 
60 
40 
20 
0 
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6. Add 95 µl dH2O and 5 µl of each protein sample (cell or tissue lysate) to the appropriate tube 
7. Vortex all tubes briefly 
8. Add 900 µl Bradford working solution to each tube, vortex again 
9. Incubate the tubes for at least 5 min at room temp. (the reaction takes about two minutes to 
complete and is stable for up to 60 min) 
10. In the meantime, switch on the spectrophotometer, allow it to calibrate, and set the 
wavelength to 595 nm 
11. Read absorbances, twice each, for each tube 
12. If sample values fall outside the range of the highest protein standard, dilute with RIPA buffer 
13. Use excel to draw a linear plot of standard absorbances, and calculate the protein 
concentration in each sample in order to make aliquots of equal protein amounts (in µg) 
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Appendix C – Western blotting protocol 
 
Blue sample preparation 
Laemmli sample buffer 
dH2O – 3.8 ml 
0.5 M Tris-HCl, pH 6.8 – 1.0 ml 
Glycerol – 0.8 ml 
10% (w/v) SDS – 1.6 ml 
0.05% (w/v) bromophenol blue – 0.4 ml 
 
Materials 
1.5 ml microcentrifuge tubes 
Sharp tweezers 
Ice 
Heating block 
β-mercaptoethanol 
Microtube centrifuge 
Vortex 
 
Sample preparation: 
1. Set the heating block to 95°C 
2. Make up a working solution of sample buffer by combining 850 µl Laemmli buffer stock 
solution and 150 µl β-mercaptoethanol (work in fume cabinet), vortex thoroughly 
3. Calculate the appropriate volume of each sample to give equal protein amounts (eg. 50 µg 
per sample) and calculate the number of sample sets needed 
4. Label microcentrifuge tubes for each sample and sample set 
5. Add a volume of working sample buffer equal to 1/3 of the total sample volume (2/3 protein 
+ 1/3 sample buffer) as calculated, to each appropriate tube (work in fume cabinet) 
6. Add the appropriate volume of protein sample to each tube 
7. Punch small holes in the lid of each tube using the sharp tweezers 
8. Heat samples on the heating block (95°C) for 5 min 
9. Vortex each tube, spin down contents briefly (~10 seconds) and place on ice immediately 
10. Samples can now be applied to gels for SDS-PAGE or stored at -20°C for future use  
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SDS-PAGE and Western blotting 
Buffers: 
10 X SDS running buffer (1 L) 
10 g SDS 
30.3 g Tris 
144.1 g Glycine 
Dissolve in 800 ml dH2O 
Adjust volume to 1 L using dH2O 
Store at room temperature 
 
1X Transfer buffer (semi-dry blots) (1 L) 
Dilute 100 ml of 10X stock solution (from Bio-Rad) in 500 ml dH2O 
Add 200 ml methanol (20% final conc.)  
Adjust volume to 1 L with dH2O 
Store at 4°C 
 
1X Transfer buffer (wet blots) (1 L) 
2.9 g Glycine 
5.8 g Tris 
0.37 g SDS 
200 ml methanol 
Adjust volume to 1 L with dH2O 
Store at 4°C 
 
Blocking buffer Constituents 
1% w/v BSA 
5% w/v BSA 
5% w/v fat-free milk 
1g BSA/100 ml 1X TBS-T 
5g BSA/100 ml 1X TBS-T 
5g fat-free dried milk 
powder/100ml 1X TBS-T 
Choice of suitable blocking buffer is dependent on specific antibody/antigen; blocking buffer must be filtered prior to use 
 
SDS-PAGE: 
1. Clean pairs of spacer plates and short plates, casting frames, casting stands and rubber 
gaskets 
2. Place gaskets in grooves at the base of the casting stands 
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3. Assemble glass plates in green casting frames with the short plates facing to the front – push 
the clips outward to tighten the assembly and secure plates 
4. Place the plate assembly onto the rubber gasket in the base of the casting stand, pushing 
down firmly while securing the clip 
5. Add dH2O between the plates to check for leakage 
6. Get three small beakers, three disposable Pasteur pipettes and a small stirring bar 
7. Label one beaker and add dH2O to it, and label the other two beakers for the resolving and 
stacking gel respectively 
8. Make up the required resolving gel according to the appropriate recipe: 
Resolving gel recipes: 
Gel constituent 6% 8% 10% 12% 15% 
dH2O 
30% Acrylamide solution 
1.5 M Tris-HCl, pH 8.8 
10% w/v SDS 
10% w/v APS 
TEMED 
2.6 
1.0 
1.3 
0.05 
0.05 
0.004 
2.3 
1.3 
1.3 
0.05 
0.05 
0.003 
1.9 
1.7 
1.3 
0.05 
0.05 
0.002 
1.6 
2.0 
1.3 
0.05 
0.05 
0.002 
1.1 
2.5 
1.3 
0.05 
0.05 
0.002 
          Gel recipes are for 1 x 1 mm gel; values represent milliliter solution to be added to gel mixture 
9. Add all constituents except the APS and TEMED, stir briefly and let solution stand for a few 
minutes to degas 
10. Add APS and stir briefly (~30 seconds) 
11. Add TEMED, stir briefly and quickly pour the gel mixture between the plates using a Pasteur 
pipette – be sure to avoid bubbles in the gel and leave enough space for the stacking gel (this 
can checked beforehand by inserting a comb and marking the position) 
12. Add a layer of dH2O on top of the gel to prevent oxidation and bubbles 
13. Allow gel to set for 1 hour while preparing 1:10 dilutions of SDS running buffer and TBS-T as 
well as the appropriate transfer buffer – place buffers in fridge to cool before use 
14. After 45 min, start preparing the stacking gel: 
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4% stacking gel recipe: 
Gel constituent 1 ml 2 ml 4 ml 8 ml 
dH2O 
30% Acrylamide solution 
1.0 M Tris-HCl, pH 6.8 
10% w/v SDS 
10% w/v APS 
TEMED 
0.68 
0.17 
0.13 
0.01 
0.01 
0.001 
1.4 
0.33 
0.25 
0.02 
0.02 
0.002 
2.7 
0.67 
0.5 
0.04 
0.04 
0.004 
5.5 
1.3 
1.0 
0.08 
0.08 
0.008 
                    Note: Different Tris-HCl buffers are used for stacking and resolving gels respectively 
15. Once resolving gel has set, wash dH2O off 
16. Add APS and TEMED to the stacking gel solution and pour between plates 
17. Gently insert appropriate combs, pushing down and avoiding bubble formation (make sure 
combs correspond to gel thickness) 
18. Allow to set for 30 minutes 
19. Retrieve standard protein marker from freezer and allow it to equilibrate to room temp 
20. Retrieve samples from freezer (if previously stored) and equilibrate it to room temp (if 
samples have been prepared freshly, i.e. boiled, allow it to equilibrate to room temp) 
21. Vortex each sample and spin down momentarily (~10 seconds) 
22. Carefully remove combs from gels and  gently wash wells with dH2O 
23. Remove plates from the casting stands and frames, and place in the U-shaped adaptor with 
the short plates facing inward 
24. Insert assembly into the loading system and close the latches by pushing them inward while 
pushing down on the plates (the center will now form the buffer dam) 
25. Fill the buffer dam with cold 1X running buffer until the buffer spills into the wells 
26. Add 7.5 µl of the protein marker to the first lane on the far left of each gel 
27. Add blue samples to the appropriate lane – use a micropipette and loading tips to apply the 
marker and samples 
28. After loading of the gels, place the assembly inside a gel tank, fill the buffer dam to the top 
and add extra buffer into the tank – fill the tank to approximately 1 cm below the wells 
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29. Place the green lid with appropriate leads (black-to-black and red-to-red) on top of the tank 
and connect to the powerpack 
30. Switch on the powerpack and perform an initial 10 min run at 100 V (constant) and 400 mA – 
this run will cause the samples to migrate through the stacking gel 
31. Next, run the gels at 180 – 200 V until the sample dye front and smallest standard of the 
protein marker reaches the bottom of the gel – approximately 1 hour (running times may be 
adjusted according the specific protein of interest) 
32. Switch off power and disconnect electrodes before removing gel plates from the tank and 
assembly 
33. Do not allow gels to stand at this point as proteins may dissolve from gels – move to 
electrotransfer step immediately 
 
The choice of blotting procedure (wet vs. semi-dry) is mainly dependent on specific characteristics of 
the protein of interest, including size and solubility. Be sure to check these characteristics and employ 
suitable transfer method. 
 
Electrotransfer (semi-dry blotting): 
1. Cut two pieces of Bio-Rad extra thick blotting pads and one PVDF membrane per gel (cut 
these to the same size as the gel) – do this while the gels are running 
2. Remove the prepared 1X transfer buffer from the fridge and get methanol ready – pour 
these solutions into separate tubs 
3. Soak one blotting pad in transfer buffer and place on anode plate – role flat using a test tube 
to remove air bubbles 
4. Soak the membrane in methanol for ~15 seconds, followed by soaking in transfer buffer 
5. Place membrane on top of the pad and role flat 
6. Carefully remove gels from glass plates using the green lifter – do so by holding the plates in 
one hand with your thumb on one side and other fingers on the other side, insert lifter 
between plates and gently lift the short plate with an upward motion, keeping both plates in 
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your hand – the gel should stick to one of the plates – place the plate with gel in transfer 
buffer and allow buffer to wash gel from the plate 
7. Remove gel from the transfer buffer and place on top of the membrane – role flat with the 
tube (be careful when handling gels as they are fragile) 
8. Soak the second blotting pad in transfer buffer and place on top of the sandwich – role flat 
9. Insert the cathode plate and close the transfer system 
10. Connect the electrodes and switch on the powerpack 
11. Run at 0.5 A and 15 V for one to two hours (depends on size of protein of interest) 
12. After transfer, remove membranes from system and place in 1X TBS-T to wash (see probing 
the membrane below) – gels may be stained using Coomassie blue to check transfer – 
membranes may also be stained with Poncaeu red before washing in TBS-T 
 
Electrotransfer (wet blotting): 
1. Cut two pieces of Whatman paper and one PVDF membrane per gel (8 X 6.3 mm) 
2. Soak membrane in methanol for 5 – 10 min, and soak Whatman paper in transfer buffer 
3. Retrieve 2 black fiber pads and soak in transfer buffer  until use 
4. Retrieve cassettes and assemble sandwich on black side as follows: black fiber pad, Whatman 
paper, gel (with marker on the right), membrane, Whatman paper, fiber pad – make sure to 
roll stack with a tube to remove bubbles 
5. Close the cassette and place in the Transblot module (black side of cassette to black side of 
the module 
6. Place inside tank and fill with cold transfer buffer 
7. Cover the tank with green lid (with electrodes inserted correctly) 
8. Switch on powerpack and run at 160 mA (constant) for 90 min  
9. Proceed to preparation of membrane 
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Preparing membranes for antibody probing 
1. Remove membranes from transfer apparatus, place in a tub with TBS-T and wash 3X, 5 min 
each, on a bellydancer/shaker replacing TBS-T after each wash 
2. Block membranes using suitable blocking buffer for 1 hour at room temp. (blocking buffer 
and time should be optimized depending on protein of interest) 
3. Wash membranes 3 X 5 min each with TBS-T as before 
4. Prepare primary antibodies by diluting in 5 ml TBS-T in a 50 ml falcon tube (the optimal 
dilution for each experiment should be determined, recommended dilutions for most 
antibodies are 1:1000 – 1:5000) 
5. Incubate the membranes in the primary antibody overnight at 4°C while rotating on a tube 
roller 
6. Wash membranes 3 X 5 min each with TBS-T as before  
7. Prepare HRP-conjugated secondary antibodies by diluting in 5 ml TBS-T in a 50 ml falcon tube 
(the optimal dilution should be determined, recommended dilutions for most secondary 
antibodies are 1:4000 – 1:10 000) 
8. Incubate membranes in secondary antibody for 1 hour at room temp. while rotating on a 
tube roller 
Developing Western blots 
1. Take ECL reagents from fridge and equilibrate to room temp., cut pieces of x-ray film (do so 
in the dark room), and prepare membrane cassettes by folding a booklet of transparencies 
on the inside 
2. Wash membranes 3 X 5 min each with TBS-T as before 
3. Prepare ECL substrate in a 1:1 ratio of reagent A and reagent B in a foil covered tube 
4. Place membranes In a flat surface container and add ECL, spreading it evenly over the 
surface of the membranes 
5. Incubate for 1 min at room temp. 
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6. Drain the ECL from the membranes and insert it between the two sheets of transparency, 
avoiding formation of air bubbles 
7. Close the membrane cassette and go the dark room 
8. Place a piece of film on the membrane to expose (best exposure time should be optimized, 
start off with 1 min and reduce or increase time accordingly) 
9. Remove film from the cassette and place in developer solution until bands appear (this 
reaction takes about 7-10  seconds to occur) 
10. Immediately remove film from the developer, wash thoroughly with water and place in fixer 
solution 
11. Wash once more with water and allow film to dry 
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